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ABSTRACT 
 
 
Despite several progresses in terms of early diagnosis and prevention, coronary heart disease 
and heart attack are still the most common causes of death in Western countries. Cardiac 
Regenerative Medicine appears to be a promising alternative to pharmacologic treatment or 
organ transplantation although cellular therapies based on progenitor cell injection are still 
problematic. Myocardial Tissue Engineering (MTE) is a Regenerative Medicine approach, able 
to integrate cell therapy with the use of polymeric substrates (myocardial scaffolds or heart 
patches) that can reduce cell loss and potentially prevent remodeling and fibrotic processes. In 
in vivo MTE strategies, scaffolds should be capable to recruit cardiac progenitor and 
differentiated cells which are present in the adult heart and promote their 
proliferation/differentiation. Consequently, these substrates have to meet strict requirements 
in terms of biological, mechanical, surface, biodegradability properties. In particular, they 
should mimic the natural Extracellular Matrix (ECM), achieving a chemical, morphological 
and mechanical biomimicry.  
In this thesis work, biomimetic polymeric constructs are proposed as heart patches for 
myocardial functions restoration and cardiac tissue regeneration after a myocardial infarction. 
These constructs were prepared as dense (films) and porous scaffolds from synthetic 
biodegradable polyurethanes (PURs), that were selected because of their chemical versatility 
and elastomeric mechanical behavior. In detail, poly(ester urethanes) and poly(ether ester 
urethanes) were synthesized starting from poly(ε-caprolactone) (PCL) and poly(ethylene glycol) 
(PEG) as macrodiols, 1,4-diisocyanatobutane (BDI) as diisocyanate, L-Lysine Ethyl Ester and 
Alanine-Alanine-Lysine (AAK) as chain extenders. PCL was selected to confer 
biodegradability to the final PUR, while PEG was added in low amounts to tune wettability, 
mechanical and biological properties of films and scaffolds. BDI was selected since it is an 
aliphatic diisocyanate and its biodegradation products are non toxic. L-Lysine Ethyl Ester and 
Alanine-Alanine-Lysine were selected as chain extenders for their biocompatible degradation 
products and because biodegradability properties can be tuned thanks to the introduction of 
AAK peptide in the polymer chain, since the Alanine-Alanine sequence is a target for the 
elastase enzyme. Spectroscopic and chromatographic analysis demonstrated the successful 
synthesis of the designed PURs. Films, obtained by hot pressing, were thermally and 
mechanically characterized. They were all characterized by an elastomeric behaviour with 
elastic moduli ranging from 7 to 14 MPa. Contact Angle measurements revealed slightly 
hydrophobic film surfaces with contact angle values in the range 78-94°. Based on mechanical 
testing results, two formulations (KBC1250 and KBC1250-E1500-20) were processed into 
scaffolds by Thermally Induced Phase Separation (TIPS) with the application of a thermal 
gradient, that allowed the formation of stretched and unidirectional pores. These 
microstructures, that were studied trough Scanning Electron Microscopy (SEM) micrographs, 
mimicked the striated muscle tissue. Tensile tests revealed lower mechanical properties for 
scaffolds with respect to films (elastic moduli of about 2 MPa, maximum stress in the range 
0.3-0.6 MPa and maximum strain in the range 120-160%). Nevertheless, both porous 
substrates have suitable elastomeric behaviours for contractile tissues regeneration, with elastic 
ix 
 
moduli closer to that of myocardial tissue (20 kPa-0.5 MPa) for porous constructs. Viability 
tests on cardiomyocytes revealed the best cell response for dense film and porous scaffold 
obtained from the polyurethane KBC1250, with an increasing  viability for the porous 
substrate, which is ascribable to its microstructure features. Hydrolytic and enzymatic 
degradation tests showed a faster weight loss for the scaffolds in the presence of the enzyme 
(lipase), probably because the enzymatic degradation mechanism takes place on surface and 
porous constructs exhibit a larger exposed area. Moreover, elastase degradation tests 
demonstrated that additional degradation through biological processes can be achieved for 
these polymers by the simple introduction of specifically designed peptide sequences in the 
PUR backbone.   
Based on biological and mechanical characterization, dense and porous KBC1250 constructs 
were selected to be surface functionalized by the covalent attachment of Arginine-Glycine-
Aspartic Acid (RGD) peptides, in order to promote cell adhesion and proliferation and obtain 
a “chemical biomimicry”. These peptide is the active sequence of laminin and fibronectin 
proteins, that are responsible for the adhesion of cells to the ECM. This chemical 
modification was performed on films homogeneously or through a silicone mask, in order to 
create a linear RGD micropattern. Analogous laminin and fibronectin patterns revealed 
promising from literature data in promoting mesenchymal stem cell differentiation and 
cardiomyocyte spatial organization. Spectroscopic analysis, increase in surface wettability and 
colorimetric assays demonstrated the successful surface modification of PUR films and 
scaffolds. Functionalized films were characterized by an optimal hydrophylicity (65°) and 
peptide density (3.2 and 1.7 nmol/mm2) for cell adhesion promotion. Peptide quantification 
and cell viability tests demonstrated indirectly the successful use of the siloxane mask in 
allowing the RGD attachment on the uncovered areas. Cell viability tests and SEM 
micrographs showed the positive effect of film modification on cardiomyocyte viability and 
adhesion. Although the same successful peptide attachment was obtained on scaffold surfaces, 
the biological response on this type of substrate was just slightly higher after the surface 
modification. This result can be explained considering that the porous surfaces, although an 
increase in wettability after the functionalization, are still far from the optimal contact angle 
value promoting cell attachment or that some not covalently bound peptides inside the 
scaffold microstructure can induce cell detachment and apoptosis.  
KBC1250 substrates were also tested with human cardiac Mesenchymal Stem Cells (MSCs) 
and Cardiosphere Derived Cells (CDCs), which belong to the progenitor cell reservoir present 
in the adult myocardium. MSCs were detected and extracted for the first time in a human 
heart by Dr Rachel Oldershaw and Dr Annette Meeson of Newcastle University, while CDCs 
were extracted from human biopsies through the creation of Cardiospheres (cell clusters 
containing cardiac stem cells, differentiating progenitors and spontaneously differentiated 
cardiomyocytes). Subsequent culture of these CDCs and MSCs on KBC1250 films and 
scaffolds revealed promising results for the application of the porous constructs in MTE. 
Viability cell test showed that scaffold promoted CDC and MSC growth. Although a decrease 
in cell health after 14 culture days was observed for MSCs, these preliminary tests on human 
cardiac progenitor cells showed that  KBC1250 porous scaffolds are suitable substrates for 
both CDC and MSC proliferation.  
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THESIS OUTLINE 
 
 
The thesis is divided in 5 chapters, whose content is summarized below. 
 
Chapter 1 gives an overview of the state of the art of the current knowledge cornering 
myocardial tissue regeneration, focusing on both scientific and technological aspects, crucial 
for successful approaches in cardiac repair. At the end of the chapter, the goal of the thesis is 
also described. 
 
Chapter 2 deals with the first experimental step in which polymeric materials such as 
biodegradable polyurethanes were synthesized and characterized. Two of these formulations 
were later processed for the preparation of myocardial tissue constructs (both dense and 
porous ones). The physical-chemical, mechanical and the biological properties of these 
constructs are also accurately described.  
 
Chapter 3 is focused on the surface chemical modification (functionalization) performed on 
both the dense and the porous constructs obtained from one of the tested formulations. 
These constructs were previously selected on the base of their mechanical and biological 
characteristics. The surface characterization and the biological tests (on cardiomyocytes) of the 
functionalized substrates are also showed. 
 
Chapter 4 describes additional biological tests performed to further characterize the same 
previously selected constructs (without surface functionalization) and applied to progenitor 
cells extracted from human cardiac biopsies. These experiments were carried out in the 
laboratory of Dr Annette Meeson  at Newcastle University (Newcastle, UK). 
 
Chapter 5 contains a general discussion of the obtained results together with the conclusions, 
referring the goals, the drawbacks and the potential future developments of the presented 
experimental work. 
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CHAPTER 1 
Myocardial regeneration: state of the art and future trends 
 
 
1.1 Introduction 
 
According to the World Health Organization (WHO), Cardiovascular Diseases (CVD) are the 
number one cause of deaths in the world (30% of total deaths) and, in particular, Coronary 
Heart Disease (CHD) represents 42% of all CVD deaths (7.3 million of people). In addition, it 
has been assessed that by 2030 about 23 millions of people will die mainly from heart disease 
and stroke, CVD  remaining the leading causes of death worldwide [1]. Based on these data, it 
is evident that the study and the development of resolving and definitive treatments for 
cardiovascular pathologies has become a demand of prime importance. 
Myocardial infarction (MI) is one of the most common CVD. While significant progresses 
have been made in preventing death from MI, it appears still complex to avoid a common 
progression to heart failure in the patients who survive the initial acute event [2]. Since adult 
cardiomyocytes have very limited ability to proliferate [3] and the stem/progenitor population 
within the adult heart do not provide the adequate replacement needed after a substantial 
damage [4], myocardial infarction results in the formation of scar tissue with different 
contractile, mechanical and electrical properties from that of native tissue [5].  
As alternatives to pharmacologic treatments or organ transplantation, new approaches 
belonging to the large field of Regenerative Medicine have been proposed. In particular, 
Myocardial Tissue Engineering (MTE), which combines different strategies to solve problems 
of delivery, retention and recruitment of cells, seems to be the most promising means for the 
treatment of infarcted myocardium. 
In this chapter an overview of the characteristics of cardiac tissue, myocardial infarction, 
materials and devices used in tissue engineering approaches, and the goal of this thesis work 
will be described and discussed. 
 
 
1.2 The heart  
 
The heart is the muscular organ of the circulatory system that constantly pumps blood 
throughout the body. It has approximately the size of a clenched fist and it is composed of 
cardiac muscle tissue that is able to contract and relax rhythmically throughout a person's 
lifetime [6].  
The heart is located between the lungs in the middle of the chest, behind and slightly to the 
left of the sternum. A double-layered membrane called the pericardium surrounds the heart 
like a sac. The outer layer of the pericardium surrounds the roots of the heart's major blood 
vessels and is attached by ligaments to the spinal column, diaphragm, and other parts of the 
body. The inner layer of the pericardium is attached to the heart muscle. A coating of fluid 
separates the two layers of the membrane, letting the heart move as it beats. 
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The heart is characterized by four separate compartments or chambers. The upper chambers 
are called the left and right atria, which receive and collect the blood coming to the heart, and 
the lower chambers are called the left and right ventricles, which pumps blood away from the 
heart through powerful, rhythmic contractions. A wall of muscle called the septum separates 
the left and right atria and the left and right ventricles (see figure 1.1).  
Four types of valves regulate blood flow through the heart: 
 the tricuspid valve, which regulates blood flow between the right atrium and right 
ventricle;  
 the pulmonary valve, which controls blood flow from the right ventricle into the 
pulmonary arteries that carry blood to your lungs to pick up oxygen;  
 the mitral valve, which lets oxygen-rich blood from the lungs pass from the left atrium 
into the left ventricle;  
 the aortic valve, which opens the way for oxygen-rich blood to pass from the left 
ventricle into the aorta, body's largest artery, where it is delivered to the rest of the 
body [7].  
 
 
Fig. 1.1 Anatomy of the heart [8]. 
 
The human heart can be considered two pumps in one. The right side receives oxygen-poor 
blood from the various regions of the body and delivers it to the lungs. Here blood absorbs 
oxygen and get the left side of the heart. This oxygen-rich blood coming from the lungs is 
delivered to the rest of the body [6]. 
The contraction of the cardiac muscle tissue in the ventricles is called systole. When the 
ventricles contract, they force the blood from their chambers into the arteries. The left 
ventricle empties into the aorta and the right ventricle into the pulmonary artery. The 
increased pressure due to the contraction of the ventricles is called systolic pressure. The 
relaxation of the cardiac muscle tissue in the ventricles is called diastole. When the ventricles 
relax, they make possible to accept the blood from the atria. The decreased pressure due to 
the relaxation of the ventricles is called diastolic pressure [6]. 
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A network of nerve fibers coordinates the contraction and relaxation of the cardiac muscle 
tissue to obtain an efficient, wave-like pumping action of the heart. The Sinoatrial Node (or 
SA node) serves as the natural pacemaker for the heart. Nestled in the upper area of the right 
atrium, it sends the electrical impulse that triggers each heartbeat. The impulse spreads 
through the atria, prompting the cardiac muscle tissue to contract in a coordinated wave-like 
manner. The impulse that originates from the sinoatrial node strikes the Atrioventricular node 
(or AV node) which is situated in the lower portion of the right atrium. The atrioventricular 
node in turn sends an impulse through the nerve network to the ventricles, initiating the same 
wave-like contraction of the ventricles. The electrical network serving the ventricles leaves the 
atrioventricular node through the Right and Left Bundle Branches. These nerve fibers send 
impulses that cause the contraction of cardiac muscle tissue [6]. 
 
 
1.2.1 Cardiac muscle  
The heart is composed mainly of muscle tissue. The muscular walls of the heart consist of 
three major "layers". The myocardium constitutes the bulk of the walls and it is enclosed on 
the outside by the epicardium and on the inside by the endocardium. As described in the 
previous paragraph, the heart is also covered completely by a protective sac called the 
pericardium. 
The myocardium is responsible for the contraction and relaxation of the ventricles and atria 
and it is  composed almost completely of cardiomyocytes  (CM) [9]. These cells, also called 
myocardiocyteal muscle cells, contain one, two, or very rarely three or four cell nuclei [10], are 
narrower and much shorter than skeletal muscle cells, being about 0.02 mm wide and 0.1 mm 
long, and are more rectangular than smooth muscle cells, which are normally spindle-shaped. 
They are often branched, and contain a high number of mitochondria, which provide the 
energy required for contraction. Only 20–40% of the cells in the heart are CMs, but they 
occupy 80–90% of the heart volume [11]. 
Fibroblasts (FBs) and smooth muscle cells (SCMs) are other two cellular components of the 
myocardial tissue and collectively range in size 3–15 μm. Cardiac FBs, that constitute most of 
the non-myocytes in the myocardium, secrete the components of the ECM and transmit 
mechanical force by the receptor mediated connections to the ECM [12]. Endothelial cells 
(ECs) line the blood vessels of the myocardial vasculature and engage in cross-talk with CM 
through several secreted factors [13]. It was also reported that the heart contains small 
numbers of resident cardiac progenitor cells (~1 in 107 cells) [14, 15], as it will be discussed in 
chapter 4. 
Like the skeletal muscle, the cardiac muscle is striated with narrow dark and light bands, due 
to the parallel arrangement of actin and myosin filaments that extend from end to end of each 
myocyte (see figure 1.2). 
A prominent and unique feature of cardiac muscle is the presence of irregularly-spaced dark 
bands between myocytes. These are known as intercalated discs, and are due to areas where 
the membranes of adjacent myocytes come very close together. From a mechanical point of 
view, intercalated discs are the “glue” that enables contractile force to be transmitted from one 
cardiomyocyte to another [17]. They are complex adhering structures which connect single 
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cardiac myocytes to an electrochemical syncytium (in contrast to the skeletal muscle, which 
becomes a multicellular syncytium during mammalian embryonic development) and are mainly 
responsible for force transmission during muscle contraction. Intercalated discs also support 
the rapid spread of action potentials and the synchronized contraction of the myocardium [18]. 
Cardiac-muscle contraction is actin-regulated and, in contrast to skeletal muscle, requires 
extracellular calcium ions. They bind to an enzyme complex on myosin, called calmodulin-
myosin light chain kinase. The enzyme complex breaks up ATP (adenosine triphosphate) into 
ADP (adenosine diphosphate) and transfers the phosphate directly to myosin. This phosphate 
transfer activates myosin, that forms crossbridges with actin (as occurs in skeletal muscle). 
When calcium is pumped out of the cell, the phosphate gets removed from myosin by another 
enzyme. The myosin becomes inactive, and the muscle relaxes [19]. 
 
 
 
Fig. 1.2 Cardiac muscle tissue [16]. 
 
 
1.3 Myocardial infarction 
 
The general term infarction refers to tissue death or necrosis due to an obstruction of the 
tissue's blood supply, leading to a local lack of oxygen. The resulting lesion is defined as an 
infarct [20]. 
A myocardial infarction (MI), also known as a heart attack, is the death of heart cells from the 
sudden blockage of a coronary artery by a blood clot. Blockage of a coronary artery deprives 
the heart muscle of blood and oxygen, causing injury to the heart muscle. Injury to the heart 
muscle causes chest pain and chest pressure sensation. If blood flow is not restored to the 
heart muscle within 20-40 minutes, irreversible death of the heart muscle will begin to occur. 
Muscle continues to die for six to eight hours at which time the heart attack is usually 
"complete." 
A very common cause of a heart attack is atherosclerosis that consists is a gradual process by 
which plaques of cholesterol are deposited in the walls of arteries. Cholesterol plaques cause 
hardening of the arterial walls and narrowing of the inner channel (lumen) of the artery. 
Plaques can become unstable, rupture, and additionally promote a thrombus (blood clot) that 
occludes the artery, resulting in a heart attack (see figure 1.3). The cause that leads to the 
formation of a clot is still unknown, but contributing factors may include cigarette smoking or 
other nicotine exposure, elevated low-density lipoprotein cholesterol, elevated levels of blood 
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catecholamines (adrenaline), high blood pressure, and other mechanical and biochemical 
stimuli. 
Typical symptoms of acute myocardial infarction include sudden chest pain (typically radiating 
to the left arm or left side of the neck), shortness of breath, nausea, vomiting, palpitations, 
sweating, and anxiety (often described as a sense of impending doom) [21]. Women may 
experience fewer typical symptoms than men, most commonly shortness of breath, weakness, 
a feeling of indigestion, and fatigue [22]. A sizeable proportion of myocardial infarctions (22–
64%) are "silent", that is without chest pain or other symptoms [23]. 
 
 
 
Fig. 1.3 Myocardial infarction [24]. 
Myocardial infarction can be categorized on the basis of anatomic, morphologic, and 
diagnostic clinical information. From an anatomic or morphologic point of view, we can 
distinguish transmural and nontransmural MI. A transmural MI is characterized by ischemic 
necrosis of the full thickness of the affected muscle segment, extending from the endocardium 
through the myocardium to the epicardium. A nontransmural MI reefers to an area of 
ischemic necrosis that does not extend through the full thickness of myocardial wall segment. 
In a nontransmural MI, the area of ischemic necrosis is limited to the endocardium or to the 
endocardium and myocardium. It is the endocardial and subendocardial zones of the 
myocardial wall segment that are the least perfused regions of the heart and the most 
vulnerable to conditions of ischemia.  
MI may be classified by the clinical scenario into various types. Type 1 is a spontaneous MI 
related to ischemia from a primary coronary event (e.g., plaque rupture, thrombotic occlusion). 
Type 2 is secondary to ischemia from a supply-and-demand mismatch. Type 3 is an MI 
resulting in sudden cardiac death. Type 4a is an MI associated with percutaneous coronary 
intervention, and 4b is associated with in-stent thrombosis. Type 5 is an MI associated with 
coronary artery bypass surgery.  
A more common clinical diagnostic classification is also based on electrocardiographic 
findings as a means of distinguishing between two types of MI: STEMI (Segment Elevation 
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Myocardial Infarction), with ST elevation in the electrocardiograph, and NSTEMI, without ST 
elevation. ST-segment elevation is associated with higher early mortality and morbidity [25].  
 
1.3.1 Inflammatory and healing response 
 
Cardiac wound healing in mammals is hampered by the fact that regeneration of heart muscle 
is virtually absent and damaged myocardium is replaced by scar tissue, in the process called 
ischemic cascade. 
After cardiomyocyte death, an inflammatory reaction starts within the first day after MI. 
Inflammatory cells invade the infarct, followed by myofibroblasts. Alterations of connective 
tissue are present as early as 40 min after an experimental coronary occlusion and degradation 
of collagen is significant at 24 h in the rat. The normal collagen structure disappears during the 
first week after the infarct. The extent of collagen damage depends by the degree of infarct 
expansion. Collagenases and other neutral proteinases increase their activities rapidly 
degrading extracellular matrix collagen in MI. Inflammatory cells release proteases and 
contribute to removal of died tissue, while myofibroblasts reconstruct a new collagen network. 
The actions of myofibroblasts are constant and essential for the organization of scar 
formation under the difficult condition of the rhythmic contraction of the heart. After several 
weeks, a solid scar has been formed with a stable collagen structure, with some myofibroblasts 
that remain in the scar tissue [26, 27]. 
The collagen scar can lead to potentially life threatening arrhythmias. Injured heart tissue 
conducts electrical impulses more slowly than normal heart tissue. The difference in 
conduction velocity between injured and uninjured tissue can trigger re-entry or a feedback 
loop that is the probable cause of many lethal arrhythmias, such as ventricular fibrillation (V-
Fib/VF), an extremely fast and chaotic heart rhythm that is the leading cause of sudden 
cardiac death. Another life-threatening arrhythmia is ventricular tachycardia (V-Tach/VT), 
which may or may not cause sudden cardiac death [28].  
Ventricular remodeling is a process closely connected with the post-infarction healing 
response and the balance between these two processes constitutes the most important 
parameter that determines long-term outcome. It consists of alterations in the architecture of 
both the infarcted and non-infarcted regions of the left ventricle. It is characterized by an 
inflammatory response, initiated during the first hours after coronary occlusion, and it is 
mediated by the migration of macrophages, monocytes, and neutrophils into the infarct area. 
Degradation of the extracellular matrix by metalloproteinases results in cardiomyocyte 
slippage, which lead to the infarct area thinning and elongation (infarct expansion). 
Additionally, wall stress in the infarct area increases and the resultant distending forces 
contribute to infarct expansion. As it will be described ahead, after the initial inflammatory 
phase, collagen deposition increases and resists deformation and rupture. Infarct expansion 
increases wall stress in the remaining myocardium, resulting in dilatation of the left ventricle 
and distortion of its shape, as it is schematically illustrated in figure 1.4. These processes may 
evolve up to several months, eventually leading to impaired left ventricular function and 
cardiac failure [29].  
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Fig. 1.4 Overview of LV remodeling [30]. 
 
1.3.1.1 Phases of healing process 
 
The complex healing process after myocardial infarction can be divided in three phases, 
characterized by different structural and mechanical properties of the damaged tissue.  
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The necrotic phase 
 
The necrotic phase generally begins within a few hours, when the infarcted tissue begins to 
stiffen, and ends when the number of fibroblasts and amount of new collagen begin to 
increase rapidly in the healing infarct (approximately 7 days after infarction in the human and 
5 days after infarction in the rat). Infarct rupture is most common during this period [27].  
During this phase, within hours after infarction, several structural changes of the injured tissue 
take place. The infarcted muscle loses its striations and changes its staining properties. Within 
24 h, 94% of human infarcts have wavy fibers and 90% have clear necrosis characterized by 
altered staining properties. By the fourth or fifth day, removal of dead tissue is observed. 
Collagenase and gelatinase activity of metalloproteinase MMP-1, MMP-2, and MMP-9 is high 
and disruption of the collagen network continues. As the necrotic phase concludes, deposition 
of new ECM components begins. Fibronectin, laminin, and collagen type IV all appear at 3–4 
days in the healing rat infarct. 
In the necrotic infarct two changes mainly take place from a mechanical point of view: an 
increase of circumferential and longitudinal stiffness under multiaxial loading, and an increase 
of unstressed segment length, at least in the circumferential direction. By contrast, uniaxial 
tests of strips of healing infarct tissue have indicated that infarcted tissue properties do not 
change during the necrotic phase of healing. 
Titin and collagen are the two primary structural proteins degraded in passive myocardium 
during the necrotic phase. If these proteins normally bear some tension in the stress-free state, 
their degradation could produce the increase in unstressed segment length reported in necrotic 
infarcts, but would not explain the reported increase in infarct stiffness [27]. 
 
The fibrotic phase 
 
This phase is characterized by new collagen deposition, that is determinant for structural and 
mechanical changes. It starts when the number of fibroblasts and amount of new collagen 
begin to increase rapidly and ends when collagen production slows and mechanical properties 
become independent from collagen content. This occurs at approximately 3 weeks in large 
animal models, presumably earlier in the rat and later in humans [27]. Proliferating fibroblasts 
acquire specialized contractile features differentiating into contractile cells, termed 
myofibroblasts. These phenotypically modulated fibroblasts secrete large amounts of 
extracellular matrix proteins in the infarct [31]. The healing infarcted tissue generally contains 
a mixture of collagen types I, III, and other minor subtypes. In detail, an initial mesh of type 
III collagen forms the scaffold for subsequent deposition of large, highly aligned type I 
collagen fibers. 
During this phase infarct stiffness achieves the higher value and the healing infarct acquires a 
distinctive anisotropy. Since infarct stiffness and collagen amount increase in parallel, it can be 
deduced that collagen content mainly determines the mechanical properties of the healing 
infarct during this phase. The primary determinant of infarct mechanical properties in the 
fibrotic phase is the presence of a highly aligned large collagen fiber structure, oriented in the 
circumferential direction, where the scar is stiffer. 
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The remodeling phase 
 
During this phase, although collagen content may continue to rise for several weeks, 
mechanical properties of the infarct become independent from collagen amount and a 
remodeling process takes place, at the macroscopic and microscopic level. At the macroscopic 
level, the shrinkage of the scar occurs, occupying a reduced percentage of the left ventricular 
(LV) wall. A changes in size, shape, and function of the left ventricle occurs. At the 
microscopic level, even if rise in collagen content slows, the process of fiber cross-linking 
continues to increase and mechanical properties seem to be dependent by the degree of 
collagen cross-linking. In addition, most fibroblasts and vascular cells undergo apoptosis [27]. 
Several studies have noted an initial improvement in ventricular function during this phase, 
but with further expansion, function declines. Over time, as the heart undergoes ongoing 
remodeling, it becomes less elliptical and more spherical. Spheralization has been shown to be 
associated with higher end-systolic wall stress and an abnormal distribution of fiber shortening. 
More spherical ventricles are characterized by severely depressed contractility at rest and have 
been correlated with reduced survival. 
 
 
1.4 Treatments of myocardial infarction [25, 32]  
 
1.4.1 Pharmaceutical and surgical treatments  
 
The modern treatment of acute myocardial infarction consist mainly in reperfusion therapy, 
which is aimed to open the blocked artery and restore blood flow to the damaged area of the 
heart. Reperfusion can be obtained through a pharmaceutical or surgical approach. In both 
cases, this therapy is also aimed at preventing further damage and the possibility of other heart 
attacks in the future. The most common therapeutic approaches used are listed and described 
below. 
 
Anti-platelet medicines 
 
Anti-platelet medicines, such as aspirin, reduce the tendency of platelets to clump and clot. 
Within minutes, aspirin prevents additional platelet activation and interferes with platelet 
adhesion and cohesion. This effect benefits all patients with acute coronary syndromes, 
including those with amyocardial infarction. Aspirin alone has one of the greatest impacts on 
the reduction of MI mortality. Its beneficial effect is observed early in therapy and persists for 
years with continued use. 
 
Nitrates 
Nitrates, such as Nitroglycerin, have a vasodilator effect. They are metabolized to nitric oxide 
in the vascular endothelium. Nitric oxide widens the blood vessel by relaxing the muscular 
wall of the blood vessel. Clinical trial data have supported the initial use of nitroglycerin for up 
to 48 hours in MI. There is little evidence that nitroglycerin provides significant benefit as 
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long-term post-MI therapy, except when severe pump dysfunction or residual ischemia is 
present. 
ACE (angiotensin converting enzyme) inhibitors 
ACE inhibitors, another type of vasodilator, improve the heart muscle healing process, by 
blocking the production of a hormone called angiotensin II. Contraindications to ACE 
inhibitor use include hypotension and declining renal function. For patients intolerant of ACE 
inhibitors, angiotensin receptor blocker (ARB) therapy may be considered. 
Beta-blocking agents 
Beta-blocking agents interfere with the nerves controlling the heart by blocking the action of 
noradrenaline, that they release. They also block the  adrenaline hormone, carried in the blood. 
This makes decrease the rate and force of myocardial contraction and decreases overall 
myocardial oxygen demand, helping to prevent serious arrhythmias and reinfarction. The use 
of a beta blockers have some recognized adverse effects. The most serious are heart failure, 
bradycardia, and bronchospasm. Beta blocker therapy is recommended within 12 hours of MI 
symptoms and is continued indefinitely. During the acute phase of a MI, beta blocker therapy 
may be initiated intravenously; later, patients can switch to oral therapy for long-term 
treatment. In some patients who are considered high risk due to age or hemodynamic 
instability, intravenous therapy can be avoided. 
Unfractionated Heparin 
Unfractionated Heparin is beneficial until the inciting thrombotic cause (ruptured plaque) has 
completely resolved or healed. This drug has been shown to be effective when administered 
intravenously or subcutaneously according to specific guidelines. The minimum duration of 
heparin therapy after MI is generally 48 hours, but it may be longer, depending on the 
individual clinical situation. Heparin has the added benefit of preventing thrombus through a 
different mechanism than aspirin. 
 
Low-Molecular-Weight Heparin (LMWH) 
LMWH can be administered to MI patients who are not treated with fibrinolytic therapy and 
who have no contraindications to heparin. The LMWH drugs includes a large number of 
agents that have distinctly different anticoagulant effects. LMWHs are proved to be effective 
for treating acute coronary syndromes characterized by unstable angina and NSTEMI. Their 
fixed doses are easy to administer, and laboratory testing to measure their therapeutic effect is 
usually not necessary. 
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Warfarin 
 
Warfarin is not routinely used after MI, but it has a role in selected clinical settings. The use of 
this drug is recommended for at least 3 months in patients with left ventricular aneurysm or 
thrombus, a left ventricular ejection fraction less than 30%, or chronic atrial fibrillation. 
 
Fibrinolytics 
 
Fibrinolytics are indicated for patients who present with a STEMI (which is the most severe 
type of heart attack and is characterized by the completely blocked off coronary artery). In 
within 12 hours of symptom onset without a contraindication. Absolute contraindications to 
fibrinolytic therapy include history of intracranial hemorrhage, ischemic stroke or closed head 
injury within the past 3 months, presence of an intracranial malignancy, signs of an aortic 
dissection, or active bleeding. An example of this type of drug are plasminogen activators, 
which have been shown to restore normal coronary blood flow in 50% to 60% of STEMI 
patients.  
Glycoprotein IIb/IIIa Antagonists 
Glycoprotein IIb/IIIa receptors on platelets bind to fibrinogen in the final step of platelet 
aggregation. Antagonists to glycoprotein IIb/IIIa receptors are potent inhibitors of platelet 
aggregation. The use of these inhibitors during percutaneous coronary intervention (PCI) and 
in patients with MI and acute coronary syndromes has been shown to reduce the risk of death, 
reinfarction, and the need to revascularize the target lesion at follow-up.  
Supplemental Oxygen 
Oxygen should be administered to patients with symptoms or signs of pulmonary edema or 
with pulse oximetry less than 90% saturation. Because MI impairs the circulatory function of 
the heart, oxygen extraction by the heart and by other tissues may be diminished. 
Supplemental oxygen guarantees that erythrocytes will be saturated to maximum carrying 
capacity. The recommended duration of supplemental oxygen administration in a MI is 2-6 
hours, longer if congestive heart failure occurs or arterial oxygen saturation is less than 90%. 
However, there are no published studies demonstrating that oxygen therapy reduces the 
mortality or morbidity of an MI. 
Concerning the surgical approach for restoring blood flow in a MI,  several solutions are 
applied, depending on the severity of the damage and the specific clinical pre-status of the 
single patient. A set of the most common interventions is listed below. 
Percutaneous Coronary Intervention 
PCI consists of diagnostic angiography combined with angioplasty and, usually, stenting. It is 
well established that emergency PCI is more effective than fibrinolytic therapy in centers in 
which PCI can be performed by experienced personnel in a timely fashion. Centers that are 
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unable to provide such support should consider administering fibrinolytic therapy as their 
primary MI treatment. 
PCI can successfully restore coronary blood flow in 90% to 95% of MI patients. Several 
studies have shown that PCI has an advantage over fibrinolysis with respect to short-term 
mortality, bleeding rates, and reinfarction rates. However, the short-term mortality advantage 
is not durable, and PCI and fibrinolysis appear to yield similar survival rates over the long 
term. PCI provides a definite survival advantage over fibrinolysis for MI patients who are in 
cardiogenic shock. The use of stents with PCI for MI is superior to the use of PCI without 
stents, primarily because stenting reduces the need for subsequent target vessel 
revascularization.  
 
Surgical Revascularization 
 
Urgent coronary artery bypass grafting (CABG) is necessary in case of failed PCI in patients 
with hemodynamic instability and coronary anatomy amenable to surgical grafting. Surgical 
revascularization is also indicated in the setting of mechanical complications of MI, such as 
ventricular septal defect, free wall rupture, or acute mitral regurgitation. Restoration of 
coronary blood flow with CABG can limit myocardial injury and cell death if performed 
within 2 or 3 hours of symptom onset.  
 
Implantable Cardiac Defibrillators 
It has been observed a 31% relative risk reduction in all-cause mortality with the prophylactic 
use of an Implantable Cardiac Defibrillators (ICD) in post-MI patients. Nevertheless, the 
current guidelines recommend waiting 40 days after an MI to evaluate the need for ICD 
implantation.  
Heart transplantation [33]  
Heart transplantation is the procedure by which the failing heart is replaced with another heart 
from a donor.  It is appropriate for patients with end-stage congestive heart failure (CHF) and 
a life expectancy of less than one year without the transplant or that have not been helped by 
conventional medical therapy or that have been excluded from other surgical options because 
of the poor condition of the heart.  
Temporary therapies, including the described oral pharmaceutical agents or mechanical 
support with the intra-aortic balloon pump (IABP) or implantable assist devices (left 
ventricular assist devices), can be for some patients as a bridge to transplantation. However, 
mechanical support does not improve waiting list survival in adult patients with congenital 
heart disease.  
The annual frequency of heart transplantation is about 1% of the general population with 
heart failure. Improved medical management of CHF has decreased the candidate population; 
however, organ availability remains an issue [33].  
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1.4.2 Regenerative Medicine and Myocardial Tissue Engineering 
 
Despite optimal medical therapy, thousands of patients per year worldwide, who survive an 
extensive myocardial infarction, develop advanced heart failure [34]. Heart transplant remains 
the best solution to patients with this pathology but problems such as the decrease of donor 
supply, that increase the gap between supply and demand for heart replacement therapies, are 
still present. Left ventricular assist devices may provide a temporary therapeutic solution for 
patients with heart failure, but they serve as only a bridge to transplantation and do not 
provide a definitive therapy [35]. As a result, there has been great interest in alternative 
therapeutic strategies to treat this common and deadly disease [36]. 
Cardiac regeneration is an exciting novel therapeutic approach for the treatment of heart 
diseases, in particular of infarcted myocardium. The revolutionary base-concept introduced by 
Regenerative Medicine consists in growing heart muscle and vascular tissue through cellular 
therapies. Cardiac repair strategies mainly include the direct transplantation of cells into 
damaged environments and Tissue Engineering (TE) techniques for the development of 
replacement tissue. 
 
 
1.4.2.1 Cell injection therapy  
 
Transplantation or injection of cells has been researched since the early 1990’s and focuses on 
repopulation of the injured myocardium by the use of healthy cells. Although the mechanism 
of myocardial tissue regeneration has not been completely cleared, many researchers have 
demonstrated that transplanted cells secrete several cytokines which promote 
neovascularization, prohibit fibrosis, and recruit stem cells, leading to heart function 
improvement [37]. Several cell types have been considered, such as fetal cardiomyocytes, 
skeletal myoblasts, and bone marrow stem cells. Nevertheless, they have all shown to be not 
efficient in restoring damaged heart tissue and its function, since they failed to produce new 
myocardial tissue, causing cell loss and cell death after engraftment [36]. 
According to cell sourcing, different routes are used for cell administration. Systematic 
intravenous infusion is performed through a central or peripheral vein. This method is simple 
and less invasive, although widespread distribution cause low ratio of cell engraftment. The 
most common approach is intracoronary cell infusion via a balloon-catheter. Injected cells are 
reached directly in the target myocardial region but cells have to transmigrate across the  
endothelium wall. Intracardiac injection is performed via pericardium during open heart 
surgery and via endocardium by a catheter with a 3-D electromechanical mapping system 
(NOGA mapping system). These methods realize relatively targeted delivery, but problems 
such as myocardial damage and arrhythmia induction may arise. 
Future clarification will be needed to understand which is the best approach for cell injection 
[37]. 
 
Skeletal myoblasts 
 
Skeletal myoblasts were the first cell source to be used in clinical applications for cardiac repair. 
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They lie in a quiescent state on the basal membrane of myofibers and can proliferate and 
differentiate into skeletal muscle in response to muscle damage. They can be isolated 
autologously and be expanded from a single biopsy. In addition, they are relatively resistant to 
ischemia. Menasche and colleagues first applied skeletal myoblast injection via epicardium for 
patients undergoing coronary artery bypass grafting (CABG) [38]. Although the phase I 
clinical study have shown the feasibility of the implantation of this type of cells, it increased 
risk of ventricular arrhythmias after the operation [39]. On the other hand, the trial indicated 
the possibility that high dose cell injection might recover left ventricular dilatation. Therefore, 
this cell source should not be excluded for heart tissue repair [37]. 
 
Bone marrow-derived cells 
 
Bone marrow-derived cells are the most used cells in clinical trials for myocardial tissue repair 
[40]. Bone marrow cells contain different stem and progenitor cells which can differentiate 
into various types of cells including endothelial cells, smooth muscle cells and cardiomyocytes. 
Bone marrow mononuclear cells (BMNCs) can be isolated simply by gradient sedimentation 
after bone marrow aspiration without culture expansion. BMNCs include heterogeneous cell 
population of monocytes, hematopoietic stem cells and endothelial progenitor cells (EPCs). 
As another cell population, mesenchymal stem cells (MSCs) have been deeply researched and 
clinically used. MSCs represent between 0.01 and 0.001% of all nucleated cells in bone 
marrow but they can be readily expanded in culture. These cells have the potential to 
differentiate into various types of cells and seem to differentiate into myocardial cells when 
injected in heart. Recent studies have revealed that MSCs rarely differentiate into 
cardiomyocytes and that recover of heart function is due to their cytokine secretion and partial 
differentiation into vascular cells. As a unique feature, MSCs have the potential to escape from 
immune detection due to the direct inflammatory inhibition and the lack of cell-surface 
molecules. This property allowed allogenic mesenchymal stem cell transplantation to be 
applied in the clinics, with consequent high impact on the cell therapy research field [37]. 
 
Adipose-derived stem cells 
 
Adipose tissue-derived stem cells (ASCs) are stem cells isolated from the stroma of adipose 
tissues. They have features similar to that of bone marrow-derived MSCs with additional 
angiogenic potential. Some studies have also revealed cardiomyocyte differentiation from 
ASCs. It has not been clarified which mesenchymal stem cells are superior to other cell types, 
however, relatively easy isolation of adipose tissue may push the clinical application of ASCs 
[37]. 
 
Cardiac stem cells 
 
Another possible cell source for myocardial tissue regeneration is given by cardiac stem cells 
(CSCs), discovered by two research groups in 2003 [14, 41]. Until then, it was common 
knowledge that heart was a post mitotic organ, but those reports pushed the researches to 
identify surface marker of CSCs and culture them. Islet-1, Sca-1 and c-kit have been known as 
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CSC markers. Recently, it has been also confirmed that heart has renewal ability at normal 
state and the annual rate of turning over is 1% at the age of 25 [42]. Although the ability of 
CSCs may increase after heart injury, newly formed cardyomyocytes are not sufficient for 
replacing damaged muscle tissues. Therefore isolation and expansion of CSCs have been 
extensively examined. Some groups have used the approach of cardiospheres from biopsied 
myocardium, which lead to efficient CSC expansion [37, 43]. This type of study will be 
discussed in chapter 4. 
 
Embryonic stem cells 
 
Although many studies have demonstrated that MSCs, ASCs and CSCs have the potential of 
cardiomyocyte differentiation for their gene and protein expression, there are no studies 
clearly showing beating cardiomyocytes differentiated from those stem cells. On the other 
hand, several researchers have showed that embryonic stem cells (ESCs) can differentiate into 
beating cardiomyocytes in vitro and that implantation of ESC-derived cardiomyocytes 
improves damaged heart function. Fibloblast growth factor (FGF), retinoic acid, ascorbic acid 
and cyclosporine A seem to enhance cardiac differentiation from ESCs. An important issue is 
also the purification of cardiomyocytes from heterogeneous cell mixture, because the presence 
of immature cells leads to teratoma formation [44]. Immune response of the host is another 
critical issue. Nuclear transfer or cell banking is a possible approach to avoid immune-reaction. 
Electrical communication and simultaneous beating of implanted ESC-derived 
cardiomyocytes should be also requested for improving damaged heart function without 
arrhythmia. In vivo electrophisiological analyses and the transplantation technology for 
synchronization will be essential for clinical application of these cells [37]. 
 
Induced pluripotent stem cells 
 
Induced pluripotent stem cells (iPSCs) also seemed to be promising for myocardial tissue 
engineering [5]. Terminally differentiated cells can be reprogrammed to have the same 
potential as ESCs by introducing 3 or 4 transcriptional factor genes. The advantageous aspect 
of iPSCs to ESC is that these cells are autologous and therefore do not cause immune 
response. Cardiac differentiation of human iPSCs has been reported as for ESCs. Several 
critical issues must be clarified for clinical use, but ESCs/iPSCs-derived cardiomyocytes 
should give a very significant contribution to myocardial tissue engineering especially for their 
pulsatile function [37].  
 
 
1.4.2.2 Problems of cell injection therapy 
 
Cell injection therapies for heart failure are now world-widely performed. Nevertheless, 
although  moderate success of direct cell injection has been observed, none of the cell types 
studied seemed to trigger the restoration of the damaged heart tissue and its function, since 
they failed to produce new myocardial tissue, causing cell loss and cell death after engraftment 
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[36]. Optimization of cell source, cell preparation process, injection route, injection timing and 
patient population are needed to increase the effectiveness of this therapy.  
One of the essential issues is the procedure adopted for cell delivery, since cell injection 
therapy has significant difficulties about cell retention in the target tissue. The shape, size, and 
position of the grafted cells are often uncontrollable and large amount of the cells are washed-
out. In addition, most of retaining cells die due to necrosis and apoptosis. In the clinical trial 
using bone marrow-derived cells, it has been also demonstrated that only 1-3% of the cells 
infused via coronary arteries could be detected by 3D positron emission tomography imaging 
of the patient heart. In this study, a large percentage of cells were found in the liver and spleen 
immediately after the operation [45].  
To solve the problem of cell loss, hydrogel-cell mixture injection has been considered. Fibrin, 
collagen and alginate hydrogels are now used as carriers. They are injected with cells as a liquid 
phase through syringe or catheter and fixed in the target tissues [46]. In hydrogel-cell mixture 
injection therapy, local tissue damage due to space occupation of hydrogel itself and 
inflammatory reaction due to hydrogel biodegradation products can turn out problematic. In 
conclusion, more advanced cell delivery systems are required to spread cell therapy as a  
reliable treatment for myocardial infarction [37].  
 
 
1.4.2.3 Myocardial Tissue Engineering  
 
Tissue engineering adopts the principles of engineering and of life sciences in order to 
understand the structure-function relationships in normal and pathological tissues and to 
develop engineered substitutes that can restore, maintain or improve native tissue and organ 
function.  
The approach of myocardial TE is based on the transplantation of a tissue-engineered 
construct (“myocardial patch”) covering the damaged heart surface instead of simple cell 
injection into myocardium. Grafted cells within myocardial patches can survive more and 
secrete more cytokines, resulting in increased heart function improvement [37].  
As illustrated in figure 1.5, scaffold-, hydrogel- and cell sheet-based TE are three different 
strategies for in vitro myocardial patch fabrication. The most popular strategy consists in 
seeding cells into 3-D pre-fabricated biodegradable scaffolds which are made from synthetic 
polymer or biological material [37]. As showed in detail in figure 1.6, specific cells are isolated 
through a biopsy from a patient (a) and expanded (b), to grow them on a three-dimensional 
(3D) biomimetic scaffold under precisely controlled culture conditions (c, d), to implant the 
construct to the desired site in the patient’s body (e), and to direct new tissue formation into 
the scaffold that can be degraded over time. As it will be discussed in the following section, 
scaffold modification can control its biodegradation and tissue formation while the presence 
of biomolecules, such as growth factors, leads to acceleration of tissue formation.   
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Fig. 1.5 Tissue engineering in vitro strategies for myocardial repair. 
 
 
 
 
Fig. 1.6 Classic scaffold- based TE in vitro strategy [47]. 
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The second approach is to form 3-D tissues by gelling of cardiac cells and matrix solution 
mixture. Generally collagen gel is used to suspend cells. The mixture is poured into a mold 
and after gelling, constructs are stretched with a mechanical devise [48].  
In contrast to scaffold- and hydrogel-based tissue engineering, another approach has been 
developed, involving 2-D cell sheet stacking to fabricate 3-D tissues without scaffold [49]. Cell 
sheets are harvested from smart “temperature-responsive culture surface”, which are 
covalently grafted with temperature-responsive poly(N-isopropylacrylamide) (PIPAAm) [50]. 
The surfaces are slightly hydrophobic and cell-adhesive at 37°C, while they change into 
hydrophilic and not cell adhesive below 32°C. Confluent cultured cells on the surface can 
detach as a whole cell sheet simply by reducing temperature. Cell sheet-based TE has been 
employed for several regenerative medicine applications, including corneal epithelial 
replacement, heart tissue and liver repair.  
Concerning the optimal cell for in vitro myocardial TE, it should be easy to harvest, 
proliferative, nonimmunogenic, and has the ability to differentiate into mature and functional 
cardiomyocytes. As for injection cell therapy, several cell types have been proposed for 
myocardial tissue engineering, including donor (allogenic) and autologus cells. Allogenic cells 
are relatively easy to obtain but can provoke immune suppression. Autologous cells, on the 
other hand, are more difficult to obtain and to expand but cause no immunological reaction. 
Cardiomyocytes appear to be the ideal donor cell type due to their natural electrophysiological, 
structural, and contractile properties. However, cardiomyocytes are difficult to obtain, to 
expand, are sensitive to ischemic insults, and are allogenic, evoking an immune response in the 
host tissue. The use of autologous adult stem cells is particularly restricted by their low 
recovery from the bone marrow, adipose tissue, or circulation, and therefore, the difficulty in 
obtaining reasonable numbers of cells [51].  
Furthermore, as previously discussed, safety issues have been raised regarding the use of 
various cells for myocardial repair: arrhythmias with skeletal myoblasts [39], cardiac 
calcifications with bone-marrow mononuclear cells [52], myocardial scarring with 
mesenchymal stem cells [49], and teratoma with human embryonic stem cells [44]. However, 
the search for an efficient and reproducible method to control and direct cell proliferation and 
differentiation, in myocardial tissue engineering continues.  
In addition to in vitro TE strategies, in vivo TE methods has been investigated. While in vitro 
TE envisages the use of a culture dish or a bioreactor to produce an engineered cardiac graft 
from a scaffold or gel seeded with cells, in vivo TE uses an unseeded scaffold recruiting 
endogenous cells after implant [36]. Injection of thermo-responsive polymeric solutions 
(hydrogel forming at body temperature) are also included in this type of approach. A wide 
range of hydrogels from purely biological materials such as fibrin, collagen and alginate to the 
fully synthetic ones such as polyethylene glycol (PEG) and thermoresponsive poly-N-
isopropyl acrylamide hydrogels have been shown to provide  potentially therapeutic outcomes 
after delivery. Decreased infarct size, increased wall/scar thickness, reduction of LV 
remodeling and improvement of functional parameters have been demonstrated [53]. 
Both in the case of seeded and unseeded scaffolds, crucial issues, that are objective of TE 
researchers, are the appropriate scaffold 3D-structures and their chemical, biological and 
mechanical properties, as discussed in the following sections. 
 
19 
 
1.4.2.3.1 Scaffold and biomaterials requirements for MTE  
 
TE approach is particularly appropriate for the regeneration of tissues that require a 
mechanical support to the reparative process, such as the cardiac one [36]. As already 
discussed, one of the most fatal consequences of MI is LV remodeling, which consists in 
changes in size, shape, and function of the ventricle and is due to the cascade of biochemical 
intracellular signals that regulate the reparative processes, such as dilatation, hypertrophy, and 
the formation of a collagen scar [54]. As a consequence, a critical requirement for a MTE 
scaffold (also called heart patch) is to mechanically support the infarcted left ventricle. In order 
to restore its right shape and functionality, a heart patch should show suitable strength and an 
elastomeric mechanical behavior, able to temporarily support the regeneration of the 
contractile tissue. However, a 3D scaffold may offer other several advantageous functions: (i) 
to temporarily replace the injured tissue, providing a transitional support to cell colonization, 
migration and proliferation and degrading with times compatible with native tissue 
regeneration; (ii) to allow the control over graft dimensions, shape, mechanical properties and 
composition; (iii) to avoid cell loss, a process that generally takes place with cell injection, 
where about 90% of the injected cells is lost to the blood circulation and 90% of the 
successfully injected ones dies within a week; (iv) to control their distribution in the infracted 
area (generally 1.3-17.8% of the injected cells reaches the infracted area [123]) [122, 124-126]. 
In order to fulfill the described functions, MTE scaffolds have to meet restrictive 
requirements that concern both the biomaterial and the structure of the substrate.  
The first and most important requirement is ECM biomimicry: the scaffold should replicate 
cardiac ECM properties in terms of chemical and biological characteristics (to interact with the 
surrounding cells), structure, morphology and mechanical behavior [55]. Therefore, the 
scaffold has to be able to promote specific cellular responses during the regeneration process 
[56].  
The biological and chemical biomimicry can be mainly obtained selecting an appropriate 
biomaterial. It should show not only cell- and tissue compatibility with a minimal 
inflammatory response after implantation, but especially the capability to support cell 
attachment, differentiation, and proliferation. In order to achieve specific interaction with cells, 
biomaterials are often enriched with bioactive molecules, such as growth factors. In MTE, a 
crucial role is assigned to the vascular endothelial growth factor (VEGF), whose concentration 
in the micro-environment around the implanted matrix seems to be very important for the 
development of vascular networks. It has also observed that an excessive amount of VEGF 
can cause an abnormal growth of blood-vessels [57]. So far, significant therapeutic effects of 
VEGF have not been reported, probably due to its short half life after direct injection in bolus. 
The tuning of VEGF release kinetics over time through the use of scaffolds loaded with 
micro- or nano-particles could offer a solution [58]. 
Biomimetic materials may be obtained also by the incorporation of proteins or peptides able 
to specifically interact with receptors on the cellular surface. Whole proteins, such as 
Fibronectin and Laminin (cell adhesion proteins of the ECM), are characterized by low 
stability and availability and high costs. As alternatives, cheaper and more stable short peptides, 
containing the amino acid sequences that are responsible for the bioactivity of these proteins, 
can be synthesized [59, 60] and linked to the polymer chains (bulk modification) or to the 
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biomaterial surface (surface modification). In the case of surface modification, both the 
chemical nature of the ligand and the spatial distribution on the material’s surface have to be 
considered to have a successful biomaterial-cells interaction [59]. Bulk modifications may be 
achieved through a copolymerization reaction or by attachment of functional groups to the 
polymer chains, followed by reaction with the desired biomolecule. Since these reactions can 
alter polymer mechanical properties and its processability, surface functionalization is generally 
preferred to bulk modification. Surface functionalization is often carried out introducing 
functional groups, such as amino and carboxylic groups, by irradiation (e.g. plasma), layer-by-
layer coatings, or chemical methods (e.g. aminolysis). These groups can successively react with 
proteins or peptides forming amide bonds [61].  
Another key requirement for MTE scaffolds is (bio)degradability: scaffolds should degrade in 
vivo at rates compatible with cardiac tissue regeneration, after myocardial functions have been 
restored, without the release of toxic products. This property and its kinetics strongly depends 
from the chemical characteristics of the biomaterial and, in case of enzymatic degradation, 
from the porosity grade of the scaffold. Since enzymatic degradation processes generally take 
place on the scaffold surface, the rate of the degradation process can depend on the amount 
of exposed surface.  
Porosity is also fundamental for the promotion of cell penetration, tissue growth and 
vascularization and nutrient delivery [62]. In detail, a MTE scaffold should have an 
interconnected porous structure, with appropriate pore dimensions. It is known that large 
pores favour cell colonization and migration and nutrients supply, while small pores (tens μm) 
can promote vascularization [55, 63, 64]. A pore diameter of about 40 μm seems to be the 
right compromise  to favor cellular homing and migration, vascularization and nutrients, 
metabolites and oxygen diffusion [55, 64].  
Since myocardial infarction can damage up to 50 g of tissue [65], scaffold micro-architecture 
should be characterized by high cellular density, capillary density in the range of 2400-3300 
capillaries/mm2 and intercapillary distance of about 20 μm [57, 62, 66]. 
It has also observed that the presence of oriented and well-defined pores has positive 
influence on the mechanical and biological performance of scaffolds for tissues with 
anisotropic mechanical and structural properties, such as muscles, since they are able to guide 
tissue regeneration and mechanical transduction along preferred directions [63, 67, 68]. In 
particular, in vitro cell tests showed a higher cell viability and a greater amount of ECM on 
scaffolds with an oriented internal structure, probably because a more efficient cell seeding 
and nutrients and oxygen diffusion are promoted  [67, 68]. Based on these results, MTE 
researchers have recently given an higher attention on scaffold topography and internal 
architecture, besides to bioactive functionalization of biomaterials. 
Concerning matrix thickness, some restrictions exist for non-porous membranes since the 
maximum distance that nutrients and oxygen are able to cover by diffusion is 200 μm. A 
possible solution to this restriction can be the promotion of angiogenesis [65, 69].  
For both dense and porous matrices, mechanical features are particularly important since the 
heart patch should restore the heart geometry and provide a mechanical support to the 
damaged left ventricle, accommodating to the rhythmic movements of the heart without 
plastic deformation or failure [70]. This goals can be achieved if scaffolds have mechanical 
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properties mimicking those of the native tissue, where the most abundant ECM protein is 
elastomeric collagen. 
The myocardium collagen matrix mainly consists of types I and III collagens, characterized by 
different physical and mechanical properties. Type I collagen mainly provides rigidity, while 
type III collagen contributes to elasticity. The two types of collagens jointly support myocytes 
to maintain their alignment, whereas their tensile strength and resilience resist the deformation, 
maintain the shape and thickness, prevent the rupture and contribute to the passive and active 
stiffness of myocardium [71]. The content of different collagen types is very important for the 
resulting mechanical performance of the heart. It is well known that tissues with 
predominance of type I collagen (such as tendon) are characterized by relatively higher 
strength and stiffness, whereas tissues containing large amount of type III collagen (such as 
skin) are characterized by greater flexibility (compliance) [71]. After myocardial infarction, the 
fibrotic phase of cardiac reparative process is characterized by collagen deposition that induce 
structural and mechanical changes. In detail, an increase of collagen type I takes place and this 
process can explain the observed increase in tissue stiffness.  
A more direct reference for the mechanical requirements is given by the mechanical properties 
of heart muscle. Figure 1.5 shows that the passive strains of the heart muscle could reach 
values up to 15–22% at the end of diastole. Therefore the heart muscle mainly works within 
the nonlinear elastic region. The stiffness (Young Modulus) of the heart muscle about 10–20 
kPa at the early stage of diastole (strain <10%), and rises up to 50 kPa (healthy heart) or 200–
300 kPa (congestive heart failure) at the end of diastole. Stress and strain at break should be 
respectively in the ranges of 3-15 KPa and 22-90% [72, 73]. 
 
 
 
 
Fig 1.6. Passive stress-strain curves of heart muscles of different murine and human [74]. 
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Consequently, an ideal heart patch should be characterized by Young Moduli encompassing 
from tens of kPa to 1MPa [62] and by an elastomeric behaviour, able to withstand the 
contractile and expansive forces originated during the cardiac cycle [74]. 
Based on the described requirements for MTE scaffolds, both several biomaterials and 
scaffold fabrication techniques have been deeply explored in search of a suitable chemical 
formulation and scaffold architecture able to promote cardiac tissue regeneration.  
In the next sections, an overview of the main polymeric materials (natural and synthetic) 
studied and used in myocardial tissue engineering (see Table 1 for a list) and of the different 
conventional and unconventional technique for scaffold preparation are discussed. 
 
Table 1. Natural and synthetic polymeric materials for myocardial tissue engineering. 
Natural materials Synthetic Materials 
Collagen 
Gelatin 
Matrigel 
Fibrin 
Alginate 
Cellulose 
Chitosan 
Hyaluronic Acid 
Silk Fibroin 
Polylactide (PLA) 
Polyglycolide (PGA) 
Polylactide-co-glycolide (PLGA) 
Poly-ε-caprolactone (PCL) 
Poly(glycolide-co-caprolactone) (PGCL) 
Polyurethanes (PUR) 
Poly(Glycerol Sebacate) (PGS) 
Poly(1,8-octanediol-co-citric acid) (POC) 
Poly(L-lactic acid)-co-poly(ε-caprolactone) (PLACL) 
Poly(N-isopropyl acrylamide) (PNIPPAm) 
Polyaniline (PANi) 
 
 
1.4.2.3.1.1 Natural polymers  
 
Natural polymers are generally highly biocompatible, leading to a weak in vivo inflammatory 
response and providing a natural substrate for cell attachment, proliferation, and 
differentiation in their native state [75]. They particularly favour cell attachment and 
proliferation, due to their adhesion properties [76, 77]. Despite these positive features, natural 
polymers are often characterized by poor mechanical properties, poor workability and rapid 
degradation kinetics, which limit their clinical applications [76-78]. In addition, depending on 
their source, proteins can provoke immune rejection or pathologies and the transmission of 
disease [79]. 
These types of natural polymers are generally ECM components [78, 80]. It is well known that 
ECM has a fundamental role for tissue life, since it provides support to cells, regulates the 
intercellular communication and is a storage of growth factors [81]. Recent studies suggest 
that it is also deeply involved in the regulatory and electromechanical aspect of myocardium 
functions [79, 82, 83]. To sum up, ECM has proven to be essential for cell survival, 
differentiation, proliferation, metabolism, and integrative function, both under in vivo and in 
vitro conditions [79]. 
These results induce research efforts of cardiac tissue regeneration towards the design of 
materials as similar as possible to the ECM. Among natural polymers, collagen, gelatine, fibrin 
and alginate have been mainly investigated. 
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Collagen, Matrigel and Gelatin  
 
Collagen is the major constituent of ECM [81, 84]. Myocardium collagen matrix mainly 
consists of type I and III collagens, which are synthesised by the same type of cells, cardiac 
fibroblasts, but are characterized by different physical and mechanical properties, providing 
rigidity and elasticity, respectively [85].  
For a long time, collagen, mainly of type I, has been used in biomedical applications as 
haemostatic agent for tissue injuries [86]. After its regenerative properties were discovered, it 
found applications in 3D cell culture for TE [79]. Research groups in Germany (Eschenhagen, 
Zimmermann [87], Kofidis [88, 89]) and Canada (Akhyari [88, 89]) are currently working with 
collagen for myocardial tissue regeneration. Kofidis and Akhyari have developed a novel tissue 
engineered myocardial construct using a clinically approved collagen-based matrix (Tissue 
Fleece®, bovine collagen type I) [88, 89], while Eschenhagen and Zimmermann have studied 
a mixture of liquid collagen type I, Matrigel® [87]. This material is a basal membrane extract 
from a sarcoma cell line and is characterized by the presence of collagen, other several ECM 
proteins and bioactive substances such as growth factors. This liquid natural mixture offers 
some advantages such as versatility, since it can be combined with other ECM components, 
and the possibility to be casted in the desired shape. Nevertheless, its growth factors content 
and the regulatory approval for use in humans of some of its components have been 
questioned [79].  
Several researchers have achieved good results in heart tissue regeneration by the use of 
gelatin, denaturated collagen, obtained from connective tissue of bones, ligaments, tendons 
and cartilage [76], although it can induce an unspecific inflammatory response that can affect 
the survival and function of the inoculated cells inside the implanted matrix [79]. In 1999 Li 
and co-workers used a gelatin-mesh to seed foetal rat ventricular muscle in vitro [90]. The 
commercial product of this kind of gelatin is a foam, known as Gelfoam, made from purified 
pork skin and supplied by Upjohn, Ontario, Canada [75]. Both Akhyari  and Zimmermann 
used Gelfoam to seed heart cells [87, 91, 92]. Zimmermann described the improvement of the 
proliferation of seeded human heart cells as a consequence of applying cyclical mechanical 
stress to the material [91].  
 
Fibrin 
 
Fibrin, a natural polymer which has gained FDA approval for human use [93] is obtained 
from fibrinogen by a thrombin-mediated reaction. When fibrinogen is converted into fibrin, a 
provisional matrix is produced. Then, a degradation process by Membrane Metalloproteases 
(MMPs) starts and the fibrin matrix is replaced by an ECM, rich in collagen, hyaluronic acid 
and fibronectin [84, 94].  
This process is used by myocardial engineering through in situ matrix formation. By varying 
the concentration of fibrinogen it is possible to modulate  density and mechanical strength 
[95], while variation of the amount of thrombin or the addition of acetone can affect not only 
the mechanical properties but also the conformation of the matrix [96]. Unlike other 
xenogenic natural polymers, such as gelatin and collagen, fibrin can avoid the inflammatory 
response, since it can be extracted from the patient’s own blood [97]. Biological interaction 
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with the enclosed cells can be improved by the use of additives in the mixture before 
polymerization. An advantage derived from the addition of thrombin to the reaction mixture 
is the possibility to postpone polymerization after injection in the infarcted area [96]. 
Moreover, this approach permits an alignment of the fibrin-cell mixture within the myocardial 
fibers, that results in an increase of cell survival, a reduction of the infarct scar size and 
microvessel formation [98, 99]. 
There are several studies of the beneficial effects of the use of fibrin in infarcted myocardium, 
especially on neovascularization [100] [101]. Nevertheless, myocardium repair through the use 
of fibrin remains limited. Although the mechanical properties of this natural polymer can be 
tuned, they remain low compared with the properties of native tissue, and cardiac remodeling 
cannot be prevented [102] [103].  
 
Silk Fibroin 
 
Among natural polymers for TE, silkworm silk protein fibroin shows the highest mechanical 
performance. Scaffolds (10mm in diameter and 10mm in height) obtained by Antheraea 
mylitta silk protein fibroin are characterized by 84 kPa of compressive strength [104], while 
collagen and chitosan scaffolds have a mechanical strength of 15 kPa and 45 kPa, respectively 
[105]. In particular, this non-mulberry silk fibroin has shown to be mechanically superior to 
mulberry silk (Bombyx mori silk fibroin) [104] and highly biocompatible, with low level of 
inflammatory response  [106] [107].  
Recently, Patra and co-workers have thoroughly studied fibroin from Antheraea mylitta (AM), 
containing RGD sequences, as potential biomaterial for 3D cardiac tissue engineering 
scaffolds, comparing it with Bombyx mori silk fibroin (BM), gelatin and fibronectin [108]. 2D 
matrices have been used to investigate cellular metabolic activity, cell to-cell communication, 
cell cycle activity and contractility, with very promising results. Adhesion test on 
cardiomyocytes have revealed that only after 6 hours, significantly more cells attached on AM, 
with respect to BM and gelatin, with no differences with fibronectin, the positive control. 
MTT assays showed a similar trend: cardiomyocytes on AM and fibronectin exhibited similar 
metabolic activity at all investigated time points, and it was always higher than the activity of 
cardiomyocytes on BM. Finally, immunofluorescence analysis showed that cells on AM and 
fibronectin contained aligned sarcomeres, crucial for a high contractility, and expressed high 
amounts of connexin 43, an important protein which regulates electrical signal propagation, in 
correspondence of cellular junctions. 
 
Alginate, Cellulose, Chitosan and Hyaluronic acid 
 
Alginate, cellulose and hyaluronic acid belong to the class of polysaccharides, but only 
hyaluronic acid derives from the native ECM [109, 110].  
Alginate is made up of mannuronic acid and guluronic acid units, which can form different 
sequences affecting the 3D structure [110]. It is mainly produced by a brown seaweed, but also 
by certain types of bacteria [76]. It is known for its capacity to form hydrogels in the presence 
of calcium ions [110]. These calcium-alginate hydrogels have been used to encapsulate 
different type of cells [111-113]. Leor et al. investigated cardiac cell proliferation in alginate 
25 
 
porous scaffolds with very promising results. Cells showed viability not only during the culture 
in vitro but also during the successive implantation, after which the scaffold was completely 
absorbed in 9 weeks [114]. 
Cellulose has found several applications in the biomedical field but it has only recently been 
investigated as myocardial tissue engineering material [115]. It is the most important structural 
components of plants and made of glucose based units linked by 1,4-beta-glucosidic bonds 
[110]. It is known for being poorly water soluble and not digestible for mammals [110, 115]. 
Entcheva et al. tested cellulose acetate and regenerated cellulose as substrates for the growth 
of cardiac cells in vitro. Both materials proved to be easily casted in molds with micro and sub-
micro grooves and their scaffolds showed their potential for promoting cardiac cell 
proliferation and improving cell connectivity and electromechanical functionality. They also 
revealed in vitro resistance to biodegradation [115]. From the studies of Martson’s group, 
cellulose showed to be slowly degradable also in vivo [116].  
Chitosan is a polysaccharide derived from the partial de-acetylation of chitin, found in 
crustacean shells, and made of β(1-4) linked D-glucosamine units [117]. For a long time it has 
been studied and used for bone and dermal tissue regeneration but recently it has been 
investigated for cardiac tissue repair, mostly as injectable hydrogel [118-120]. However, several 
properties of this naturally occurring polymer have induced Nicole et al. to study and use it as 
a scaffolding material for myocardial regeneration [121] as will be described in detail below. 
The pH dependence of solubility of chitosan allows polymer processing under mild conditions 
and the fabrication of porous scaffolds and membranes [122]. The structural similarity with 
glycosaminoglycans and the hydrophilic surface [123] can allow specific interactions with 
ECM-biomolecules, such as growth factors and receptors. In addition, degradation kinetics of 
chitosan are well known [124]: chitosan membranes can be degraded in vivo by macrophages in 
12 weeks. Finally, chitosan is not only biocompatible but also non thrombogenic [125-127]. 
Hyaluronic acid acts in the ECM as space filler and significantly contributes to the mechanical 
properties of a tissue, by linking proteoglycans and maintaining hydration [109]. Its fragments 
are very important from a biological point of view, since they have a bioactive role in several 
regulatory processes, such as angiogenesis, inflammation, wound healing, tissue regeneration 
and tumor growth [128, 129]. Although positive results on cell differentiation in 
cardiomyocites have been reported for hyaluronic acid based substrates [130], this biopolymer 
often needs to be mixed with other ECM components, both natural and synthetic, in order to 
improve the mechanical and biological performance of the scaffold [131, 132]. 
 
 
1.4.2.3.1.2 Synthetic polymers  
 
Synthetic materials are widely used in myocardial tissue regeneration, due to some excellent 
characteristics. First of all, they generally show superior mechanical properties than natural 
polymers that make them suitable for mechanical support and resistance to cyclic stress of 
force-generating contractile tissue [75, 78]. In addition, these properties, together with 
hydrophilicity and degradability, can be controlled in a reproducible manner. Their drawbacks 
regard their often poor interaction with cells and the biological environment [78]. Although 
synthetic polymers are designed as biodegradable and biocompatible in order to be used for 
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TE applications, they inevitably induce a higher inflammatory reaction with respect to natural 
ones [55]. Nevertheless, they can be replaced in vivo by native ECM created by the cells seeded 
inside the scaffolding material, after a period depending on the degradation/erosion properties 
of the polymer [75, 78] and their use eliminates pathogen transmission risks, which can be 
caused by some biological materials [79]. 
 
Polyesters 
 
The most popular synthetic polymers employed in cardiac tissue regeneration are degradable 
polyesters, mainly synthesized from lactide, glycolide and ε-caprolactone. Although their 
biocompatibility has been proved and several reports on their successful applications in 
regenerative medicine exist, synthetic polymers have not yet considered optimal scaffolding 
materials. They are basically hydrophobic, preventing a good cell adhesion, and tend to 
crumble rather than slowly degrade. In addition, their acid biodegradation products can induce 
high inflammatory responses, and a drop in local pH, upon degradation process, can affect the 
viability of the surrounding cells [78]. 
Depending on the monomer, mechanical, physical and degradation properties of these 
polyesters can greatly change. For example, polylactide (PLA) is characterized by a higher 
hydrophobicity with respect to polyglycolide (PGA) and, as a consequence, by a higher 
resistance to hydrolytic degradation. From a mechanical point of view, the higher stiffness and 
plasticity allow it to support the structural integrity of 3D cell cultures [79]. Several research 
groups investigated PGA and PLA matrices for myocardial regeneration. Bursac’s group 
explored the in vitro engineering of PGA scaffolds with neonatal rat ventricle myocytes 
cultured in a bioreactor. After one week, they observed differentiated cardiac myocytes, 
organized in multiple layers [133]. Ke et al. studied embryonic stem cells (ESCs)-seeded PGA 
patches after implantation on infarcted hearts in mice and observed that after 8 weeks the 
biodegradable matrix guarantees the survival of the engrafted cells [134]. From the 
combination of lactide and glycolide, copolymers (PLGA) with new properties have been 
obtained. Like PLA and PGA, PLGA has a long history in clinical applications, as suture 
(Vycryl) and TE material [135, 136]. 
Another frequently employed monomer is ε-caprolactone. Its homopolymer poly-ε-
caprolactone (PCL) is known to be biocompatible and to have a long-term degradability, if 
compared to PLA, PGA and PLGA. PCL has also been used as suture material (Monocryl), 
but it has found few applications in TE with respect to other polyesters [79]. Nevertheless, the 
successful use of PCL based scaffold for cardiac tissue regeneration has been reported 
recently: both Shin and Ishii showed the formation of contractile cardiac grafts in vitro using 
PCL meshes as substrates for cardiomyocytes culture [137, 138]. A copolymer based on 
glycolide and ε-caprolactone (PGCL) has been evaluated by Piao et al. They demonstrated that 
a PGCL based scaffold attenuated in vivo left ventricular remodeling and systolic dysfunction 
[139]. 
In order to encourage cardiomyocytes adhesion or induce cell differentiation in myocardial 
phenotype, polyester films have been functionalized with adhesion proteins (Fibronectin, 
Laminin) or RGD based peptides. Brown et al. have investigated the effect of plasma 
modification followed by fibronectin adsorption on PLGA substrates on neonatal rat 
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ventricular myocyte (NRVM) function. They observed that NRVMs showed a better 
spreading and myofibril development on the modified films respect to the unmodified ones 
and that protein absorption affected gene expression of adherent cells [140]. The 
differentiation process can be strongly influenced by the particular protein or peptide surface 
micropattern. The work of Chor Yong Tay has shown that derived human mesenchymal stem 
cells (hMSCs) cultured on PLGA film with adhesive fibronectin strips were highly elongated, 
and markers, associated to myogenesis, were up-regulated [141]. 
Poly (Glycerol Sebacate) (PGS), a synthetic polyester obtained from the polycondensation 
reaction of glycerol and sebacic acid [142] has been explored by Qi-Zhi Chen et al., as 
potential material for the production of heart patches. Mechanical characterization of PGS 
films, synthesized at three different temperatures, demonstrated elastomeric properties very 
close to those of the heart muscle, with Elastic Moduli in the range between tens kPa and 
1MPa. Degradation tests, carried out in PBS (Phosphate Buffered Saline) and DMEM 
(Dulbecco's Modification of Eagle Medium), showed varying kinetics for the three different 
PGSs and the consequent possibility to tune this property according to specific clinical 
requirements [143].  
In a recent work by Daniel J. Stuckey and co-workers, PGS films revealed able to reduce 
hypertrophy in a rat model of myocardial infarction, limiting post-infarct remodeling. In 
addition, PGS seemed to be more suitable for the delivery of cardiac stem and progenitor cells 
with respect to other materials, such as poly(ethyleneterephathalate)/dimer fatty acid (PED), 
and TiO2-reinforced PED (PED-TiO2). Moreover, its degradation kinetics are compatible 
with the process of cell assimilation by the heart [144]. 
Poly(1,8-octanediol-co-citric acid) (POC), obtained by the reaction of 1,8-octanediol and citric 
acid, has recently been investigated as elastic scaffolding material by Yang et al. Its degradation 
rates and cytocompatibility can be tuned modifying the conditions for the synthesis and 
molecular ratios of the reagents [145]. Based on Yang’s results, Hidalgo-Bastida and his co-
workers have considered this material for cardiac tissue engineering applications. In their work 
they reported HL-1 cardiomyocyte attachment and survival on POC films coated with 
fibronectin, collagen or laminin. HL-1 cells adhered to both coated and uncoated films after 
18h of incubation. POC uncoated film showed a monolayer of cells covering less than 10% of 
the total area, while fibronectin coated films showed a higher and quicker cell adhesion and 
proliferation with respect to collagen- and laminin-coated samples. Moreover, cells seeded on 
the latter samples did not assume the characteristic elliptical shape of cardiomyocytes. The 
best biological results obtained with fibronectin coatings can be explained considering that 
fibronectin is overexpressed during cell migration and proliferation at the embryonic stage of 
heart development, while collagen and laminin levels increase during heart growth [146].  
 
Polyurethanes  
 
Polyurethanes (PURs) are a large group of polymers widely used in the biomedical and 
industrial field. Due to the possibility of selecting several different starting reagents (polydiols, 
diisocyanates and chain extenders), materials with varying chemical, mechanical, biological and 
degradation properties can be achieved [84, 147, 148]. In cardiac TE, degradable PURs, based 
on polyester polyols, have been studied for a long time, because of their biocompatibility [76, 
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77] and elastomeric properties (and, as a consequence, their capability to resist to cyclic stress 
without plastic deformation or failure) that fit the requirement of materials for cardiovascular 
applications [149].  
Rechichi et al. investigated the tuning of the properties of this kind of polymers by 
synthesizing and characterizing PCL and PCL-PEG-PCL based polyurethanes with different 
aliphatic and aminoacid-based chain extenders. Cellular tests with fibroblasts and thermal-
mechanical characterizations have showed that all these materials are non toxic and suitable 
for tissue engineering applications. However, their particular biological and mechanical 
behavior strongly depends on their chemical composition [150].  
Recently, ECM-like PURs have been synthesized, incorporating peptides and bioactive 
molecules [151, 152]. Amino-acid sequences have been introduced in PUR chains to control 
the enzymatic degradation process of the resulting scaffolds for myocardial TE. Guan and co-
workers, that successfully developed PCL and putrescine based polyurethanes in 2004 [153], 
more recently prepared an elastase sensitive PUR containing the enzyme-target Alanine-
Alanine (AA) sequence as chain extender [68]. The degradation study showed a more 
pronounced weight loss for the peptide based formulations with respect to putrescine-based 
PURs in the presence of elastase [68, 153]. As it will be discussed below, Fujimoto and 
colleagues also successfully explored a biodegradable putrescine based PUR for the 
preparation of porous scaffolds for cardiac repair [154, 155]. Ciardelli et al. investigated the 
introduction of an Alanine-Alanine-Putrescine (Ala-Ala-Put) chain extender in a PCL based 
PUR and compared mechanical, thermal and biological properties of the final polymer with 
those of other biodegradable formulations, containing aliphatic and Lysine based chain 
extenders.  Although the peptide showed the capacity to be enzymatically degraded to the 
polymer, tensile tests demonstrated that the Lysine based PUR has the mechanical properties 
closest to those required for contractile tissue regeneration (low Elastic Modulus and high 
Strain at Break) [156]. This formulation has also shown the best results in cellular adhesion 
tests, carried out on myoblasts: on this sample a significant cell spreading was observable 
already after 3 hours of incubation. This cell response could be linked to the mechanical 
properties of the polymer, since some cell types appear to be sensitive to substrate stiffness 
[157]. 
In order to impart adhesion properties to polyurethanes, laminin coated PURs were realized 
by McDevitt et al. to pattern cardiomyocyte cultures. They printed laminin lanes 5–50 μm 
wide on polymer surface to guide cardiomyocyte alignment and observed highly organized 
arrays [158]. Siepe et al. subsequently investigated the use of myoblasts in similar patterns and 
have observed that cells survived in vitro for several weeks, maintaining the initial spatial 
distribution. Even if no differentiation in cardiomyocytes was obtained, the investigated 
substrates seemed to be promising for myocardial tissue engineering [159].  
 
 
1.4.2.3.1.3 Polymer Blends  
 
A very interesting strategy to produce suitable materials for myocardial engineering is to blend 
two different polymers, generally a natural and a synthetic one. The purpose is to obtain a 
material that combines the biocompatibility and the biological ECM properties of the natural 
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component and the superior mechanical characteristics of the synthetic one, the latter acting 
as a physical support and degrading then with the desired pattern [76]. In literature, blends 
where the natural component is either collagen or gelatin have been mainly investigated. 
Mukherjee’s group evaluated the biocompatibility of poly(L-lactic acid)-co-poly(ε-
caprolactone)/collagen (PLACL/collagen) composite, fabricating nanofibers in order to 
mimic the native myocardial environment for freshly isolated cardiomyocytes. The study 
demonstrated that cell proliferation is significantly higher on PLACL/collagen nanofibers with 
respect to the synthetic  co-polymer alone [160]. “Bioartificial systems” based on poly(N-
isopropyl acrylamide) (PNIPPAm) with collagen, gelatin and alginate, respectively were also 
investigated, including a blend of PNIPAAm/alginate/gelatin, and their biological behavior 
was compared with that of a tri-block poly(ester-ether-ester) co-polymer and a PCL based 
PUR [161, 162]. Biological analyses were performed on C2C12 cell line of skeletal myoblasts, 
as a model of a possible cell source for myocardial regeneration. Proliferation and adhesion 
tests highlighted the best results for collagen and gelatin blends, the three components blend 
and the two single synthetic polymers, even if a general decrease of cell number at three or 
five days after seeding, followed by a new increase, is observed. Differentiation tests, evaluated 
as the elongation of actin filaments, showed to be the most suitable evaluation parameter for 
the bioartificial systems [162]. 
Another important subset of polymer blends includes formulations based on conductive 
polymers that can allow control of tissue contraction and electrical signals transmission [163]. 
The use of these materials as cell culture substrates shows that some cell functions, such as 
adhesion, migration, proliferation and differentiation, can be promoted and influenced by 
electrical cues [164]. In detail, previous studies have highlighted the possibility to induce cell 
orientation, angiogenesis, muscle tissue regeneration, cardiomyogenesis and mature cardiac 
phenotype taking advantage of electrical stimulations [165-167]. 
Polyaniline (PANi) is one of the conducting polymers explored for myocardial regeneration, 
since it has revealed to be biocompatible for a certain number of cell lines, including cardiac 
myoblasts [168]. Mengyan Li has examined a novel type of blend, composed of gelatin and 
polyaniline. Conductivity measurements and biological tests evidenced an increase of 
conductivity by increasing PANi percentage, with the more promising results obtained for rat 
cardiac myoblast cells proliferation for the hybrid substrates [169]. In order to enhance PANi 
biocompatibility and provide the resulting scaffold with swelling and adhesive properties to 
promote cardiac cells attachment, infiltration, proliferation and differentiation, Fernandes at al. 
functionalized it by grafting a peptide sequence (hyperbranched poly-L-Lysine dendrimes) 
prior to scaffold fabrication [170]. D. A. Stout’s group considered the addition of carbon 
nanofibers (CNF) to Poly(lactic-co-glycolic acid) to obtain a conductive scaffold. They 
examined different PLGA/CNF ratios on cardiomyocytes cultures and observed that 
conductivity and cell functions were enhanced by increasing the CNF content. It was assumed 
that the CNF nanoscale geometry mimics the ECM, determining an improved 
cytocompatibility [171]. Ming-Chia Yang and colleagues used polysaccharides and silk fibroin 
(SF) to produce SF/chitosan (CS) or SF/CS–hyaluronic acid (SF/CS–HA) microparticles, that 
were mechanically pressed and cross-linked with genipin to obtain cardiac scaffolds. Biological 
tests performed with rat mesenchimal stem cells on hybrid patches and on fibroin control, 
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showed higher cell growth rates and cardiomyogenic differentiation for the blended substrates 
[172]. 
 
 
1.4.2.3.2 Scaffold preparation techniques 
 
Among conventional scaffold fabrication techniques, solvent casting/particulate leaching, 
freeze drying, electrospinning, thermally induced phase separation (TIPS), particles pressing 
and photolithography have been extensively studied for the production of scaffolds for 
cardiac regeneration.  
 
Solvent casting/particulate leaching technique 
 
In solvent casting and particulate leaching (SCPL), a polymer is dissolved in an organic solvent 
and particles, generally salts, are then added to the solution. The mixture is shaped into its 
final geometry,  onto a glass plate or in a three dimensional mold. After the solvent has 
evaporated, the resulting composite material is placed in a bath which dissolves the particles, 
leaving behind a porous structure [173]. This technique is one of the most popular scaffold 
fabrication procedure since it allows an easy and quick production of porous structures [174]. 
Hidalgo-Bastida et al. used salt leaching to produce elastomeric, flexible, porous patches 
starting from POC. These scaffolds showed suitable properties for application in myocardial 
repair since scaffolds stiffness and elongation at break varied in the range of 0.2-3.3 kPa and 
60-95%, respectively [146]. Lee at al. prepared PGCL-based scaffolds showing a rubber-like 
behavior with and ability to sustain cyclic tensile loading [175]. These scaffolds were used by 
Piao used thes scaffolds to develop cardiac patches cellularized with rat bone marrow-derived 
mononuclear cells and cell-free scaffolds, both implanted on the epicardial infarcted surface of 
a rat model. Four weeks after implantation, connective tissue covered both the scaffolds, some 
cells underwent differentiation into cardiomyocytes and newly blood vessels formed with a 
higher blood vessel density in the cell-seeded scaffolds compared to the non-cell-seeded ones 
[139].  
Radisic and coworkers prepared bioresorbable, elastomeric macroporous PGS-based scaffolds 
containing micropores through a modified salt leaching technique [176, 177]. They 
demonstrated that a pretreatment with cardiac fibroblasts prior to cardiomyocytes seeding can 
create a suitable environment for cardiac myocytes adhesion, migration, proliferation and 
contraction [176, 178, 179]. Preliminary in vivo tests carried out in a rat model with cell-free 
scaffolds, showed that these matrices could be easily sutured, did not induce any infection and 
completely integrated in the host tissue within two weeks [176].  
A mixed technique based on gas foaming (described ahead) and particulate leaching has been 
used by Park and colleagues to produce composite scaffold based on poly(DL-lactide-co-ε-
caprolactone), PLGA and type I collagen. These scaffolds showed the highest cell density and 
metabolic activity when compared with their controls (collagen or PLGA sponges) probably 
due to their higher elasticity and mechanical stability. In addition, cells seeded on their surface 
responded to electrical cues with a synchronous contraction and expressed troponin I (TnI) 
and connexin-43 (Cx43) [180].  
31 
 
Pressing of particles 
 
A simple and fast technique based on the pressing of particles to produce porous scaffolds has 
been employed by Yang and colleagues [172]. They first spray-dried microparticles of silk 
fibroin (SF) or its blend with chitosan (SF/CS) or chitosan-hyaluronic acid (SF/CS-HA), then 
they pressed the produced particles using a mechanical pressing machine at room temperature 
and finally crosslinked with genipin. SF/CS and SF/CS-HA scaffolds showed promising 
cellular response when cultured with rat mesenchymal stem cells (rMSCs). Cell proliferation 
on SF and SF-hybrid scaffolds significantly exceeded that of the control (cell culture plates) on 
day 7 post seeding. In addition, SF-hybrid scaffolds showed a higher proliferation rates 
compared to SF substrates, demonstrating that the incorporation of polysaccharides 
significantly contribute to mimic ECM microenvironment. Concerning differentiation, SF-
hybrid scaffolds induced rMSCs to upregulate cardiac markers, such as NKx2.5, Gata4, Tnnt2 
and Actc1, and express some cardiac proteins, such as cardiotin and connexin 43 [172]. More 
recently, Chi et al. studied the effects on LV remodeling and cardiac repair induced by the 
implantation of cellularized (bone marrow mesenchymal stem cells -BMSCs-) and non-
cellularized SF/HA porous patches, obtained by this fabrication technique, in rat hearts [181]. 
Eight weeks after implantation weak signs of immunological response were observed in rats 
treated with non-cellularized and cellularized patches, respectively, while two months after 
implantation, SF/HA-treated rats showed improvement in cardiac function compared to the 
non-treated animals. This effect is ascribable to the mechanical and biochemical properties of 
the developed scaffolds. Moreover, cellularized scaffolds prevented cardiomyocytes apoptosis, 
induced the restoration of contractile proteins and promoted the release of vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and hepatocyte 
growth factor (HGF) [181]. 
 
Freeze drying  
 
Freeze-drying, also known as lyophilisation, is a dehydration process that works by freezing 
the material and then reducing the surrounding pressure to allow the frozen water in the 
material to sublimate directly from the solid phase to the gas phase [182]. 
These technique has been mainly used for the fabrication of porous scaffolds obtained from 
natural polymers. Cohen’s group produced cellularized alginate-based scaffolds that were 
completely integrated in the host tissue and totally coated with vascularized connective tissue, 
with myofibrils showing the typical striations and gap junctions of cardiac muscle, after two 
months after implantation [114, 183-187]. A reduction in cardiac remodeling was also 
observed [114, 184]. The same research group successively studied the implantation of 
analogue uncellularized scaffolds demonstrating that, even in these conditions, scaffolds 
promoted new blood vessels formation and stem cells recruitment in the infarcted area, 
providing a mechanical support to angiogenesis probably because alginate has a chemical 
structure similar to heparin sulfate, an ECM component regulating a wide variety of biological 
activities, including angiogenesis [184].  
Perets and coworkers incorporated PLGA microspheres loading bFGF into the previously 
described scaffolds. They demonstrated that bFGF-loaded scaffolds induced cardiac fibroblast 
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proliferation and enhanced vascularization with respect to unloaded ones [186]. Dvir and 
colleagues proposed a pre-vascularization process to be performed before scaffold 
implantation [188]. They seeded the previously described alginate scaffolds with neonatal 
cardiac cells and loaded them with pro-survival and pro-angiogenic factors (insulin-like growth 
factor-1 -IGF-1-, stromal-cell derived factor1 -SDF-1- and VEGF) to promote cell survival 
and vascularizatio and induce maturation of the newly formed tissue. After 48 hours of cell 
culture, the pre-vascularization process started with scaffold implantation onto the omentum, 
a membrane rich in blood vessels. On day 28 post implantation, the vascularized scaffold 
showed integration in the host tissue from the structural and electrical points of view.   
These alginate-based scaffolds were bulk functionalized by Sapir et al. prior to scaffold 
fabrication with two peptides: an amino acid sequence containing the adhesion triplet RGD 
and a heparin-binding peptide (HBP). After 14 days of cell culture with cardiac cells, 
RGD/HBP-functionalized samples showed a newly formed contractile tissue, while single-
attached scaffolds (RGD- and HBP-attached scaffolds) exhibited a less organized tissue. 
These results suggested that HBP contributes in promoting cardiac tissue development, 
probably retarding the spreading process that appears only after the reorganization of cells 
into a cardiac-like arrangement [185].  
Blan and Birla used freeze-drying to prepare chitosan-based scaffolds, characterized by the 
addiction of fibrin gel to favor cell retention. The in vitro formation of contractile tissue 
compared to the direct cell injection was observed [121]. Shi and co-workers covalently 
functionalized freeze-dried collagen-based sponges with the anti-Sca-1 antibody that is able to 
recruit and capture Sca-1 expressing hematopoietic, cardiac and skeletal muscle stem cells, 
demonstrating that the functionalized collagen scaffolds had the capacity for inducing an 
enhancement in cardiomyocytes regeneration when used to treat myocardial defects in mice 
[189]. 
At the beginning of the XXI century, the gelatin sponge Gelfoam® turned out to be an 
attractive substrate for myocardial TE, able to promote cell infiltration and engraftment [90, 
190]. Since Gelfoam® scaffolds lack in suitable mechanical properties and show a thickness 
that makes oxygen and nutrients supply difficult, Miyagi et al. proposed a modified Gelfoam® 
scaffold (MGF) [191, 192],  spray-coated on one surface with PCL to improve its mechanical 
behavior. To induce neoangiogenesis, the implanted MGF and the infarct border zone were 
injected with a biodegradable, thermo-sensitive hydrogel based on a triblock copolymer of 
poly δ-valerolactone-b-poly ethylene glycol-b-poly δ-valerolactone loaded with pro-angiogenic 
cytokines and/or bone marrow mesenchymal stem cells (BMSCs). Animals treated with the 
MGF scaffold showed an improvement in cardiac function compared to non-treated rats and 
animals treated with un-modified Gelfoam® [191]. More recently, Grover and colleagues used 
this technique to prepare porous scaffolds based on a blend of type I collagen and gelatin or 
elastin [193]. The addiction of gelatin or elastin to collagen allows to reduce its stiffness and, in 
the case of elastin, to increase strain at break. The replacement of collagen with gelatin in the 
blends with elastin seems not to be promising for cardiac TE since it induces a reduction in 
mechanical performances.  
Patra et al. used freeze-drying to produce 3D scaffolds starting from non-mulberry silk fibroin 
extracted from Antheraea Mylitta (AM) [194]. AM seemed to be a good substrate for 
cardiomyocytes adhesion and spreading. In details, cell tests on AM showed better results than 
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those carried out on silk fibroin extracted from Bombyx mori (BM) probably due to the 
presence of RGD sequences inside the polymer chains. AM exhibits higher elasticity and 
tensile strength compared to BM, resulting a more suitable substrate for cardiac TE constructs. 
Cardiomyocytes seeded on freeze-dried AM scaffolds appeared to be uniformly distributed on 
pores’ wall, expressed connexin 43, beat spontaneously and synchronously for at least 20 days 
and exhibited aligned sarcomers [194]. 
Collagen scaffolds with an internal honeycomb structure, characterized by parallel pores 
whose diameter ranged between 100 and 1000 μm, can be produced by freeze-drying a 
neutralized atelopeptide Type I collagen solution (1%, pH 3.0) [195]. The formation of the 
honeycomb structure is induced by neutralization of an acidic collagen solution with ammonia 
gas that cause insoluble collagen fibrils separation and rearrangement in multiple cores that 
grow from the surface to the bottom of the solution. Pore size can be varied depending on 
concentration of the collagen solution or that of ammonia gas. To improve mechanical 
properties of the scaffold, heat crosslinking was performed. In 2012, Guo and colleagues 
investigated rat cardiac cell behavior on this type of scaffolds [196]. After 16 days of culture, 
the seeded cells successfully adhered to scaffolds’ walls and by the first day of cell culture, cells 
started to beat with a frequency rate higher that that observed on cell culture plates [196].  
 
Thermally Induced Phase Separation (TIPS) 
 
According to TIPS, polymer is dissolved at high temperature in a solvent with high freezing 
point (typically dimethyl sulfoxide or dioxane) and subsequently the solution is quenched, in 
order to decrease polymer solubility and induce its separation. Then the frozen solvent is 
washed away, leaving a porous structure. 
Guan et al. used this technique to obtain scaffolds with random and oriented pores, using the 
previously described polyurethane based on PCL-diol, 1,4-diisocyanatebutane and the peptide 
sequence Ala-Ala-Lys. Subcutaneous implantation in rats demonstrated the absence of 
postoperative infections and the progressive cell infiltration inside the scaffold [68]. Fujimoto 
et al. explored a similar polyurethane containing putrescine as chain extender to produce 
porous interconnected scaffolds for cardiac TE [153-155]. In vitro cell tests showed promotion 
of cell adhesion, migration and proliferation, while in vivo tests carried out by implantation of 
acellular patches on rat model infracted area showed that the patch surface was completely 
integrated in the host muscle, eight weeks after implantation [153-155, 197]. In the case of  
scaffold-treated animals, it was observed that the infarcted area was rich in proteins connected 
to cardiac functionality, such as caldesmon and calponin and a there was a high capillary 
density and the re-establishment of the ventricular wall thickness [155].  
 
Electrospinning  
 
It is a highly versatile technique used to produce continuous fibers from submicron to 
nanometer diameters. Generally, a polymeric solution is fed through a spinneret and a high 
voltage is applied to the tip. The buildup of electrostatic repulsion within the charged solution, 
causes it to eject a thin fibrous stream. A collector plate or rod with an opposite charge draws 
in the continuous fibers, which will form a highly porous network. A typical electrospinning 
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set-up requires a high voltage power supply (up to 30 kV), a syringe, a flat tip needle and a 
conducting collector. By modifying parameters such as the distance to the collector, 
magnitude of applied voltage and solution flow rate, it is possible to change the scaffold 
architecture and, as a consequence, its physical and mechanical properties [198]. 
This technique was used by Kai and colleagues to produce scaffolds with both random or 
oriented morphology, showing that fiber alignment promoted cardiomyocytes adhesion and 
orientation [199]. Zong and coworkers also demonstrated that cardiomyocytes seeded on 
oriented PLLA-scaffolds tended to assume an elongated morphology compared to randomly 
oriented ones [136]. Similar results on cell behavior and morphology were obtained by 
Rockwood et al. that studied electrospun structures fabricated using a biodegradable 
polyurethane based on PCL-diol, 2,6-diisocyanate methylcaproate and 1-phenylalanine as 
chain extender [200].  
The same polyurethane was used by Fromstein and coworkers to produce collagen IV coated 
structures by electrospinning and TIPS and study the effect of scaffold architecture on cell 
response. The different thickness of the two scaffolds (1000 μm for TIPS scaffolds vs 70 μm 
for electrospun ones) affected oxygen and nutrients supply and, as a consequence, embryonic 
stem cell-derived cardiomyocytes morphology and viability. In details, cells seeded on TIPS 
scaffolds exhibited a rounded shape and preferably localized themselves on the surface, while 
the same cells cultured on electrospun constructs spread and colonized all the thickness. 
Despite these differences in cell morphology, cells on both scaffolds expressed sarcomeric 
myosin and Cx43 and exhibited spontaneous contractility [201]. 
More recently, Prabhakaran et al. reported for the first time the electrospinning of the 
elastomeric POC blended with poly(L-lactic acid)-co-poly(ε-caprolactone) (PLCL) [202]. 
POC/PLCL scaffolds resulted characterized by a lower fiber diameter with respect to pure 
PLCL fibers. In addition, blended scaffolds showed Young Modulus (0.5-1 MPa) and 
elongation at break (150-280%) suitable for application in cardiac TE. Cell tests carried out 
with H9C2 cardiac myoblasts showed increased cell proliferation, organization, alignment, 
migration and spreading in the composite scaffolds compared to PLCL fibrous substrates.  
Stankus and colleagues developed a new technique for the preparation of in vitro cellularized 
graft [203] based on smooth muscle cells electrospray combined with electrospinning of a 
biodegradable, cytocompatible and elastomeric poly(ester urethane)urea synthesized from 
PCL-diol, 1,4-diisocyanatobutane and putrescine [153, 203]. A fiber orientation able to 
promote cell alignment in a preferred direction was achieved, allowing a better mimesis of the 
anisotropic properties of the cardiac tissue [203]. More recently, Guan and colleagues 
employed this technique to integrate mesenchymal stem cells (MSCs) with an elastic poly(ester 
carbonate urethane)urea (PECUU) [204]. An anisotropic cellularized scaffold with MSCs 
uniformly distributed along its thickness was produced. It exhibited a non-linear anisotropic 
mechanical behavior that matched that of porcine cardiac tissue. However, since MSCs didn’t 
align themselves to PECUU fibers and maintained a round shape, the cellularized constructs 
were cultured under stretching in order to induce cell alignment. Both in the presence and 
absence of a mechanical strength, the cellularized construct upregulated MEF2C, Nkx2.5 and 
GATA4. In the case of strengthen of scaffolds, this upregulation was strongly increased. 
These results suggest that a cardiac-like structural and mechanical environment can promote 
MSCs differentiation toward the cardiac lineage, without biochemicals or co-culture with other 
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cells, but simply mimicking structure, mechanical properties and cell organization of the native 
tissue [204].      
The research group of Vacanti used PCL-based porous and randomly oriented electrospun 
scaffolds to develop cardiac grafts by overlapping several cell sheets. Cells cultured on the 
different sheets started to show a synchronized contraction with increasing strength with time 
[137, 138]. Moreover, the sheets connected each other created an homogeneous tissue 
showing cardiac-like structures. However, this approach is limited by the absence of a 
vasculature network able to supply nutrients and oxygen in the deeper regions of the graft 
[137, 138]. Kenar et al. overcame this limit developing a cellularized myocardial patch with a 
tubing system for nutrients supply [205].  
Nanofibrous electrospun matrices can be easily functionalised to biochemically promote tissue 
regeneration and improve cell adhesion and proliferation [206-209]. Heydarkhan-Hagvall and 
colleagues prepared electrospun scaffolds from a blend of PCL with a natural polymer 
(collagen/elastin or gelatin type B) [210]. Spadaccio and colleagues functionalized PLLA 
electrospun scaffolds incorporating the granulocyte colony-stimulating factor (G-CSF), which 
stimulate angiogenesis, Cx43 expression and the hemodynamic cardiac function after MI [208, 
211-213]. G-CSF has also an antiapoptotic activity, inhibits LV remodeling and protects the 
heart from arrhythmias [208, 211-213]. Myoblasts C2C12 seeded on these scaffolds adopted 
an elongated muscle-like morphology and expressed TnI and Cx43 [208, 213].  
Ravichandran and colleagues experimented coaxial electrospinning to produce core/shell 
fibers containing the elastomeric synthetic PGS as core and a natural polymer as shell. PGS 
was used to obtain mechanical properties matching those of the native cardiac tissue while the 
natural polymer was used to promote cell adhesion and proliferation [214, 215]. Fibrous 
scaffolds produced with gelatin as shell resulted biocompatible and had promising mechanical 
properties for cardiac TE application [214]. Then, they replaced xenogenic gelatin with 
fibrinogen because it can be extracted from patient’s own blood avoiding risk of foreign body 
reaction [215] and obtained scaffolds with Young Modulus of about 3 MPa, matching that of 
the myocardial tissue. showed normal expression of cardiac markers (α-actinin, Troponin, ß-
myosin and connexin 43) and formed gap junctions to each other. The biological response of 
neonatal cardomyocytes cultured on these substrates was more promising, with higher 
expression of cardiac marker proteins, formation of gap junctions and functionality, with 
respect to  fibrinogen control and tissue culture plates. Probably higher elasticity of 
PGS/fibrinogen core/shell fibrous structures allows cardiomyocytes to maintain their 
contractility and electrical activity [215].  
 
Photolithography  
 
Photolithography is a technique in which microscale features are fabricated based on selective 
exposure of a material to light. It allows to fabricate scaffolds with well-defined and 
geometrically precise topographies [216]. In 2003, Motlagh et al. demonstrated that 
topographical properties significantly affect cardiomyocytes morphology, gene expression and 
protein distribution. Cardiomyocytes seeded on textured substrates tended to adhere to the 
vertical surface of pegs or grooves and exhibited a decrease in cell area and an increase in the 
thickness of the myofibrillar layer due to changes in cell shape [217]. As previously discussed, 
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bioartificial systems based on PNIPAm and natural polymers have been studied for their 
application in cardiac TE [162]. More recently, the same research group assembled 
microfabricated substrates of a blend of poly(NIPAAm-co-HEMAHex), alginate and gelatin, 
having a rectangular geometry, in order to reproduce the architecture and anisotropic 
mechanical properties of the cardiac ECM [161, 218]. The micropatterned geometry was 
characterized by rectangular cavities (500 x 100 μm) able to lodge 2-3 cardiomyocytes and 
thick lines of 30 and 70 nm that reproduced the regions of connective tissue present in the 
native tissue [219]. Preliminary cell tests carried out with myoblasts showed scaffold ability to 
promote cells proliferation and orientation in a preferred direction [161].  
In 2012, Srinivasan and Sehgal, that previously proposed a microbial treatment to extract 
collagen fibers from Achilles tendons of bovine origin maintaining collagen fibers’ properties 
unchanged [220], wove collagen fibers to produce 3D fleece with good mechanical strength 
and handiness to be a suitable substrate for application as a cardiac patch [221]. Neonatal 
ventricular rat cardiomyocytes (NVRCMs) cultured on these scaffolds remained viable and 
metabolically active, and showed pulsation up to 18 days of culture, probably due to the 
suitable mechanical properties and elasticity of the developed substrates [221].  
 
Rapid prototyping techniques (RP) 
 
Rapid prototyping techniques (RP) are considered non conventional techniques and have been 
recently introduced to overcome the limitations of conventional scaffold fabrication methods, 
since they allow the fabrication of scaffolds with controlled resolution [222-228]. They include: 
selective laser sintering (SLS), pressure-assisted microsyringe (PAM) and laser microablation 
[222, 227].  
Yeong et al. recently used SLS to produce porous PCL-based scaffolds with a well-defined 
porosity, geometry and mechanical properties [229]. The selected repetitive unit (square 
pyramid-shaped) allowed the production of an omogeneus interconnected porosity that favors 
nutrients and catabolites exchange and promotes cell homing and migration [229, 230]. This 
scaffold fabrication technique allows to obtain both micro- and macro-porosity as a result of 
the low particle-particle compaction force and the chosen repetitive cell, respectively. C2C12 
myoblasts seeded on these scaffolds were found to proliferate up to 4 days; after 7 days a 
decrease in cell population was observed probably due to the beginning of differentiation 
phenomena that led myoblasts to fuse and create multinucleated cells [229].  
Laser-based techniques have been largely employed in recent years due to the possibility to 
modify a wide family of materials at micro- and submicro-scale in a short time and in a 
computer-controlled manner [231]. Patz et al. studied the possibility to modulate C2C12 
myoblasts adhesion, alignment, proliferation and differentiation acting on surface structure, 
particularly on the diameter of the channels produced on agar surface by excimer laser 
ablation. C2C12 seemed to have a better alignment, proliferation and differentiation on 
surfaces exposing channels with diameter of 60-150 μm [231, 232]. Moreover, this technique 
can be easily combined with others, such as photolithography and electrospinning [209, 233, 
234]. Guillemette and colleagues demonstrated the possibility to successfully combine 
photolithography and laser ablation to produce PGS-based scaffolds with anisotropic and 
elastomeric mechanical properties that met the force-generating demands of myocardial tissue. 
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Cell tests carried out with C2C12 myoblasts showed that the topographical features created by 
photolithography and the pores produced by laser ablation induced a preferential cell 
alignment in a parallel direction to the linear pattern and the pore sides [233]. Park at al. used 
the same polymer and combined technique to produce multi-layered elastomeric scaffolds 
with an accordion-like honeycomb structure, mimicking the ondulated shape of perimysial 
collagen fibers [235-237]. Heart cell culture studies showed poor apoptosis and Cx43 
expression [236].  
A well-defined geometry at both micro- and macro-scale can also be achived by PAM [238, 
239]. A comparative study carried out by Mattioli-Belmonte et al. between PAM and salt-
leached scaffolds showed that, under application of a load, the former underwent a 
reorganization of its structure with fiber alignment in the direction of the applied force 
compared to the latter [238, 240]. In addition, only PAM-fabricated scaffolds assured 
homogeneous cell-substrate interactions, uniform distribution of cells inside the scaffold and 
good perfusion [238].  
On the basis of the promising results reported by Lionetti et al. [241] and the success in skin, 
cartilage, vessels and nerves repair [242], several researchers have investigated the possibility to 
employ the commercial hyaluronan-based biomaterial HYAFF®  for application in myocardial 
TE [243, 244]. Gallina and colleagues studied the interaction between a knitted HYAFF® mesh 
(HYALONECT®) and neonatal murin ventricular myocytes (NMVMs) [243]. Adhesion tests 
after 24h of cell culture revealed an adhesion of about 5% of the seeded cells that can be 
ascribed to the HYALONECT® structure, characterized by large empty spaces between its 
knittings. It was also observed a progressive change in cell morphology, from rounded-shaped 
with low degree of organization on day 1 to spindle- and spreaded-shaped and aligned 
organization in the fiber direction on day 7 post seeding, and a spontaneous contractile 
activity up to 48h. This feature is almost completely lost on day 7 post seeding due to the 
progressive cell differentiation toward an adult phenotype, characterized by absence of 
spontaneous contractile activity [243].  
 
 
1.4.2.3.3 Conductive scaffolds 
 
Scaffold conductivity is an important property that may allow the control on tissue 
contraction and electrical signals transmission within the graft. As previously described, 
several conductive polymers have been studied for cardiac TE applications.  
Kai and colleagues developed electrospun scaffolds starting from a blend of PCL, gelatin and 
PPy (PPG). Cells cultured on PPG scaffolds showed a higher expression of Cx43 compared to 
PCL/gelatin constructs, due to the improvement in electrical and chemical signals 
transmission, resulting from the presence of PPy [245]. Similar conductive electrospun 
scaffolds were produced by Li and colleagues starting from a blend of gelatin and PANi. 
These scaffolds were cultured with cardiac myoblasts H9C2 and revealed able to promote cell 
adhesion and proliferation. In detail, scaffolds with smaller fiber diameter showed better 
results in term of cell spreading and muscle-like morphology, probably because they provided 
a more faithful reproduction of the ECM structure [169].  
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Carbon nanotubes (CNTs) are now being largely used as conductive components of scaffolds 
for cardiac TE. Mooney and colleagues studied the effects of single-walled CNTs (SWNTs) on 
human mesenchymal stem cells (hMSCs) demonstrating that at low concentrations SWNTs 
did not have negative effects on cell viability, proliferation and differentiation [246]. Based on 
these results, Mackle et al. produced electroactive randomly oriented electrospun fibrous 
scaffolds from a composite of SWNTs (2 wt%) dispersed in a poly-L-lactide acid (PLA) 
matrix. Degradation tests, demonstrated that the addiction of SWNTs increases scaffold 
structural stability and induces only slight alteration in PLA mechanical properties [247]. 
hMSCs seeded on these substrates and subjected to electrical stimulation adopted an 
elongated morphology and rearranged perpendicularly to the direction of the applied stimulus 
[248]. Moreover, hMSCs upregulated several cardiac markers, suggesting that electroactive 
stimuli can guide hMSCs differentiation to the cardiac phenotype [248].  
Dvir, Timko and colleagues developed 3D freeze-dried scaffolds based on alginate and gold 
nanowires (Alg-NW) [249]. Gold nanowires have been adequately designed to minimize 
toxicity and have suitable size to be longer than pore wall thickness (approx. 500 nm) to 
promote signal transmission and cell-cell interaction through the scaffold. Cell tests carried 
out with cardiomyocytes and fibroblasts extracted from neonatal rats’ left ventricles showed 
that the introduction of gold nanowires promotes the formation of more aligned and thicker 
tissues with respect to those observed in case of culture on pure alginate scaffolds. Moreover, 
cells seeded on composites scaffolds showed spontaneous and synchronous contraction when 
electrically stimulated and expressed higher level of proteins involved in contractility 
(Troponin I and connexin 43). Interestingly, gold nanowires seem to have positive effects on 
the physiology even in absence of an applied electrical stimuli, inducing cells to produce 
higher levels of connexin 43 on Alg-NW scaffolds compared to virgin alginate scaffold [249].  
 
 
1.5 Thesis goal 
 
The main purpose of this work is the fabrication of biomimetic bioartificial constructs 
(heart patches), able to restore myocardial functions and promote cardiac tissue 
regeneration after a myocardial infarction. These scaffolds are based on synthetic 
biodegradable polyurethanes and are prepared as dense (bidimensional) and porous 
(tridimensional) constructs.  
 
Since biomimicry is a key requirement for applications of biomaterials in tissue engineering, 
they are prepared as biomimetic devices, from a mechanical, morphological and biochemical 
point of view.  
Mechanical biomimicry is achieved by using elastomeric polymeric materials. In this work, the 
selected materials belong to the large family of polyurethanes, that will be widely described in 
the next chapter. As discussed above,  the most employed synthetic polymers in myocardial 
TE are degradable polyesters, thanks to their biodegradability and biocompatibility. However, 
they are generally characterized by high stiffness, unsuitable for soft and contractile tissue 
regeneration [78]. A fine tuning of chemical, mechanical and degradation properties is required 
in the fabrication of heart patches and a restrict number of polymers, such as PGS [142] [143] 
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[144], POC [145] [146] and  PURs [84, 147, 148], assure such requirements. Among these, 
polyurethanes seem to be the most versatile, since they can be prepared starting from a large 
number of building blocks (macrodiols, diisocyanates and chain extenders), opening the way 
to the introduction of peptide-sequences and several types of biomolecules in the polymeric 
chain. In cardiac TE, degradable PURs have been studied for a long time, thanks to their 
biocompatibility and elastomeric behavior that makes them capable to withstand cyclic 
stresses without incurring in plastic deformation or failure [76, 77]. 
In this thesis work, biodegradable poly(ester urethanes) and poly(ether ester urethanes) based 
on poly(ε-caprolactone) (PCL) and poly(ethylene glycol) (PEG) as macrodiols, 1,4-
diisocyanatobutane (BDI) as diisocyanate, L-Lysine Ethyl Ester and Alanine-Alanine-Lysine 
(AAK) as chain extenders, are proposed as starting materials for the fabrication of heart 
patches. PCL is introduced in the polymer backbone to confer biodegradability to the final 
PUR. PEG is added in low amounts to tune wettability, mechanical and biological properties 
of films and scaffolds. BDI is an aliphatic diisocyanate, which is selected because its 
biodegradation products are non toxic [150]. Amino acids-based chain extenders are also 
chosen for their biocompatible degradation products. 
Alanine-Alanine-Lysine peptide can be introduced also to tune biodegradability properties, 
since the Alanine-Alanine sequence is a target for the elastase enzyme. This enzyme is a 
member of the chymotrypsin family of proteases and it is involved in ECM degradation. 
Elastases can cleave elastin as well as having a broad substrate portfolio including collagen, 
fibronectin and other ECM proteins [250].  
In this work, morphologically biomimetic scaffolds are obtained processing the synthesized 
PURs into tridimensional porous structures by Thermally Induced Phase Separation, with the 
application of a thermal gradient. In this way, the formation of oriented stretched pores is 
pursued, with a resulting anisotropic structure that confers to the substrates a remarkable 
similarity to the streaked muscle tissue. Similar scaffolds fabricated by Guan at co-workers 
gave promising results in terms of muscle-derived stem cell growth with respect to random 
orientated scaffolds [68]. 
In order to increase biocompatibility and surface wettability, and promote cell adhesion, 
proliferation and differentiation, the produced dense and porous constructs are surface 
functionalized by covalently linking RGD (Arginine-Glycine-Aspartic Acid) adhesion peptides. 
The process involves the activation of the top nanometer surface of the biomaterial by a 
plasma treatment to initiate graft copolymerisation of acrylic monomers. The formed carboxyl 
groups are used to covalently bind the bioactive molecule. 
As it will be discussed in Chapter 3, ECM proteins containing this amino acid sequence, such 
as laminin and fibronectin (which are responsible for cell attachment to the ECM) have been 
successfully and widely employed in myocardial tissue engineering [158] [159] [251]. The use 
of their active sequences has been less investigated, but it seems to be a cheaper and 
promising strategy to promote myocardial regeneration [252]. Several authors have also 
studied the importance of density and distribution of adhesion proteins and RGD peptides on 
biomaterial surfaces, obtaining interesting results. For example, Rowley and co-workers 
created a range of surface density (1-100 fmol/cm2) on alginate substrates and observed that 
myoblast proliferation and differentiation can be regulated by varying RGD density and the 
alginate monomeric ratio  [253]. Moreover, the effect of fibronectin and lamin linear micro-
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patterns on new tissue growth (cardiomyocytes organization and proliferation) [158] and 
mesenchymal stem cells differentiation into myogenic lineage [159] has been successfully 
studied.  
Based on these observations, surface functionalization with the RGD peptide is performed in 
this work on both dense and porous substrates. In details, surface modification on films is 
carried out homogenously and with linear micro-patterned RGD domains, by using a silicone 
stencil after the plasma treatment, that allows for a regular distribution of biomimetic cues on 
the polymer surface.  
Dense and porous scaffolds are biologically characterized by viability tests with 
cardiomyocytes. The most promising formulations are selected to be surface modified and 
tested with progenitor cells (Human Cardiac Mesenchymal Stem Cells and Cardiosphere-
derived Stem Cells) in order to investigate the effect of the anisotropic structure on stem cells 
proliferation and differentiation.  
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CHAPTER 2 
Fabrication of myocardial patches based on synthetic 
biodegradable polyurethanes  
 
 
Abstract 
 
The production of efficient heart patches for myocardium repair requires the use of 
biomaterials with high elastomeric properties and controllable biodegradability. In this chapter, 
biodegradable poly(ester urethanes) and poly(ether ester urethanes) are proposed as 
scaffolding polymeric materials for MTE. They were synthesized from poly(ε-caprolactone) 
(PCL) and poly(ethylene glycol) (PEG) as macrodiols, 1,4-diisocyanatobutane (BDI) as 
diisocyanate, L-Lysine Ethyl Ester and Alanine-Alanine-Lysine (AAK) as chain extenders. 
This peptide was used to tune biodegradability, since the Alanine-Alanine sequence is a target 
for the elastase enzyme. Two formulations were processed into scaffolds by Thermally 
Induced Phase Separation (TIPS). Scanning Electron Microscopy (SEM) micrographs revealed 
promising microstructures, which mimicked the striated muscle tissue. 
 
 
2.1 Introduction: Polyurethanes  
 
Polyurethanes (IUPAC abbreviation PUR, but commonly abbreviated PU) are a large family 
of polymeric materials which are characterized by a large diversity of chemical compositions, 
mechanical properties, tissue-specific biocompatibility and biodegradability, with mechanical 
flexibility and moderate blood compatibility. Thanks to their variable composition and 
mechanical properties, PURs are among the most extensively used synthetic polymers in 
biomedical applications after half a century of use in the healthcare system [1]. These polymers 
played a major role in the development of durable cardiovascular devices since the 1980s, such 
as blood bags, vascular catheters, bladders of the left ventricle assist device (LVAD), the total 
artificial heart (TAH) and small caliber grafts for vascular access and bypass surgery [2]. 
However, they also showed some problems in long-term stability applications, such as 
pacemaker leads and breast implant coatings [3]. During the next decade, researchers focused 
their attentions on PURs susceptibility to biodegradation. Research efforts towards 
understanding their biodegradation have yielded novel PURs with improved stability for long-
term implantable  devices, as well as an entirely new class of bioresorbable PURs .  
 
 
2.1.1 Synthesis of PURs 
 
Polyurethanes belong to the group of block copolymers and are characterized by the presence 
of a significant number of urethane groups. The urethane-forming reaction involves the 
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isocyanate and the hydroxyl group OH, as illustrated in figure 2.1. As a consequence, the 
synthesis of PURs requires two essential components: isocyanate (typically diisocyanate) and a 
bi- or multi-functional polyol with two or more hydroxyl terminal groups. 
 
 
 
Fig. 2.1 Urethane-forming reaction. 
 
 
The use of a diisocyanate and a bi-functional polyol (or macrodiol) results in thermoplastic 
polymers without covalent crosslinking, whereas the use of components with more than two 
functional groups (e.g., triisocyanate or a multi-hydroxyl polyol) determines PUR three-
dimensional networks.  
The third important reagent for PUR synthesis is the chain extender. The reaction of a 
diisocyanate with a polyol usually produces a soft polymer with a low molecular weight. A 
chain extender, which may be a diol or a diamine with lower molecular weight with respect to 
long chain diols, can be added in order to produce a higher molecular weight PUR. A 
polyurethane-urea is obtained if a diamine is used, while if a diol is used a polyurethane is 
produced (see figure 2.2). The chain extender may be added and react after the low molecular 
weight PUR (prepolymer) formation (two steps synthesis) or in a single step with the 
diisocyanate and the macrodiol (one step synthesis). 
 
 
 
 
Fig. 2.2 Two steps synthesis of polyurethane and polyurethane-urea.  
 
 
The properties of the final PUR are primarily dependent on the chemical nature (type of diol, 
diamine, or diisocyanate) of these three building blocks, and the relative proportions used 
during synthesis [4]. In tables 2.1 and 2.2 are collected the most common macrodiols and 
diisocyanates used. 
isocyanate hydroxyl group urethane
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Table 2.1 Typical macrodiols for PUR synthesis. 
Name Chemical Structure 
  
 
 
Table 2.2 Typical diisocyanates for PUR synthesis. 
Name Chemical Structure 
  
 
 
 
2.1.2 Phase segregation of PURs 
 
Hydrogen bonding can occur between the isocyanate-derived groups (urethanes and ureas) of 
different polymeric chains. Because of these bonds and the differences in polarity between the 
segments, PURs can undergo microphase separation to form hard, pseudo-crystalline domains 
and soft domains [5] (see figure 2.3). The soft domains of PURs are generally composed of 
long chain polyols and result amorphous and elastomeric at room temperature because the 
glass transition temperature is below room temperature. PURs can exhibit rubber-like 
behavior since the hard domains, made of  segments resulting from the linking of 
diisocyanates and chain extender molecules,  act as physical crosslinks that fix each soft 
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segment at its two ends and thus prevent the chains from flowing apart when they are 
stretched under applied stress. Without flow, the stretched polymer segments can then 
reshape elastically when stress is released [6].  
 
 
 
Fig. 2.3 Microphase separation of PURs 
 
Unlike chemical crosslinks, these physical crosslinks are not thermally stable. Subject to 
sufficient heat treatment, the semi-crystalline hard phase can be melted as for any other 
thermoplastic polymer. Consequently, segmented PURs are typical thermoplastic elastomers, 
exhibiting rubber-like mechanical properties and thermo-plastic characteristics.  
 
 
2.1.3 Biocompatibility of PURs 
 
The biocompatibility of several type of PURs has been widely studied both in vitro and in 
vivo for a wide range of applications, from durable medical devices (such as vascular catheters, 
the total artificial heart and small diameter vascular grafts for artificial reconstruction or bypass 
surgery) [3] to biodegradable implants for tissue engineering [6].  
The cell types used to assess the biocompatibility of PURs in vitro are often fibroblasts and 
endothelial cells, which are among the most commonly used cell types for cytotoxicity tests of 
biomaterials. Other types of cells used include specific types of leukocytes, as well as specific 
epithelial cells depending on the targeted site of implantation (e.g., skin, blood vessel, 
tympanum and cornea [4]). In general, PURs are recognized to have good biocompatibility, 
maintaining sufficient cell adhesion and proliferation rates in vitro [7], however this short-term 
cytocompatibility (several days) does not assure a longer-term efficacy and safety of PURs in 
vivo (weeks to months).  
While PURs were recognized in the 1970s and 1980s as stable materials for blood contact, and 
had been applied in a wide range of cardio-vascular devices  [3, 8], their application in long-
term implants fell under discussion because of the failure of pacemakers and breast implants 
[9]. The biological toxicity of degradation products of PURs was also investigated. Aromatic 
diisocyanates (e.g., 4,4-methylenediphenyl diisocyanate (MDI) and toluene diisocyanate (TDI)) 
revealed as potentially source of carcinogenic by-products of PUs [10]. As a consequence, 
aliphatic diisocyanate such as lysine diisocyanates (LDI) and 1,4-diisocyanatobutane (butyl 
diisocyanate, BDI), have often replaced the use of aromatic diisocyanates [11] for the synthesis 
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of biodegradable PURs. These polymers exhibit better blood and tissue compatibility, showing 
no adverse tissue reaction both in vitro and in vivo in comparison to those made using 
aromatic [2].  
 
 
2.1.4 Degradability of PURs 
 
As mentioned, PURs were traditionally developed as long-term implant materials, and many 
attempts were made to create formulations resisting to biodegradation processes [3]. Since the 
late 1990s attempts have been made to enhance the biodegradability of PURs for applications 
in tissue engineering [12]. The susceptibility of biodegradable PURs lies in macrodiol 
components of the polymer, which is generally a polyester. They are degraded by hydrolytic 
mechanisms (see figure 2.4) and have been made with varied molecular structure to allow 
controlled hydrolysis rates. 
 
 
 
Fig. 2.4 Scheme showing the sites of attack and possible by-products following breakdown of l-lysine-based 
poly(ester-urethane) by hydrolysis [1]. 
 
Along with hydrolysis of ester bonds, several degradation mechanisms have been identified in 
PURs including oxidation, environmental stress cracking (ESC) and enzymatic degradation 
[13]. (i) Environmental stress cracking: Poly(ether urethane) materials are susceptible to a 
degradation phenomenon involving crack formation and propagation. This micro-cracking 
phenomenon is probably due to residual polymer surface stress, which may have been 
introduced during fabrication process. (ii) Oxidation: Implanted poly(ether urethane) devices 
containing metallic components have been subject to bulk oxidation, catalyzed by the aqueous 
ionic environment of the implant site. (iv) Enzymatic degradation: PUR degradation can also 
take place because  of water soluble enzymes present in the physiological environment. While 
most enzymes have evolved with highly specific affinities for particular biological substrates, 
some appear capable of recognizing and acting upon no specific substrates, including synthetic 
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PURs. (iv) Mineralization/calcification: Calcification (deposition of calcium-containing apatite 
minerals) has also been reported to occur in cardiovascular and non-cardiovascular medical 
devices. Calcification is the leading macroscopic cause of failure for most prosthetic heart 
valves and blood pumps, limiting the functional lifetime of the device by loss of elasticity in 
the PUR parts [1]. Among these mechanisms, ESC, oxidation and calcification show evident 
effects only after a long-term implantation of several years. For biodegradable PURs, which 
are designed to degrade in a relative short period (several months), the main degradation 
mechanisms are hydrolysis with or without the enzymatic catalysis [14]. As shown in figure 2.4, 
ester linkages have been believed to hydrolyze both in vitro and in vivo, yielding hydroxy-acid 
degradation products, as well as urethane and urea fragments with terminal acid groups [14]. 
The further degradation of urethane and urea fragments to free polyamines is currently under 
discussion. For lysine-derived polyisocyanates, hydrolysis of urethane linkages to lysine has 
been reported [15].  
 
 
2.1.5 Biodegradable PURs for Tissue Engineering 
 
Polyurethanes for tissue engineering applications and drug delivery systems are designed to 
undergo faster or modulated hydrolytic degradation to non cytotoxic decomposition products 
in vivo. A very common strategy for achieving biodegradation of PURs is to incorporate a 
polyester macrodiol that hydrolyzes in vitro and in vivo, such as poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA) [16] and polycaprolactone (PCL). Poly(ester urethane ureas) 
(PEUUs) synthesized from 1,4-diisocyanatohexane (BDI) and PCL have been reported to be 
completely resorbed in rats after only 12 weeks [17]. Biodegradation of PURs can be tuned by 
enhancing degradation of hard segments through the incorporation of a chain extender that is 
recognizable by enzymes [18, 19]. In PUR elastomers having Alanine-Alanine-Lysine (AAK) 
peptide as chain extender, the linkage between two alanine units can be cleaved by a specific 
elastase. PURs synthesized from the AAK chain extender have shown a significantly faster 
degradation with respect to those synthesized from a putrescine chain extender, with no 
cytotoxic products [19].  
 
 
2.1.6 Thermal properties and processability of PURs 
 
While chemical crosslinking makes materials insoluble and unable of being further shaped by 
heat and pressure, physically crosslinked PUR elastomers have a good processibility [20], since 
they can be easily melted around 50 °C. They can be fabricated into different shapes, such as 
fibers, sheets, and highly porous scaffolds by a number of techniques, such as extrusion [21], 
wet spinning [22], electrospinning [23, 24], thermally induced phase separation [25] and salt 
leaching/freeze-drying [26, 27]. Depending on the particular fabrication technique, different 
porosities, surface-to-volume ratios and three dimensional structures may be obtained. 
Consequently,  modulation in mechanical properties can be achieved to meet the requirements 
of a wide range of tissue engineering applications, including repair of cardiovascular, muscular 
and neuronal tissue. 
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2.2.7 Polyurethane synthesis and scaffold fabrication in the present work 
 
In this chapter the synthesis and characterization of poly(ester urethanes) and poly(ether ester 
urethanes) biodegradable biomaterials for MTE scaffolds are described. The proposed 
formulations are based on poly(ε-caprolactone) (PCL) and poly(ethylene glycol) (PEG) as 
macrodiols, 1,4-diisocyanatobutane (BDI) as diisocyanate component, L-Lysine Ethyl Ester 
and Alanine-Alanine-Lysine as chain extenders. PCL was selected since it can confer 
biodegradability to the final PUR, while PEG was added in low amounts to tune mainly 
wettability, mechanical and biological properties of the final constructs. BDI was chosen 
because it is an aliphatic diisocyanate, which is used due to its corresponding, non-toxic, 
biodegradation products [2].  
Amino acids-based chain extenders were used for their biocompatibility. Alanine-Alanine-
Lysine peptide was selected especially to tune biodegradability properties, since, as it has been 
discussed previously, the Alanine-Alanine sequence may be cleaved by the elastase enzyme.  
The obtained polymers were processed into films and tridimensional porous scaffolds. The 
latter were prepared by the Thermally Induced Phase Separation technique, with the 
application of a thermal gradient. It allows the formation of oriented stretched pores with a 
resulting anisotropic structure that confers to the substrates a remarkable similarity to the 
streaked muscle tissue [28].  
 
 
2.2 Materials and methods  
 
2.2.1 Polyurethane synthesis 
 
PURs were synthesized through a two steps procedure [29, 30]. Poly(ε-caprolactone) diol 
(Polysciences, Mw=1250 g/mol) and Poly(ethylene glycol) (Sigma-Aldrich, Mw=1500g/mol) 
were used as macrodiols and dissolved in 1,2-dichloethane (DCE, Sigma-Aldrich). The 
solution was azeotropically dried by refluxing under nitrogen over molecular sieves. 1,4-
diisocyanatobutane (BDI, Aldrich) was reacted (2:1 molar ratio) with the macrodiols in 
presence of the catalyst (Dibutyltindilaureate, Fluka) to form the prepolymer. At the end of 
this first step (150 min, 80°C), the chain extender (L-Lysine Ethyl Ester (Sigma-Aldrich) or 
AAK (Advanced ChemTech) and Lysine Ethyl Ester 50/50), was dissolved in anhydrous 
DCE with Triethylamine (TEA, Sigma-Aldrich) and added at 1:1 molar ratio with respect to 
macrodiols at room temperature. Chain extension reaction was stopped after 16 hours by the 
addition of methanol (MeOH, Sigma-Aldrich). The polymers were collected by precipitation 
in petroleum ether (Sigma-Aldrich) and purified by dissolution in dimethylformamide (DMF, 
Sigma-Aldrich) followed by precipitation in methanol. The obtained powder was dried under 
vacuum at 40°C for 72h. 
The code name used for PCL-based PURs is XBC1250-type, where X, B, C1250 respectively 
indicate: the chain extender (K for Lysine ethyl ester and A for Alanine-Alanine-Lysine/ 
Lysine 50/50), the diisocyanate (BDI), the macrodiol (PCL) and its molecular weight (1250 
g/mol). For PCL-PEG based PURs the code name is KBC1250-E1500-N’-type, where E1500 
corresponds to the PEG macrodiol and its molecular weight (1500 g/mol), while N’ indicates 
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the weight percentage of PEG with respect to PCL mass. Codes and compositions of all 
synthesized PURs have been reported in table 2.3. 
 
Tab. 2.3 Polyurethanes Composition 
PURs CODES PEG Mw(g/mol) % PEG w/w Chain Extender 
KBC1250 - - Lysine Ethyl Ester 
KBC1250-E1500-10 1500 10 Lysine Ethyl Ester 
KBC1250-E1500-20 1500 20 Lysine Ethyl Ester 
ABC1250 - - Lysine Ethyl Ester/Alanine-Alanine-Lysine 
 
 
2.2.2 Polymer characterization and processing 
 
PURs were chemically characterized through ATR-IR (Attenuated Total Reflection Infrared 
Spectroscopy) by using a Perkin Elmer Spectrum 100 equipped with an ATR attachment 
(UATR KRS5) with Diamond crystal.  
Number average molecular weights (Mn) and molecular weight distributions (Mw/Mn) of PURs 
were measured by Size Exclusion Chromatography (SEC) using an Agilent Technologies 
instrument (1200 Series) equipped with a RI detector and two Waters styragel columns at 
35°C. The measurements were performed using Tetrahydrofuran (THF, Sigma-Aldrich) as 
eluent (0.4 ml/min) and narrow polystyrene standards for calibration.  
Thermal characterization was performed by Differential Scanning Calorimetry (DSC), using a 
TA Instrument DSC Q20. The thermal curves were obtained heating samples from -60°C to 
150°C under nitrogen flow, cooling from 150°C to -60°C and heating again from -60°C to 
150°C, with 10°C/min heating/cooling rate. For PCL based PURs the crystallinity grade has 
been calculated from DSC first cycle curves, through the formula: 
 
C% = (ΔHm ∙ 100)/(w ∙ ΔH°m) (1) 
 
Where ΔHm is the heat of fusion of the material, ΔH°m is the heat of fusion of the starting 
PCL diol (70,7 J/g) and w is the PCL weight fraction in the copolymer [31]. 
Films of the synthesized PURs were obtained by hot pressing and mechanically characterized 
in triplicate by stress-strain tests, performed by using a MTS QTest/10 Elite Controller. The 
displacement rate was 10 mm/min and the load limit of the sensor was 500 N. Static Contact 
Angle measurements were carried out on films (three points for each sample) in order to study 
their hydrophylicity, by a KSV INSTRUMENT CAM2000 and water as test liquid (5 μl of 
drop volume). 
 
Hydrolytic and Enzymatic degradation tests  
 
Hydrolytic and enzymatic degradation tests with Elastase (from porcine pancreas, Sigma 
Aldrich) were carried out on square 0.3 mm thick films of ABC1250 and KBC1250 as control. 
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Hydrolytic and enzymatic tests with Lipase (from porcine pancreas, Sigma Aldrich) were 
performed on both square 0.3 mm thick films and square 1 mm thick scaffolds of KBC1250. 
Both degradation tests were carried out at 37°C. The samples were placed in vials containing 
0.1 ml of phosphate buffer (PBS, pH = 7.6)/mg of PUR (hydrolytic tests) and 0,3 mg of 
enzyme/ml of PBS solution (enzymatic tests). 
The degradation medium was renewed every 3 days and three samples were taken once a week 
(for five weeks), washed with distilled water and then vacuum dried at 40°C for three days.  
At every time interval, % weight loss of the specimens was evaluated according to the 
formula:  
 
% weight loss = [(W0-W)/W0] x100 (2) 
 
where W0 is the initial weight of the sample, while W is its weight after degradation, at a 
particular time interval. 
 
Scaffold preparation and characterization 
 
Polyurethanes were processed in scaffolds by Thermally Induced Phase Separation (TIPS) 
according to the following procedure. The polymers were dissolved in dimethyl sulfoxide 
(DMSO, Sigma-Aldrich) (7% w/v) at 80°C. The solutions were poured in parallelepiped 
stainless steel molds (55mm x 20mm x 25mm) and quenched at -80°C for 3h. The frozen 
solutions were then washed in ethanol/water (90/10 v/v) for 5 days and finally lyophilized. In 
order to obtain scaffolds with oriented pore structures, a thermal gradient was applied during 
the freezing-phase of  TIPS [28]. 
The resulting microstructures were characterized by Static Contact Angle measurements, by 
the same instrument and test parameters used for PUR films, and Scanning Electron 
Microscopy (SEM), by a LEO 1420 microscope (Zeiss). Stress-strain tests were performed 
using the MTS QTest/10 Elite Controller. The displacement rate was 10 mm/min and the 
load limit of the sensor was 500 N. 
Image data were imported into ImageJ software for analysis. The average pore size was 
obtained by measuring the maximum and minimum diameter of 20 pores chosen at random 
throughout the central section of the samples. 
 
Cell viability (MTS assay) 
 
Cell viability tests were performed on films and scaffolds (1 x 1 cm2), that were previously 
sterilized through immersion in ethanol/water (70/30) solution and UV treatment (10 min), 
using a rat heart cell line (H9C2cardiomyoblasts). Cells were cultured in DMEM (Dulbecco's 
Modified Eagle Medium, Gibco) enriched with 10% fetal bovine serum (FBS), glutamine 
(2mM), penicillin (100 U/ml) and streptomycin (100 µg/ml) (Euroclone, Italy). Cells were 
maintained at 37° C in a humidified atmosphere with 5% CO2 and used at 10
5 x cm2 on the 
samples’ surfaces. To evaluate cell viability, MTS assay was performed (CellTiter 96® 
Aqueous Non-Radioactive Cell Proliferation Assay, Promega, Italy). It is a colorimetric assay 
for measuring cellular metabolic activity via NAD(P)H-dependent cellular oxido-reductase 
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enzymes that reduce the tetrazolium dye, MTS, to its insoluble formazan, giving a purple color 
with an absorbance maximum at 490-500 nm in phosphate-buffered saline.  
Cells were cultured on the different surfaces for 24 and 72h. A MTS solution was added to the 
culture medium. After 3h, the culture medium was removed and the solution was read in UV-
VIS spectroscopy (V-630 UV-Vis Spectrophotometer, Jasco, USA) at 490 nm. The 
absorbance was directly proportional to viable cells amount. Cells seeded on cell culture Petri 
dishes were used as positive control. 
 
Western Blot (Vinculin, Myf5, PCNA) 
 
H9C2 cardiomyoblasts were cultured for 24 and 72 hours on different materials. Culture 
medium was then discarded and a lysis solution (SDS 2.5%, Tris-HCl pH 7.4, 0.25 M in 
bidistilled water) was placed on the different samples. Cell proteins were quantified through 
BCA assay (Thermo Scientific, USA). For electrophoresis, 10 μg of total proteins were used. 
Samples were diluted with Laemmli reducing buffer (60 mM Tris-Cl pH 6.8, 2% SDS, 10% 
glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue), and electrophoresed on 7.5% 
sodium dodecylsulfate polyacrylamide gels (SDS-PAGE). The proteins were blotted onto 
nitrocellulose membranes. The membranes were incubated for 1 h in 5% blocking solution 
(non-fat dry milk in PBS), then incubated overnight with 1:500 dilution of primary antibodies 
(Vinculin – Calbiochem, USA-, PCNA and Myf5 – Millipore, Italy), followed by incubation 
with appropriate secondary antibody HRP-conjugated (Perkin-Elmer). Proteins were detected 
by Western Lightning plus-ECL (Perkin-Elmer, USA), and protein bands were then visualized 
by Bio-Rad VersaDoc™ imaging system.  
Statistical Analysis 
 
Data obtained from stress-strain tests, contact angle measurements and cell viability test were 
investigated for statistical significance using one-way analysis of variance (ANOVA). A p-value 
less than 0.05 was considered significant. 
 
 
2.3 Results and discussion 
 
2.3.1 Polyurethane synthesis 
 
All PURs formulations were successfully synthesised, as demonstrated by ATR-IR 
spectroscopy. The spectra of the polyurethanes are reported in Figure 2.5. The peak 
observable in the region between 1630 and 1640 cm-1 corresponds to the stretching of the 
urethane C=O (amide I) and the peak at 1530 cm-1 represents N-H bending vibrations (amide 
II), which indicates the formation of urethane linkages. The absorption at 1721cm-1 represents 
the stretching of the carboxyl group (C=O) due to ester groups.  
The N-H stretching of the urethane group can be observed at 3330 cm-1. The absorption at 
1106 cm-1 can be ascribed to the stretching of the C-O-C linkage of both urethane and ether 
groups. This peak is more intense for KBC1250-E1500-20 due to the higher PEG content 
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into this polymeric formulation. The spectra of ABC1250 showed a broad peak in the region 
of the N-H bending (amide I): multiple signals overlapped, due to the absorption of peptide 
groups (at higher frequencies) and urethane groups (at lower frequencies). 
 
 
 
 
Fig. 2.5 FT-ATR spectra of KBC1250, KBC1250-E1500-10, KBC1250-E1500-20 and ABC1250. 
 
Average numeral molecular weights (Mn) and polydispersity indexes (Mw/Mn) of the 
synthesised polymers, obtained by SEC analysis, are collected in Table 2.4. 
 
Tab. 2.4 Polyurethane average numeral molecular weights (Mn) and polydispersity indices (Mw/Mn) 
PURs Mn ×103 (g/mol) Mw/Mn 
KBC1250 20 1.6 
KBC1250-E1500-10 41 1.3 
KBC1250-E1500-20 43 1.2 
ABC1250 41 1.7 
 
 
2.3.2 Thermal and mechanical properties of the synthesized PURs 
 
DSC characterization showed different thermal properties for the PURs obtained. The 
thermograms of the samples are compared in Figure 2.6 a (first cycle) and 2.6 b (third cycle) 
together with the curves of the PCL diol. Experimental data are collected in Table 2.5.  
The first heating cycle shows a broad exothermic peak between -50°C and 0°C for all the 
compositions. This transition could be attributed to a cold crystallization, due to the 
rearrangement of the amorphous regions into a crystalline phase during heating [32]. These 
crystallization temperatures (Tc) decrease by increasing PEG content. This trend could be 
linked to the presence of PEG blocks: with increasing PEG amount, polymeric chains become 
more flexible and able to crystallize or rearrange themselves at lower temperatures. For mixed 
PCL-PEG based PURs, melting peaks appear lower and broader with respect to KBC1250. 
Broad peaks are the result of crystals with different sizes, since polyurethane chains have a 
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more irregular chemical structure because of the presence of PEG segments. However, all the 
samples show two melting peaks in the first heating cycle, due to the presence of two different 
crystalline domains for PCL segments. The existence of these two domains appears clear in 
the first heating cycle of the PCL diol alone, containing two well defined melting peaks at 36 
and 55°C. In the third cycle, all the samples (except PCL diol) show one melting peak, 
probably because the fast cooling and heating do not allow the rearrangement of the polymer 
chains into two crystalline phases . 
The cristallinity grade of KBC1250 and ABC1250 was calculated using formula (1), starting 
from their overall melting enthalpies in the first cycle (26 and 21 J/g, respectively). The result 
was 53% for KBC1250 and 41% for ABC1250. The cristallinity grade was not calculated for 
the mixed PCL-PEG based PURs because the formula applied in the calculation does not take 
into account the possible contribution of PEG segments in the formation of crystalline 
domains. Glass transitions cannot be observed because they are outside of the range 
considered (Tg of the oligomeric PCL diol is at -70.3 °C [33]). 
 
 
 
 
 
 
 
 
Tab. 2.5 PUR Crystallization and melting temperatures 
PURs 
Tc(°C) Tm(°C) 
I cycle III cycle I cycle III cycle 
KBC1250 -5 15 36 56 42 
KBC1250-E1500-10 -19 -2 20 63 36 
KBC1250-E1500-20 -24 - 21 48 36 
ABC1250 -16 6 31 57 40 
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(a) 
 
(b) 
 
Fig. 2.6 DSC curves of the synthesised PURs: (a) I cycle, (b) III cycle. 
 
PUR films were characterized by stress strain tests and results are collected in Table 4. All the 
curves, shown in Figure 2.7, present a typical elastic behaviour up to 20% of strain 
approximately, followed by a short plastic deformation. An increase in the stress response can 
be observed, probably due to the strain-induced crystallization of the macrodiols [34]. This 
behaviour is marked for the PURs containing PEG. 
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Data in Table 2.6 show that the polymers have Young Moduli encompassing from 7 to 14 
MPa and the elastic modulus decreases with increasing PEG content. The stress-strain curves, 
shown in Figure 3, and the histograms, shown in Figure 4, highlight that  the maximum stress 
and the corresponding strain increase with increasing PEG content. In detail, the statistical 
analysis (one-way ANOVA) showed that there are significant differences on elastic moduli for 
KBC1250 and KBC1250-E1500-20, KBC1250-E1500-10 and KBC1250-E1500-20 (p<0.05). 
In addition, the differences on stress values are all significant, while those on % strain are not 
significant for KBC1250 and KBC1250-E1500-10, and KBC1250 and ABC1250. 
These results demonstrate the possibility of tuning the mechanical properties of PURs by 
slightly varying the PEG content. 
 
Tab. 2.6 Experimental mechanical data of the synthesized PURs. 
PURs Young Modulus (MPa) Average Max Stress (MPa) Average Max % Strain 
KBC1250 14.3 ± 1.1 5.0 ± 0.4 515± 81 
KBC1250-E1500-10 12.2 ± 1.6 9.9 ± 1.0 596 ± 90 
KBC1250-E1500-20 7.2 ± 1.8 16.9 ± 0.9 1081 ± 84 
ABC1250 9.4 ± 1.5 2.0 ± 0.3 453± 80 
 
 
 
 
 
 
 
 
 
Fig. 2.7 Stress-strain curves of PURs. 
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Fig. 2.8 Comparison of mechanical parameters of the KBC-series of PURs. 
 
 
2.3.3 Surface properties of PUR films 
 
Contact angle measurements, whose results are collected in Table 2.7, demonstrated a low 
hydrophobicity for all the polyurethane films. No significant differences in contact angle can 
be observed between KBC1250, KBC1250-E1500-10 and KBC1250-E1500-20, probably due 
to the low difference in the PEG content.  
 
Tab. 2.7 Contact Angle values for PUR films. 
PUR FILMS Contact Angle (°) 
KBC1250 78 ± 2 
KBC1250-E1500-10 81 ± 2 
KBC1250-E1500-20 81 ± 1 
ABC1250 94 ± 1 
 
Nevertheless, after about one month of film ageing at room temperature in air, a significant 
decrease in contact angle value has been observed, particularly for mixed PCL-PEG PURs, 
that reached a contact angle vale of about 40°. The observed increase in hydrophilicity is 
probably due to a slow process of surface segregation, typical of multiconstituent systems, 
such as polyurethanes, characterized by the presence of a two-microphase structure with 
regions enriched in either hard or soft segments. This phase separation generates a dynamic 
system that tends to segregate on the surface the lowest surface energy component in order to 
decrease the surface energy [35]. A second contribute to this change in hydrophilicity could be 
given by another typical process for polyurethanes: water adsorption from air, which causes 
the hydrolysis of ester bonds in the polymeric chain and a slow surface degradation [36]. 
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2.3.4 Enzymatic (elastase) and hydrolytic degradation tests 
 
The results obtained by the elastase degradation test, carried out on ABC1250 and KBC1250 
films, are shown in Figure 2.9. After the first week of incubation, where no degradation effects 
were observable for both samples, ABC1250 exhibited a progressive weight loss, up to about 
5% after 5 weeks. KBC1250, used as control, showed a more constant weight loss of about 
2% during the whole degradation test. These data reveal a significant effect of the presence of 
the AAK peptide introduced into the PUR backbone on the enzymatic degradation behaviour. 
Guan and co-workers obtained 2-25% weight loss for similar polyurethane films having 100% 
AAK peptide in the chemical composition in analogous enzymatic degradation tests (elastase 
concentration 0,3 mg/ml) [19]. Our results demonstrate that the replacement of 50% AAK 
peptide with Lysine in the PUR backbone leads to a fine tuning of the enzymatic degradation 
behaviour, resulting in a plain slowing down of the degradation process.  
 
 
 
Fig. 2.9 Weight loss of ABC1250 and KBC1250 films in PBS with 0,3 mg/ml elastase. 
 
 
2.3.5 Morphological, thermal and mechanical properties of the scaffolds 
 
Based on the observations that KBC1250-E1500-20 showed the mechanical properties closest 
to those required for the perspective application (the lowest Elastic Modulus and the highest 
Maximum % Strain), this polymer was selected to prepare porous scaffolds. Scaffolds with 
KBC1250 were also prepared as reference for materials without PEG.   
SEM micrographs of the scaffolds produced by TIPS are collected in Figure 6. The 
longitudinal and cross sections showed a porous microstructure characterized by long and 
stretched pores. The pores are oriented in one direction in accordance to the thermal gradient 
applied during the quenching step of scaffolds preparation. The resulting anisotropic structure 
(Figure 6a and 6c) seems to mimic the striated muscle tissue. Guan and colleagues reported 
that a similar structural biomimicry promotes adhesion and proliferation of muscle cells [28]. 
SEM micrographs elucidated also differences in the porous structures of the two materials. 
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The scaffold fabricated from KBC1250 has interconnected porosity and pores of 98 ± 14 μm 
(see Figure 2.10 a and 2.10 b), while the scaffold obtained by the PCL-PEG based PUR is 
characterized by well aligned tubes with smooth walls and pore size of 15 ± 2μm (see Figure 
6c and 6d). The formation of these two micro-architectures could be linked to the different 
molecular weight of the two formulations (20000 g/mol for KBC1250 and 43000 g/mol for 
KBC1250-E1500-20), as observed also by other authors [37]. However, they can promote 
different processes: it is known that large pores favour cell colonization, cell migration and 
nutrients supply, while small pores (tens μm) can promote vascularization [38, 39]. 
 
 
  
(a) (b) 
  
  
(c) (d) 
 
Fig. 2.10 SEM images of: longitudinal (a) and cross (b) sections of KBC1250 and longitudinal (c) and cross (d) 
sections of KBC1250-E1500-20. 
 
Thermal and mechanical properties of the prepared scaffolds have been evaluated. For both 
KBC1250 and KBC1250-E1500-20 scaffolds, the first heating cycle is characterized by a 
melting peak at 58 and 55°C, respectively (see Table 2.8 and Figure 2.11). In the third cycle a 
melting peak is observable at lower temperatures and a very low crystallization peak is present 
for KBC1250 scaffold. In the third cycle the thermal behavior of processed and non-
processed materials result similar (see Figure 2b) as a consequence of thermal history removal. 
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Tab. 2.8 Scaffold crystallization and melting temperatures. 
PUR 
SCAFFOLDS 
Tc(°C) Tf (°C) 
I cycle III cycle I cycle III cycle 
KBC1250 - -7 58 37 
KBC1250-E1500-20 - - 55 36 
 
 
(a) 
 
(b) 
 
Fig. 2.11 DSC curves of KBC1250 and KBC1250-E1500-20 based scaffolds: (a) I cycle, (b) III cycle. 
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DSC characterization revealed satisfactory thermal properties for the porous scaffolds, 
because they both show melting temperatures significantly higher than the physiological 
temperature. This aspect has to be taken into account since the mechanical performance of 
the myocardial patch can be affected by the melting or softening of parts or domains of the 
materials.  
The crystallinity grade for KBC1250, which was calculated by the enthalpies in the first 
heating cycle (ΔHm= 45J/g), is 90%. It is much higher than the crystallinity percentage 
obtained for non porous KBC1250 (40%, see Table 3). This significant difference is probably 
due to the high level of order of the polymeric chains in the scaffold microstructure, where 
they tend to align to form long oriented pores, as a consequence of the thermal treatment 
during TIPS. 
Tensile tests were performed on scaffolds along the direction of the stretched pores. As 
shown in Figure 2.12, the resultant Stress-Strain curves present an initial elastic deformation, 
followed by a plastic behavior.  
 
Tab. 2.9 Experimental mechanical data of the prepared PUR scaffolds. 
PUR 
SCAFFOLDS 
Young Modulus 
(MPa) 
Average Max Stress  
(MPa) 
Average Max % Strain 
KBC1250 2,8 ± 0,9 0,6 ± 0,2 155 ± 56 
KBC1250-E1500-20 1,6 ± 0,3 0,3 ± 0,1 126 ± 25 
 
 
 
Fig. 2.12 Stress strain curves of KBC1250 and KBC1250-E1500-20 based scaffolds. 
 
The statistical analysis showed that there are no significant differences on the elastic modulus, 
and stress and strain behaviour for  the two scaffolds. Therefore, the addiction of a low 
percentage of PEG seems not to significantly affect the mechanical behaviour of the porous 
substrates, where the higher influence on mechanical performance is probably given by the 
similar microstructure with respect to the chemical compositions of the polymers. 
It is known that a heart patch should be able to mimic the mechanical behaviour of 
myocardial tissue and to withstand the strain due to cardiac beating [40-44]. The stiffness 
(Young Modulus) of myocardial tissue was evaluated in the range 10–20 kPa at the beginning 
and 200–500 kPa at the end of diastole, and the stress and strain at break respectively in the 
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ranges 3-15 kPa and 22-90% [45-48]. As a consequence, an ideal heart patch should be 
characterized by Young Moduli encompassing from tens of kPa to 1 MPa and by an 
elastomeric mechanical behaviour, able to withstand the contractile and expansive forces 
originated during the cardiac cycle [49]. Based on these considerations, proposed scaffolds 
seem to be suitable as cardiac patches, even though characterized by a lower elastic modulus, 
maximum stress and strain with respect to the corresponding films (see Table 4 and 7). Their 
elastic response corresponds to about 20% of deformation, maximum stress and strain are 
significantly higher than stress and strain at break of the myocardium and elastic moduli are 
closer to that of native tissue. 
 
 
2.3.6 Surface properties of scaffolds 
 
As shown from data collected in Table 2.10, PUR scaffolds are more hydrophobic with 
respect to the corresponding films (see Table 2.7). Several authors showed that submicron 
roughness makes an inherently hydrophobic material highly hydrophobic [50, 51]. This higher 
hydrophobicity can be attributed also to the scaffold higher crystallinity and aligned fiber-like 
structure. The correlation between crystallinity and wettability was observed for other types of 
polymeric materials by Pittman [52] and Areias [53]. In particular, Areias also observed the 
increase of surface hydrophobicity with increasing fiber orientation of poly(L-lactide) 
electrospun mats, which suggests that the orientated long tubes of PUR scaffolds can produce 
a similar effect. 
In addition, a significant hydrophilicity increase (p<0.05) for the scaffold based on the PUR 
containing PEG is observable, probably as a results of material transformation following the 
TIPS procedure. The formation of scaffold microstructure takes place in DMSO and the 
following washings are made with a solution of ethanol and water. The contact of the material 
with these polar solvents could induce a sort of segregation of the polar PEG segments on the 
exposed surfaces of the porous structure.  
 
Tab. 2.10 Contact Angle values for PUR scaffolds. 
PUR SCAFFOLDS Contact Angle (°) 
KBC1250 137 ± 2 
KBC1250-E1500-20 123 ± 2 
 
 
2.3.7 In vitro biological characterization of films and scaffolds  
 
Results of viability tests (MTS), performed with H9C2 rat heart cells (Figure 2.13), showed 
unaltered cell viability after 24 hours with respect to the control when seeded on porous and 
dense KBC1250. After 72 hours porous KBC1250 showed a significant increased cell viability 
with respect to the control and the other samples (p<0.0001). 
These results are in agreement with the observation [38, 39] that interconnected 
microstructure with pore sizes of about 100 µm can favor cell colonization. An opposite trend 
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was observed for KBC1250-E1500-20 film and its porous scaffolds. While cell viability on 
KBC1250-E1500-20 films was acceptable and only slightly decreased with respect to control, 
cells showed a significantly decreased viability after both 24 and 72 hours seeding on porous 
scaffolds. KBC1250-E1500-20 scaffold microstructure is characterized by very small pores 
that probably inhibit H9C2 cell attachment and proliferation. In this case the high 
hydrophobicity of the sample is not compensated by a suitable microstructure for cell 
adhesion.  
The increased cell viability after 72 hours indicated the cell ability to proliferate on all the 
samples with duplication rates comparable to control, with the exception of porous 
KBC1250-E1500-20. 
 
 
Fig. 2.13 Results of viability MTS tests performed on KBC1250 film and porous scaffold, KBC1250-E1500-20 
film and porous scaffolds using H9C2 rat heart cell line. 
 
Results from Western Blot are shown in Figure 2.14. Vinculin expression has been evaluated 
after 24h and 72h of cell culture on different materials. After 24h all samples displayed no 
significant changes in the expression of the adhesion protein when compared to the control. A 
significant up-regulation has been shown on porous KBC1250. The study conducted by Arai 
and co-workers demonstrated the existence of a correlation between substrate pore size and 
cardiac myocytes response [54]. They considered honeycomb-patterned substrates with 
subcellular, cellular and overcellular pore sizes. The best results in terms of cellular adhesion 
and spreading were obtained with overcellular pores, probably because cells are forced to 
stretch along the edges of the pores. If we consider that myocardial cells have typically 
dimensions encompassing from 10 to 100 µm [55][43], we can hypothesize that the larger 
pores of KBC1250 can favor cardiomyocytes attachment. However, in this work, Western 
Blot data show that after 72h, both porous materials revealed superior cell compatibility 
(stable cell adhesion) with respect to the corresponding films, and displayed vinculin 
expression comparable to control.  
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Concerning cell differentiation through a contractile phenotype, Myf5 protein expression has 
been analyzed. After 24h and 72h porous KBC1250 enhanced the contractile ability, while in 
all the other cases Myf5 expression resulted comparable to the control.  
Eventually, cell proliferation has been evaluated by PCNA expression. These data confirmed 
the cell viability data showing that KBC1250-E1500-20 inhibited cell proliferation when 
compared to both control and KBC1250 surfaces. However, the unaltered expression of 
adhesion and differentiation proteins demonstrated the presence of viable cells on all the 
studied surfaces. 
 
 
Fig. 2.14 Results of Western Blot performed on KBC1250 film and porous scaffold, KBC1250-E1500-20 film 
and porous scaffolds using H9C2 rat heart cell line. 
 
The presence of PEG in the polyurethane composition seems not to show any positive effect 
on film and porous scaffold biocompatibility, indicating that H9C2 adhesion and proliferation 
are not strictly affected by substrate hydrophobicity.  
 
 
2.3.8 Lipase and hydrolytic degradation of KBC1250 films and scaffolds 
 
Degradation properties of KBC1250 films and scaffolds in presence of lipase enzyme were 
investigated, since lipases are a subclass of esterases, which catalyze the hydrolysis of ester 
bonds in lipids. Hydrolytic degradation of the polymer was taken as control. 
As shown in figure 2.15 a and b,  weight loss during enzymatic degradation appears faster and 
more pronounced with respect to hydrolytic degradation, for both dense and porous 
KBC1250. These results were expected, since  KBC1250 is characterized in its polymeric 
chains by polyester (PCL) blocks that are susceptible to lipase activity. 
If results of hydrolytic degradation of dense and porous constructs are compared (see figure 
2.16 a), weight loss of films appears faster than weight loss of porous scaffolds. The opposite 
can be observed in the case of lipase degradation of KBC1250 films and scaffolds. As shown 
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in figure 2.16 b, a more pronounced weight loss after 2 weeks takes place for the porous 
sample, with respect to its corresponding film. This different behavior between dense and 
porous constructs in both degradation processes, could be due the different mechanism of 
hydrolytic and enzymatic degradation. Generally PCL has a mass hydrolytic degradation while 
a surface one in presence of an enzyme [56]. If we consider that KBC1250 has PCL blocks in 
its polymeric chains, a mass degradation process can be hypothesized in PBS solution, while a 
surface mechanism in lipase solution. Probably hydrolytic degradation is slower for porous 
samples because the mass mechanism is delayed by the “hydrophobic effect” of the scaffolds, 
while lipase degradation is faster for these type of constructs since they exhibit a larger 
amount of surface area, allowing for a more intense surface degradation process.  
 
 
 
 
(a) 
 
(b) 
 
Fig. 2.15 Weight loss of KBC1250 films (a) and scaffolds (b) in PBS with 0,3 mg/ml lipase. 
 
 
(a) 
 
(b) 
 
Fig. 2.16 Weight loss of KBC1250 film and porous scaffold after  hydrolytic (a) and lipase (b) degradation. 
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2.4 Conclusions 
 
The chemical, thermal and mechanical characterizations of the synthesized PURs clearly 
indicate the successful preparation of new polymeric materials with the desired physical-
chemical properties for myocardial TE applications. 
In addition, polymers could be easily processed in dense films and porous scaffolds. The latter 
showed a microstructure with elongated and unidirectional pores, which conferred to the 
substrates a remarkable similarity to the streaked muscle tissue. A "structural biomimicry", one 
of the key requirements for applications of biomaterials in tissue engineering, was achieved. 
Concerning thermal properties, porous substrates showed melting temperatures well above 
the physiological one, an important aspect for implantable devices.  
Mechanical tests have revealed that, although KBC1250-E1500-20 showed the mechanical 
properties closest to those required for cardiac repair, all the dense films have elastomeric 
behavior, high toughness and appropriate values of elastic modulus. Porous devices showed 
mechanical properties lower than the corresponding films that however do not hinder their 
potential application as heart patches, since they keep an elastomeric behavior with mechanical 
parameters very close to the required ones. 
In addition, although a fine tuning and control on mechanical (films) and surface properties 
(scaffolds) was obtained by introducing PEG segments in PUR polymeric chain, this effect 
was not completely reflected in an improvement of cell behavior as measured by biological 
tests. Both porous structures, with and without PEG segments, showed a good biological 
response in terms of cardiomyoblast adhesion. Nevertheless, the best response in terms of cell 
viability was registered for dense and porous KBC1250 substrates, with a higher value for the 
porous structure, as it is expected in view of the morphological features that are known to 
better perform in in vitro cell culture tests [18]. Hydrolytic and lipase degradation tests showed 
a different behavior for dense and porous KBC1250, with a faster weight loss for the scaffold 
in the presence of the enzyme.  
Finally, elastase degradation tests demonstrated the possibility to finely tune biodegradation 
rate of PURs through a partial introduction of an enzyme-target peptide as chain extender.  
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CHAPTER 3 
Surface modification of polyurethane films and scaffolds 
 
 
Abstract 
 
Materials and their constructs used as bioartificial tissues should not just be passively tolerated 
by the cells but should actively promote specific cell responses, acting as analogous of the 
natural ECM. To improve cell adhesion to biomaterials, a suitable method consists in 
functionalizing their surface by grafting pro-adhesive ligands, corresponding to the amino acid 
active sequences of the adhesion ECM proteins, such as fibronectin and laminin. In this part 
of the work, RGD peptides were covalently attached, following plasma assisted activation, to 
the surfaces of PUR films and scaffolds, in order to promote cardiomyocyte adhesion. ATR-
IR and XPS spectroscopy, Static Contact Angle measurements and chemical quantification 
methods were used to verify the success of peptide grafting. The evaluation of the biological 
properties of the modified surfaces, that was performed by MTS assay and SEM micrographs, 
demonstrated that the presence of RGD sequences on PUR films promoted cell adhesion and 
viability. A significant peptide-effect on cell viability was not observed for porous constructs, 
although vinculin expression was slightly higher on modified scaffolds with respect to the 
unmodified ones.  
 
 
3.1 Introduction: modification of biomaterial surfaces 
 
The interactions between cells and their environments are mediated by the “bio-recognition 
processes”, that consist in specific binding of the receptors on cell surface with their 
corresponding ligands, as it will be thoroughly described in section 3.1.2. In native tissues in 
vivo, cells attached on the extracellular matrix (ECM) are mediated by the binding between 
integrins (receptors on cell surfaces) and ECM adhesion proteins such as fibronectin, 
vitronectin, laminin and collagen. In addition to the function of a physical support, native 
ECM regulates cell behaviors by presenting various kinds of growth factors to the cells. On 
biomaterial surfaces, the same mechanisms also take place. When foreign materials come into 
contact with body fluid or cell culture medium, the initial response is protein adsorption on 
the materials‟ surfaces [1]. 
Therefore, the materials interact with the cells through the adsorbed protein layer. The 
composition and structure of this protein layer play a critical role in determining subsequent 
cell behaviors. Based on the understanding of the biorecognition process on cell behaviors, 
two main strategies in surface engineering of biomaterials are considered. Firstly, the material 
surface properties such as chemical composition, hydrophilicity/hydrophobicity (wettability), 
surface charge and roughness, etc. are modulated to allow the adsorbed proteins to maintain 
their normal conformation and bioactivity [1]. Particular attention is given to surface 
wettability, which is generally measured as the contact angle between the material surface and 
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a liquid [2]. A low contact angle (<90°) between the material and water indicate good 
spreading of water on the material surface (hydrophilicity of the material), while a high water 
contact angle (>90°)  is a sign of an hydrophobic material surface.  
Synthetic polymers used in biotechnologies and in medicine are usually too hydrophobic in 
their pristine state, showing water contact angles of about 100° or more and resulting 
unsuitable for cellular colonization. If the material is too hydrophobic, proteins which are 
spontaneously adsorbed to the materials from the culture media, blood and other body fluids, 
acquire a denatured and rigid state and the resulting conformation is inappropriate for binding 
to cells, because specific sites (e.g. RGD-containing oligopeptides) are less accessible to cell 
adhesion receptors (e.g. integrins). On the other hand, on highly hydrophilic surfaces cell 
attachment and spreading is limited or completely disabled. Highly hydrophilic surfaces bind 
proteins with weak forces, which could lead to their detachment especially at later culture 
intervals, when they bind a large number of cells. An optimal cell adhesion occurs only to 
moderately hydrophilic surfaces [3]. The wettabilty of polymeric surfaces can be modulated by 
physical methods, e.g. by irradiation by ions, plasma or ultraviolet light. These methods are 
safer than chemical methods, since they are not associated with potential retention of 
cytotoxic chemicals and their subsequent release from the material [4] [5]. This method, 
however, cannot induce specific cell behaviors due to the nonspecific protein absorption.  
The second strategy is to directly immobilize certain biomolecules on the biomaterial surfaces 
to induce specific cellular responding. Biomolecules attachment can also be performed 
through an initial physical treatment of the biomaterial surface. 
 
 
3.1.1 Plasma technique 
 
Plasma state can be considered as a high energy state of matter, in which a gas is partially 
ionized into charged particles, electrons, and neutral molecules due to high energy radiation or 
strong electric field. Plasma states can be divided in two main categories: hot plasmas (near-
equilibrium plasmas) and cold plasmas (non-equilibrium plasmas). Hot plasmas are 
characterized by very high temperatures of electrons and heavy particles, both charged and 
neutral, and they are close to 100% degree of ionization. Cold plasmas are composed of low 
temperature particles, such as charged and neutral molecular and atomic species, and relatively 
high temperature electrons and they are characterized by low degrees of ionization (less than 
10%). Hot plasmas include electrical arcs, plasma jets of rocket engines, thermonuclear 
reaction generated plasmas, etc. while cold plasmas include low-pressure direct current (DC) 
and radio frequency (RF) discharges (silent discharges), discharges from fluorescent (neon) 
illuminating tubes and corona discharges [6]. 
DC, RF, or microwave (MW) power of low-pressure non-equilibrium discharges (cold plasmas) 
is transferred to a low-pressure gas environment, with or without an additional electric or 
magnetic field. Ultimately, all these discharges are initiated and sustained through electron 
collision processes under the action of the specific electric or electromagnetic fields. 
Accelerated electrons (energetic electrons) induce ionization, excitation and molecular 
fragmentation processes leading to a complex mixture of active species, which undergo 
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recombination processes in the presence or absence of the plasma. The recombination 
reaction mechanisms are very different from those for conventional chemical processes [6]. 
High frequency (RF) plasmas can be electrodeless or electrode discharges with capacitive or 
inductive coupling configurations. In the case of electrodeless discharges, the electrodes are 
not in contact with the plasma gas and are usually located outside the plasma chamber. The 
reaction chambers employed in these cases are manufactured using nonporous insulating 
materials (e.g. glass, quartz, ceramics). Electrode discharge chambers are usually grounded, 
metallic containers where the power is transferred to the plasma gas by electrodes inserted 
into the discharge chamber through insulating, vacuum-tight, metal/ceramic feed-throughs [6]. 
 
 
Fig. 3.1 A schematic diagram showing a capacitively coupled RF-plasma reactor and the interaction of plasma 
species with the substrate [6]. 
 
RF discharges gained their name from the frequency range, which is employed to produce the 
plasma (RF band: 1 kHz–1 GHz). Although these plasmas have been investigated over the 
entire frequency range, most of the RF-installations use the standard 13.56 MHz frequency (or 
its harmonies) in order to avoid interference with communication networks. These discharges 
usually are characterized by low degrees of ionization, and operate in relatively high pressure 
environments (10–500 mTorr); they are non-equilibrium plasmas and are often called glow 
discharges. A schematic diagram of a capacitively coupled RF-plasma reactor, and the 
interaction of plasma species with the substrate are presented in figure 3.1. RF-plasmas are the 
most common choice for the microelectronic industry, since they have several advantages 
with respect to DC discharges: they can operate at lower pressures and their ionization 
mechanism is more efficient [6]. 
 
 
3.1.1.1 Plasma for biomaterials 
 
Plasma surface treatments are attractive for biomaterials thanks to: (i) their ability of changing 
surface chemistry and material properties in a controlled way; (ii) their inherent sterility; (iii) 
the possibility to modify the “final” substrates (webs, tubes, fabrics etc)  [7]. 
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The idea of employing non-equilibrium plasmas to improve biomaterial performances was 
applied first in the early 1970s [8, 9]. Since then, low-pressure plasma deposition (plasma 
enhanced chemical vapor deposition, PE-CVD), treatment (grafting of chemical 
functionalities, cross-linking) and etching processes have been widely used, and can now be 
considered as mature technologies for biomedical applications. Several processes, that employ 
radio- (RF, mainly 13.56 MHz) rather than audio-frequency (kHz) or microwaves (GHz), have 
been imported from microelectronics or developed ex novo, in order to improve the 
biocompatibility of several implantable devices, such as vascular prostheses, heart valves, 
intra-ocular and contact lenses, catheters and sensors [7]. The plasma is able to exert mainly 
four effects: (i) surface cleaning, (ii) surface ablation or etching, (iii) surface crosslinking, and 
(iv) modification of the surface chemical structure. Recently, plasma has also be optimized to 
transfer geometric micro-patterns at the surface of biomedical polymers, with the aim of 
driving the behavior of cells in tissue engineering (see section 3.1.2) [7].  
From a chemical point of view, the interaction between the ionized or high energy particles 
and the material surface leads to the cleavage of C-C and C-H bonds present in the polymer 
chains. Consequently, macromolecules split and free radicals and conjugated double bonds are 
generated on the polymer chain. The resultant radicals and functional groups may react with 
the oxygen (if present in the chamber atmosphere) and create oxidized structures, e.g. 
carbonyl, carboxyl and ester groups, which increase the polarity and wettability of the polymer 
surface [10]. Oxygen plasma is often used to impart oxygen containing functional groups to 
polymer surfaces such as poly(ε-caprolactone) (PCL), poly(ethylene glycol) (PE), and 
poly(ethylene therephthalate) (PET). In addition to oxygen, carbon dioxide plasma has been 
used to introduce carboxyl groups on polypropylene (PP), polystyrene (PS) and PE, and air 
plasma has been used to oxidize poly(methyl methacrylate) (PMMA). Ammonia and nitrogen 
plasmas have been used to impart amine groups to the surface of poly(tetrafluoro ethylene) 
(PTFE) and PS, respectively. Inert gases can be used to introduce radical sites on the polymer 
surface for subsequent graft copolymerization [10]. 
Plasma can provide modification of the top nanometer of a polymer surface without using 
solvents or generating chemical waste and with less degradation and roughening of the 
material than many wet chemical treatments. The type of functionalization imparted can be 
varied by selection of plasma gas (Ar, N2, O2, H2O, CO2, NH3), as just described, and 
operating parameters (pressure, power, time, gas flow rate) [10]. 
 
 
3.1.2 Micro- and nano-patterning  
 
During the last decade, surface micro- and nano-patterning became a very important and 
promising approach to affect cell behaviors on biomaterial surfaces. Micro- or nano-scaled 
surface patterns, either topographic or chemical ones, seem to have significant influence on 
cell behaviors in terms of cell shapes and migration, protein synthesis and gene expressions [1]. 
Several methods exist for patterning molecules and polymers with different chemical domains 
and/or topographic (tracks, grooves, pits, etc.) or random features; highly resolved lithography 
(e-beam, scanning probe microscopy) can develop nanometric features, while „soft‟ 
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lithography (microcontact printing, embossing, casting) and other techniques can pattern 
polymers at a micrometric scale [1].  
The topographic surface pattern produced on a silicon wafer can be easily replicated onto a 
polymeric material surface to form regular physical topographies. Grooves and ridges are 
among the most studied topographical patterns related to cell morphology control, since 
microgroove/ridge surfaces have shown significant control over cellular behaviors. Cell 
spreading, alignment, and migration can be oriented along these grooves/ridges. One theory 
that accounts for these phenomena is called “contact guide effect”, in which cell integrin 
receptors in focal contact transfer the variable degrees of tension or compression into the 
cytoskeleton, and cell stretch receptors subject to these stresses will be activated and 
reorganize the cytoskeleton according to the surface topography [11]. The cellular response to 
the surface topographies is also influenced by the dimensions of the surface features, ranging 
from nano, submicron to micro-scales, depending on the cell types, cell-cell interaction, as 
well as substrate composition and topography type [1].  
Besides physical topography patterns, chemical patterns were also fabricated to affect cell 
behaviors. Microcontact printing (μCP) developed by Whitesides‟s group enables translation 
of topographic surface patterns to chemical surface patterns on biomaterial surfaces [12]. 
Typically, a siloxane stamp with desired physical surface patterns is coated with a solution 
containing the substance to be printed, such as adhesion proteins. By contacting the stamp 
and the substrate, the substance can be printed on the substrate with the same patterns of the 
siloxane template. The patterning of proteins using μCP on biomaterial surfaces is an effective 
approach to control cell adhesion, spreading, orientation, and to obtain cell micropatterns. 
Different chemical domains (hydrophilic/hydrophobic, acid/base, fouling/non-fouling) can 
be created at the surface of polymers by means of plasma processes performed through 
„physical masks‟, that are micron-thick polymer or metal foils where a proper pattern is drilled 
(e.g. by laser techniques). When properly positioned (close contact) at the surface of the 
polymer under modification, and utilized with selected plasma processes, physical masks allow 
to transfer their pattern with the best reported resolution of a few microns [7]. As an example, 
Favia and co-workers combined the plasma process with the use of a copper grid (mask or 
stencil) to develop cell adhesive tracks alternated with non-fouling (PEO-like coatings) 
domains at the surface of polystyrene (PS) substrates. A first plasma process (H2 followed by 
NH3 plasma treatment) was applied to the substrates, then the masks were applied, finally a 
PEO-like non-fouling coating was plasma-deposited. The effect of the patterns and of the 
different chemical domains was evaluated on cellular adhesion, spreading and growth. 
Keratinocytes adhered and grew aligned along the uncoated PS zones corresponding to the 
border and the bars of the mask, while the wider PEO-like areas were free from cells [7].  
 
 
3.1.3 Surfaces modified with RGD peptides  
 
In multicellular organisms contacts of cells with neighboring cells and the surrounding ECM 
are mediated by cell adhesion receptors. The integrins are the most numerous and versatile 
adhesion receptors. They play an important role also in processes like embryogenesis, cell 
differentiation, immune response, wound healing and haemostasis [13] [14]. Integrins consist 
81 
 
of two non-covalently associated transmembrane subunits, called α and β (see figure 3.2). To 
date, 18 α and 8 β subunits are known, that form 24 different heterodimers [15]. The 
combination of the particular α and β subunits determines the ligand specificity of the integrin. 
Some integrins, however, are highly promiscuous,  binding to vitronectin, fibronectin, von 
Willebrand factor, osteopontin, tenascin, bone sialoprotein and thrombospondin. Vice versa, 
ECM molecules like fibronectin are ligands for several integrins [15]. 
The tripeptide RGD was identified 18 years ago by Pierschbacher and Rouslahti as the 
minimal essential cell adhesion sequence in fibronectin [16]. Then, RGD sites were identified 
in many other ECM proteins, including vitronectin, fibrinogen, von Willebrand factor, 
collagen, laminin, osteopontin, tenascin and bone sialoprotein as well as in membrane proteins, 
in viral and bacterial proteins, and in snake venoms. However, RGD sequence is not the 
„„universal cell recognition motif‟‟, but it is nevertheless unique with respect to its broad 
distribution and usage. The conformation of the RGD containing loop and its flanking amino 
acids in the respective proteins are mainly responsible for their different integrin affinity [17].  
 
 
Fig. 3.2 Cell adhesion mechanism to the ECM. 
 
The process of integrin mediated cell adhesion involves a sequence of four partly overlapping 
events [18]: cell attachment, cell spreading, organization of actin cytoskeleton, and formation 
of focal adhesions. In the initial attachment step the cell contacts the surface and some ligand 
binding occurs that allows the cell to withstand gentle shear forces. Secondly, the cell body 
begins to flatten and its plasma membrane spreads over the substratum. Thirdly, actin 
organization into microfilament bundles occurs. In the last step the formation of focal 
adhesions takes place, which link the ECM to molecules of the actin cytoskeleton. Clustered 
integrins and more than 50 other transmembrane, membrane associated and other cytosolic 
fibronectin
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citoskeleton
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molecules are involved in focal adhesion (tetraspanins, growth factors receptors, syndecans, 
lipids, tensin, talin, vinculin, paxillin, and focal adhesion kinase) [19-21]. 
It is well established that integrin-mediated cell spreading and focal adhesion are crucial for 
cell survival and proliferation [22]. On the other hand, loss of attachment may cause apoptosis 
in many cell type (“anoikis”). It can be even induced in the presence of immobilized ECM 
molecules when non immobilized soluble ligands (such as RGD peptides) are added [23-25]. 
While immobilized ligands act as agonists of the ECM, leading to cell adhesion and survival, 
non-immobilized ones act as antagonists, leading to cell detachment , a round shape and 
apoptosis. 
Since RGD peptides have been found to promote cell adhesion in 1984 [26], numerous 
materials have been RGD functionalized for academic studies or medical applications. 
Nevertheless, RGD peptides do not only trigger cell adhesion but can also be used to address 
selectively certain cell lines and promote specific cell responses [27]. 
In the last decades researchers attempted to functionalize polymers to obtain specific cell 
surface interactions. They started to experiment coatings with cell adhesive proteins like 
fibronectin, collagen, or laminin [28-30]. However, the use of proteins bears some 
disadvantages in the view of medical applications. At first the proteins have to be isolated 
from other organisms and purified, increasing the risk of undesirable immune responses and 
infections [27]. In addition, proteins are object of proteolytic degradation and needed to be 
refreshed continuously and inflammation and infection can even accelerate this degradation 
[27]. Furthermore, only a part of the proteins have proper orientation for cell adhesion [31] 
and surface properties may influence their conformation and/or the orientation [32]. As 
already stated, on hydrophobic surfaces proteins are generally subjected to denaturation, since 
they tend to maximize interaction with hydrophobic amino acid side chains [27]. Most of the 
described problems can be overcome by using the single cell recognition motifs as small 
immobilized peptides. They show higher stability towards sterilization conditions, heat 
treatment and pH-variation [33], storage [34] and conformational shifting as well as easier 
characterization and cost effectiveness [35]. In addition, while ECM proteins contain normally 
several different cell recognition motives, small peptides represent only one single motif, 
which may selectively address one particular type of cell adhesion receptors. Sometimes linear 
peptides are subjected to slow enzymatic degradation while cyclic peptides are known to 
exhibit high long time stability [27]. 
 
 
3.1.3.1 Immobilization of RGD peptides on biomaterial surfaces 
 
Stable linking of RGD peptides to a biomaterial surface is essential to promote strong cell 
adhesion, since formation of focal adhesions occurs if the ligands withstand the cells 
contractile forces. Weakly adsorbed ligands lead only to weak fibrillar adhesions and cells can 
remove mobile integrin ligands by internalization [27]. 
Therefore, RGD peptides should be covalently attached to the polymer, e.g. via functional 
groups like hydroxyl-, amino-, or carboxyl groups. Since these functional groups are not 
present in all polymers, they have to be introduced by blending, co-polymerization, chemical 
or physical treatment. 
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Concerning co-polymerization, one example is given by the introduction of the RGD 
sequence into a polyurethane (PUR) backbone [36, 37]. This bulk modification has two 
disadvantages: only a small fraction of the peptides can be detected by cells on the device 
surface and the sequences may be fixed in a conformation that is less active in integrin binding. 
As a consequence, a surface attachment is often preferred. It can be achieved by chemical and 
physical treatment, e.g. alkaline hydrolysis, reduction, oxidation, track-etching, or plasma 
deposition [27]. 
In most cases RGD peptides are linked to polymers via a stable covalent amide bond. This is 
usually done by reacting an activated surface carboxylic acid group with the nucleophilic N-
terminus of the peptide. Carboxylic acid groups may be generated grafting acrylic acid 
olygomers in a plasma chamber and can be activated by using a peptide coupling reagent, e.g. 
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC, also referred to as water soluble 
carbodiimide, WSC), dicyclohexyl-carbodiimide (DCC) or carbonyl diimidazole (CDI). Two 
problems may arise by this coupling method. Firstly, there are other reactive functional groups 
in the RGD peptide, such as carboxyl groups at the C-terminus and in the aspartic acid side 
chain and the nucleophilic guanidino group of the arginine side chain (see figure 3.3). 
Secondly, the coupling reagent and the activated carboxyl groups can be deactivated quickly by 
hydrolysis [27]. 
 
 
 
Fig. 3.3 The RGD molecular formula and nomenclature [27]. 
 
One possibility to overcome these problems is to block the reactive amino acid side chains 
with protecting groups and to use other solvents than water (e.g. DMF, dichloromethane or 
acetone). A significant drawback of this strategy is the need of harsh conditions to remove the 
protecting groups [27]. Alternatively coupling of unprotected RGD peptides in water can be 
employed by a two step procedure: first, activation of the surface carboxyl group as an active 
ester, that is less prone to hydrolysis, e.g. N-hydroxysuccinimide (NHS) esters in presence of 
EDC, and second coupling of the peptide in water (see figure 3.4) [38]. 
Best conditions for coupling the RGD peptide to the NHS active ester are pH 8–9 in 
phosphate or sodium bicarbonate buffer with a reaction time of 1–2 h. More elevated pH 
values and high concentrations of buffer or salts can reduce the half lifetime of the NHS 
active ester down to less than 1 min. Following this protocol there is no need for protecting 
groups, since in the two step procedure, the aspartate side chain carboxyl group is not 
activated for coupling, and due to protonation in water the nucleophilicity of the arginine side 
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chain is nearly abolished [27]. In some cases coupling was performed at lower pH and/or 
lower temperatures with longer coupling times resulting in higher yields. A yield increase can 
be obtained also with an excess of the peptide [39, 40].  
 
 
 
Fig. 3.4 Coupling of unprotected RGD peptides in water 
 
 
3.1.3.2 RGD modified surfaces in Myocardial Tissue Engineering 
 
The influence of the presence of adhesion proteins, such as fibronectin and laminin, on 
biomaterial surfaces for myocardium repair, has been widely investigated [41-43]. Although 
the influence of their surface micropatterning on cell response [44, 45] has been less studied, 
the promising results obtained and the discover on the bioactive properties of some ECM 
proteins-derived peptides has incited MTE researchers to modify biomaterials with cell 
binding domains, especially those based on the RGD sequence. In 2001 Rowley and co-
workers (as already described in Chapter 1) covalently modified alginates of varying 
monomeric ratio with RGD based ligands through carbodiimide chemistry in order to 
promote cell adhesion to these polymers. They investigated  a range of surface density (1-100 
fmol/cm2) on alginate substrates and observed that C2C12 skeletal myoblast proliferation and 
differentiation could be tuned by varying RGD density and the alginate monomeric ratio [46]. 
More recently, Shachar and colleagues also studied a macroporous alginate scaffold 
functionalized with RGD motif as substrate for cardiac repair. The immobilized RGD peptide 
promoted cell adhesion and prevented cell apoptosis. In addition, it accelerated cardiac tissue 
regeneration, since, within 6 days, the cardiomyocytes reorganized their myofibrils and 
reconstructed myofibers composed of multiple cardiomyocytes in a typical myofiber bundle. 
The non-myocyte cell population (cardiofibroblasts) also benefited from the presence of RGD 
modified matrix and consequently supported the cardiomyocytes [47]. 
The group of Schussler functionalized a collagen porous scaffold with RGDS peptide for 
MTE applications through a hetero bifunctional cross-linker reagent (Sulfosuccinimidyl 6-[3-
(2-pyridyldithio)-propionamido] hexanoate). They analyzed cardiomyocites contractile 
performance, viability and differentiation and observed an increased viability and a good cell 
contractile apparatus for RGDS scaffolds, with cross-striation of cardiac myocytes (not found 
in the control constructs) [48]. 
Guan and colleagues surface modified biodegradable polyurethane films using radio frequency 
glow discharge followed by coupling of RGDS with glutaraldehyde [49]. They tested 
endothelial cell adhesion on pristine surfaces and on RGDS-modified surfaces. It revealed 
higher  (>140% and >200%, respectively) with respect to tissue culture polystyrene.  
The work of Guan is an optimal starting point for a study on RGD surface modification of 
PURs for myocardial tissue engineering. The need to investigate RGD surface effects on 
PURs arises from the consideration that these polymers are suitable candidates for contractile 
EDC H2N-RGD
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tissue regeneration (especially when processed into porous structures), due to their finely 
modulated elastomeric and degradability properties. Their biocompatibility has been proved, 
too [50, 51]. Nevertheless, it is fundamental and crucial their chemical functionalization, in 
order to stimulate specific cardiomyocites and stem cells response. 
 
 
3.1.4 Surface Modification in the present work 
 
Based on the results obtained mainly by the biological characterization of PUR films and 
scaffolds (as discussed in Chapter 2), KBC1250-based dense and porous constructs were 
selected for a biochemical surface modification. In detail, RGD functionalization was 
performed in order to improve biocompatibility of the constructs and promote cell adhesion 
and proliferation. An initial plasma treatment was carried out to graft acrylic acid oligomers. 
Their terminal acidic carboxylic groups were activated in order to allow the subsequent 
covalent attachment of the peptide, trough the formation of an amide bond. On PUR films 
RGD was attached both homogenously and with a linear micropattern, in order to investigate 
its effect on cardiomyocytes response, in terms of adhesion and viability.  
 
 
3.2 Materials and methods 
 
3.2.2 Surface modification by Radio Frequency Plasma 
 
Plasma treatment was performed in two phases in a RF plasma reactor (Diener electronic - 
Plasma Surface Tecnology, Germany) on KBC1250 films and scaffolds. During the first phase, 
an Argon plasma, which was performed for 5 min with a gas pressure of 0.7 mbar, was used 
to produce active radicals on material surfaces, which were necessary for the subsequent graft 
copolymerization of acrylic acid monomers. During the second phase, a plasma treatment was 
performed in presence of acrylic acid vapours (from distilled liquid) for 15 min with a gas 
pressure of 0.1 mbar, to allow the formation of a poly (acrylic acid) (PAA) layer on the surface 
of the samples. Films and scaffolds were then washed 3 times with distilled water to remove 
any unreacted monomer. 
 
 
3.2.3 RGD attachment 
 
PAA grafted polyurethane constructs were placed in an aqueous solution with 5 mg/ml of 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, Sigma Aldrich) and 1,25 mg/ml of N-
hydroxysuccinimide (NHS, Sigma Aldrich) (pH 5.0) at 4 °C for 20 h, to activate the carboxyl 
acidic groups of the grafted PAA chains. Films and scaffolds were than washed 3 times with 
distilled water and dried in vacuum oven at 50°C for 24 h. 
After activation reaction, the samples were immersed into a Phosphate Buffer Saline Solution 
containing RGD peptide (Creo Salus, USA) 1 μM  for 2 h at ambient temperature. A siloxane 
stencil, which was fabricated through Soft Lithography by Ing. Gianni Orsi from University of 
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Pisa, was applied during RGD reaction on one film (2 x 5 cm2), in order to create a linear 
chemical micropattern on film surface. This mask contains siloxane strips 100 μm wide at 50 
μm intervals (see Figure 3.5). As a consequence, RGD lines should be 50 μm wide. 
All samples were finally washed several times with distilled water and dried in vacuum oven at 
50°C for 24 h. 
 
Fig. 3.5 Schematic structure of the siloxane mask that was used to create a linear RGD micropattern on film 
surface. 
 
 
3.2.4 Modified surface characterization 
 
Modified constructs were chemically characterized through ATR-IR (Attenuated Total 
Reflection Infrared Spectroscopy) by using a Perkin Elmer Spectrum 100 equipped with an 
ATR attachment (UATR KRS5) with Germanium crystal. KBC1250 films were also analyzed 
by XPS (X-Ray Photoelectron Spectroscopy), using a PHI 5000 Versaprobe. 
Variations in surface wettability after plasma treatments and RGD attachment were evaluated 
through Static Contact Angle measurements using a KSV INSTRUMENT CAM2000 and 5 μl 
of water drop volume. 
Quantification of the acidic COOH groups on PAA modified surfaces were carried out by 
Toluidine colorimetric assay (TBO). In detail, samples(1 x 1 cm2) were immersed into 0.05 
mM TBO aqueous solution (pH 10). The formation of ionic complexes between COOH 
groups and the cationic dye was allowed to proceed for 12 hours at room temperature. The 
samples surface was rinsed with 0.1 mM NaOH solution to remove the unbound TBO 
molecule. The bonded TBO was desorbed by incubation in 50% acetic acid solution (2 ml) for 
10 min. The absorbance at 632,8 nm was recorded by a UV–vis spectrophotometer 
(PerkinElmer, Lambda 25). The amount of carboxyl groups was calculated by referring to a 
calibration curve from 0,005% wt/v to 0.0035% wt/v of TBO/acetic acid solution (50%/50%) 
recorded at the same conditions. The calculation was based on the assumption that 1 mol 
TBO corresponds exactly with 1 mol carboxyl groups. 
 
 
 
Fig. 3.6 Reaction of Nynhydrin with amino groups, resulting in a purple compound. 
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Quantification of the attached RGD was performed by Kaiser Test, that is based on 
Nynhydrin reaction with NH2 terminal groups of the peptides, that leads to the formation of a 
purple compound (see Figure 3.6).  
In detail, the Kaiser reagents were added to squared samples (1 x 1 cm2) of functionalized 
films and scaffolds in the following order and amounts: 75 μl of Phenol, 100 μl of KCN, 75 μl 
of Ninhydrin. The mixture was heated at 95°C for 5 min and then diluted with ethanol/water 
60/40 v/v. The obtained solution were filtered by using GHP membrane filters (pores 
diameter 0,45 μm) in order to avoid light scattering phenomena, due to the presence of 
polymer particles inside the solution, that can cause a significant shift of the baseline during 
the UV test. The maximum absorbance (A) of the Kaiser product was observed at 570 nm. 
The measurements were taken over three replicate samples and then averaged. Starting from 
the averaged absorbance value, the molar extinction coefficient ε (15000 M-1 cm-1) and the 
path length b (1 cm), the molar concentration of the diluted solution was obtained through 
Lambert Beer low:  
 
 
From this molar concentration and the final volume (after dilution), the number of RGD 
moles on surface samples was calculated.  
 
Cell Viability (MTS assay)  
 
Cell viability tests were performed on functionalized and not functionalized films and 
scaffolds (1 x 1 cm2), using H9C2 cardiomyoblasts, as described in Chapter 2. Briefly, cells were 
cultured in DMEM (Dulbecco's Modified Eagle Medium, Gibco) enriched with 10% fetal 
bovine serum (FBS), glutamine (2mM), penicillin (100 U/ml) and streptomycin (100 µg/ml) 
(Euroclone, Italy). Cells were maintained at 37° C in a humidified atmosphere with 5% CO2 
and used at 105 x cm2 on the samples‟ surfaces. MTS assay (CellTiter 96® Aqueous Non-
Radioactive Cell Proliferation Assay, Promega, Italy) was used to evaluate cell viability. Cells 
were cultured on the different surfaces for 1, 3 and 7 days. A MTS solution was added to the 
culture medium. After 3h, the culture medium was removed and the solution was read in UV-
VIS spectroscopy (V-630 UV-Vis Spectrophotometer, Jasco, USA) at 490 nm. Cells seeded on 
cell culture Petri dishes were used as positive control. 
 
Cell adhesion (SEM and Western Blot) 
Cell adhesion was qualitatively investigated through SEM micrographs after 1 and 3 day 
culture on dense samples, while through the evaluation of vinculin expression (Western Blot) 
on scaffolds. 
H9C2 cardiomyoblasts were cultured for 7 days on the porous constructs. Culture medium was 
then discarded and a lysis solution (SDS 2.5%, Tris-HCl pH 7.4, 0.25 M in bidistilled water) 
was placed on the different samples. Cell proteins were quantified through BCA assay 
(Thermo Scientific, USA). For electrophoresis, 10 μg of total proteins were used. Samples 
were diluted with Laemmli reducing buffer (60 mMTris-Cl pH 6.8, 2% SDS, 10% glycerol, 5% 
β-mercaptoethanol, 0.01% bromophenol blue), and electrophoresed on 7.5% sodium 
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dodecylsulfate polyacrylamide gels (SDS-PAGE). The proteins were blotted onto 
nitrocellulose membranes. The membranes were incubated for 1 h in 5% blocking solution 
(non-fat dry milk in PBS), then incubated overnight with 1:500 dilution of primary antibodies 
(Vinculin – Calbiochem, USA), followed by incubation with appropriate secondary antibody 
HRP-conjugated (Perkin-Elmer). Proteins were detected by Western Lightning plus-ECL 
(Perkin-Elmer, USA), and protein bands were then visualized by Bio-Rad VersaDoc™ 
imaging system.  
 
Statistical Analysis 
 
Data obtained from MTS assay were investigated for statistical significance using one-way 
analysis of variance (ANOVA). A p-value less than 0.05 was considered significant. 
 
 
3.3 Results and Discussion 
 
3.3.1 Characterization of functionalized films 
 
3.3.1.1 ATR-IR and XPS 
 
ATR-IR spectroscopy and XPS demonstrated that surface modification of KBC1250 films 
was obtained successfully. In figure 3.7 ATR spectra of the pristine film, the sample modified 
with PAA and that after RGD attachment are collected. For PAA-KBC1250, an enlargement 
of the intense band at about 1720 cm-1 is observable. In detail, a shoulder, that is not present 
in KBC1250 spectrum and that can be ascribable to the presence of COOH functional 
groups, appears on the right side of this band. In RGD-PAA-KBC1250 spectrum, a peak at 
1656 cm-1, that is ascribable to the stretching of peptide bonds, indicates the presence of RGD 
sequences covalently attached to the PUR surface. The spectrum registered for the sample 
functionalized with the linear chemical micropattern is not reported, since it does not show 
the diagnostic peptide peak. This could be explained with the lower amount of RGD groups 
on PUR surface (see 3.3.1.3 section: “COOH and NH2 quantification”). 
 
 
Fig. 3.7 ATR-IR spectra of KBC1250, PAA-KBC1250, RGD-PAA-KBC1250 films. 
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(a) 
 
(b) 
 
Fig. 3.8 XPS spectra of KBC1250 (a) and RGD-PAA-KBC1250 (b) films. 
 
  
(a) (b) 
 
Fig. 3.9 Deconvolution of the carbon peak in XPS spectra of KBC1250 (a) and RGD-PAA-KBC1250 (b) films. 
 
 
NH-COO
5,48%
C-O-C
11,42%
C-C-C
83,09%
NH-COO
3,74%
C-O-C + O=C-N
23,27%
C-C-C
73,09%
90 
 
XPS spectra of KBC1250 and RGD-PAA-KBC1250 are reported in figure 3.8. The validation 
of the peptide functionalization of films was obtained by the analysis of the atomic surface 
composition and  of the carbon peak in both spectra. An increase of 0.5% of N amount is 
observable passing from the pristine PUR to the modified one (figure 3.8). By the 
deconvolution of the carbon peak, three contributions may be detected: the main peak at 284 
eV corresponds to aliphatic carbon atoms, that at 286 eV identifies carbon atoms linked to 
oxygen with ether bonds, while the one at 289 eV corresponds to carbon atoms involved in 
urethane functional groups (figure 3.9 a). For the functionalized surface, a redistribution of the 
areas of the different contribution is observable. In detail, there is an increase of 11% of the 
peak at 286 eV, that is associated to carbon atoms involved in both urethane and peptide 
bonds (figure 3.9 b) [52].  
 
 
3.3.1.2 Surface wettability 
 
The evaluation of wettability variation after plasma and RGD modification confirmed the 
successful surface functionalization. As it is possible to see in table 3.2, acrylic acid grafting led 
to a decrease of the contact angle value of about 44°, while RGD covalent attachment 
determined an increase of about 30° with respect to the PAA-KBC1250. The final contact 
angle value achieved (65°) indicates a moderate hydrophylicity for the modified surface and it 
is very close to 55°, that seems to be the optimal value to obtain the maximum  cell adhesion 
and growth, regardless of the cell type [3]. 
 
Tab. 3.2 Contact Angle values for pristine KBC1250, PAA- and RGD-PAA-KBC1250 films. 
PUR FILMS Contact Angle (°) 
KBC1250 79 ± 1 
PAA-KBC1250 35 ± 2 
RGD-PAA-KBC1250 65 ± 2 
 
 
3.3.1.3 COOH and NH2 groups quantification 
 
Acidic and amino groups were quantified after plasma treatment and RGD reaction, 
respectively. Through Toluidine assay (TBO) a density of 0.003 μmol/mm2 for COOH 
functional groups on dense samples was obtained. This density value was considered for the 
subsequent calculations of EDC and NHS amounts, in order to activate all the acidic groups. 
Nevertheless, RGD amounts for the subsequent reaction was calculated  considering that a 
density of 0,01 fmol/mm2  was reported as the minimum value for cell adhesion [53] and 
1,5x10-3-0,2 nmol/mm2 seems to be the optimal range for focal adhesion of fibroblasts [54].  
An RGD surface density of 3.2 and 1.7 nmol/mm2 was calculated through the Kaiser test for 
the homogenously modified sample and for that modified with a linear micropattern, 
respectively. These results indicate that the minimum density value to promote cell adhesion 
was exceeded and values very close to those suggested for fibroblasts adhesion were obtained. 
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However, since data in literature about the optimal RGD density to promote cardiomyocyte 
adhesion were not found, an investigation on the ideal conditions for the focal adhesion of 
this type of cells are necessary as future work. 
 
 
3.3.1.4 Cell viability and adhesion on functionalized films   
 
MTS assay was performed to quantify cardiomyocyte viability on functionalized and not 
functionalized KBC1250 films after 1, 3 and 7 culture days. As shown in figure 3.10, after 24 h 
and up to 3 days, cell viability is significantly higher for the RGD modified samples, compared 
to KBC1250 control (not functionalized) (p<0.05). In particular, cell viability appears lower 
for the samples functionalized with the RGD linear micropattern with respect to those 
modified homogeneously (p<0.05). This trend, which is repeated after 24 and 72 h, could be 
explained since the amount of RGD peptides attached on the surface functionalized by the 
use of the siloxane stencil is lower (1.7 nmol/mm2) with respect to the surface modified 
homogeneously (3.2 nmol/mm2) and, as a consequence, a lower amount of cells attached is 
expected. After 3 days a general decrease in cell viability is observable for the substrates. 
Nevertheless, it returns to increase after the seventh day of culture, with viability values 
comparable to those of the control for all the samples (p>0.05). In conclusion, the presence 
of RGD peptides on PUR film surfaces seems to accelerate the positive biological response of 
the substrates in terms of cardiomyocyte viability. 
 
Fig. 3.10 Results of viability MTS tests performed on KBC1250 films using H9C2 rat heart cell line. 
 
SEM micrographs allowed to evaluate qualitatively the effect of RGD peptides on cell 
adhesion after 24 and 72 culture hours. As shown in figure 3.11 a, after 24h, cardiomyocytes 
do not show good adhesion on KBC1250 (control), where a round cell morphology is evident. 
On modified samples (figure 3.11 b and c)  cell morphology is slightly less spherical and 
characterized by the presence of filaments. After 3 culture days, cells show a clear good 
adhesion on functionalized surfaces, with a stretched shape and filaments, especially in the 
case of the homogeneously modified KBC1250. If MTS results are considered, it is possible to 
state that, regardless of the decreased viability observed after 3 days, survived cells are well 
attached to RGD modified films. 
 
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
Ctrl KBC1250 Stencil RGD-
KBC1250
Homogeneus 
RGD-KBC1250
1 day
3 days
7 days
A
b
so
rb
an
ce
at
 4
9
0
 n
m
92 
 
 
(a)  
 
(b) 
 
(c)  
 
Fig. 3.11 SEM micrographs of KBC1250 (not functionalized) (a), KBC1250-RGD functionalized with a linear 
chemical micropattern (b) and KBC1250-RGD (c) films, after 24h of cell culture. 
 
 
 
(a) 
 
(b) 
 
(c) 
 
Fig. 3.12 SEM micrographs of KBC1250 (not functionalized) (a), KBC1250-RGD functionalized with a linear 
chemical micropattern (b) and KBC1250-RGD (c) films, after 72h of cell culture. 
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3.3.2 Characterization of functionalized scaffolds 
 
3.3.2.1 ATR-IR  
 
As for dense PUR substrates, ATR spectra demonstrated the successful surface modification 
of KBC1250 scaffolds, after plasma treatments and RGD covalent attachment. As shown in 
figure 3.13, the same enlargement of the intense band at about 1720 cm-1, observed in the case 
of PAA-KBC1250 films and ascribable to the presence of acidic carboxyl groups is present. 
Concerning RGD-PAA-KBC1250 spectrum, the peak at 1656 cm-1, corresponding to the 
stretching of peptide bonds, is observable. 
 
 
Fig. 3.13 ATR-IR spectra of KBC1250, PAA-KBC1250, RGD-PAA-KBC1250 scaffolds. 
 
 
3.3.2.2 Surface wettability 
 
Static Contact Angle measurements allowed to confirm the modification of scaffold surfaces. 
As shown in table 3.2, a significant increase in hydrophilicity was registered for the porous 
KBC1250 after acrylic acid plasma treatment. The covalent attachment of RGD peptide 
determined an increase of contact angle value corresponding to a decrease in wettability. 
Although the trend in contact angle variation was the same observed for modified PUR films, 
the final value achieved for scaffold surfaces (99°) was higher than films. The functionalization 
conditions, that were used for PUR films, modified wettability properties of scaffolds but not 
enough to achieve an optimal contact angle value for cell attachment. The “hydrophobic” 
effect of surface micro-roughness, that has been already discussed in Chapter 2, seems to be 
maintained. 
 
 
Tab. 3.2 Contact Angle values for KBC1250 scaffold and modified PUR scaffolds. 
PUR SCAFFOLDS Contact Angle (°) 
KBC1250 115 ± 1 
PAA-KBC1250 80 ± 1 
RGD-PAA-KBC1250 99 ± 1 
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3.3.2.3 COOH and NH2 groups quantification 
 
Acidic groups were quantified after plasma treatment through Toluidine assay, as for dense 
films. A COOH density of 0.004 μmol/mm3 was obtained. As in the case of films, this density 
value was considered for the subsequent calculations of EDC and NHS amounts, in order to 
activate all the acidic groups, but not for RGD amounts in the covalent attachment reaction. 
For this reagent, the same data from literature that were used for dense films were considered 
[53, 54]. Amino groups quantification was performed thorough the Kaiser test and a final 
RGD surface density of 1.4 nmol/mm3 was calculated. In this case a volume unit was 
considered for density calculation since during plasma treatment and, as a consequence, during 
the subsequent functionalization steps, reactive groups could be formed in the inner part of 
porous surfaces.  
 
 
3.3.2.4 Cell Viability and adhesion on functionalized scaffolds 
 
MTS assay was used to quantify cardiomyocyte viability also on functionalized and not 
functionalized porous constructs, after 1, 3 and 7 culture days. As shown in figure 3.14, there 
are no significant differences in cell viability passing from the unmodified sample to the RGD 
modified one (p>0.05), after 1 and 3 culture days. After 7 culture days, a slight viability 
increase can be observed for the functionalized scaffolds (p<0.05). In addition, Western Blot 
assay demonstrated a slight increase in vinculin expression at the same time interval (see figure 
3.15).   
 
 
Fig. 3.14 Results of viability MTS tests performed on KBC1250 scaffolds using H9C2 rat heart cell line. 
 
This overall biological response of the modified scaffolds could be ascribed to the 
hydrophobicity of the porous samples. Passing from the not functionalized to the 
functionalized porous constructs, a decrease in contact angle values of about 16° was 
observed, with a final value of 99°. This wettability increase after surface modification can 
have caused a negative effect on cardiomyocyte adhesion and viability, thus hindering the 
detection of any positive influence of the biomimetic surface functionalisation performed on 
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these samples. However, after 7 culture days, probably the effect of the suitable porous 
microstructure and of the attached peptides balance the negative hydrophobicity effect.  
Another explanation for these biological results could be linked to the presence of some RGD 
peptides not covalently bonded to the inner walls of the porous microstructure. As already 
discussed in the Introduction section, non-immobilized peptides can lead to cell detachment, a 
round shape and apoptosis [23-25]. 
 
 
 
Fig. 3.15 Results of Western Blot performed on KBC1250 porous scaffold, not surface modified and modified, 
using H9C2 rat heart cell line. 
 
 
3.4 Conclusions 
 
Spectroscopic (ATR-IR and XPS) analysis, increase in surface wettability and colorimetric 
assays showed the successful surface modification of both KBC1250 films and scaffolds, by 
the covalent attachment of RGD peptides. In the case of the dense substrates, Contact Angle 
measurements and Kaiser Test demonstrated respectively the presence of an optimal 
hydrophilicity and peptide density, able to promote cell adhesion. A positive effect on 
cardiomyocyte viability (already after 1 and 3 culture days) and adhesion (after 3 culture days) 
resulted from MTS tests and SEM micrographs. Although an increase in surface wettability 
and a good RGD density were obtained also for the porous constructs, the biological response 
of this type of substrates was not significantly improved by surface modification. A slight 
increase in cell viability and in the expression of the vinculin protein was observed only after 7 
days of culture. These results can be linked to the hydrophobicity of the porous surfaces (that 
was not drastically decreased after the functionalization process) or the presence of not 
covalently bound peptides inside the scaffold microstructure, that may prevent cell adhesion 
and cause cell death.  
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CHAPTER 4 
Cardiac stem cells on polyurethane films and scaffolds 
 
 
Abstract 
 
Endogenous progenitor cells are the best candidates for myocardial regeneration, both trough 
cell therapies and tissue engineering bioconstructs, since these cells are tissue-specific, pre-
committed to a cardiac fate and expandable. In this part of the work, human endogenous 
Cardiosphere Derived Cells (CDCs) and cardiac Mesenchymal Stem Cells (MSCs), were 
extracted from human cardiac biopsies and both tested on KBC1250 dense and porous 
substrates for myocardial tissue applications. Cell quantification and cell health tests, 
respectively performed by Picogreen and AlamarBlue assays, showed encouraging results for 
the porous construct, that did not display toxic effects on cells and promote their proliferation. 
 
4.1 Introduction 
Researchers have believed for a long time that the heart is a non-regenerative organ composed 
of post-mitotic cardiomyocytes in which hypertrophy (cell enlargement) of surrounding viable 
myocardium compensates for cardiomyocyte loss in an infarcted heart. Nevertheless, during 
the last two decades, attempts in the scientific community have resulted in evidences that 
challenge this dogma, such as the identification of a reservoir of resident stem cells, defined as 
cardiac progenitor cells (CPCs) [1]. These endogenous progenitors may represent the best 
candidates for cardiovascular cell therapy, as they are tissue-specific, often pre-committed to a 
cardiac fate, expandable and display a greater propensity to differentiate towards 
cardiovascular lineages [2]. 
As a consequence, new cell-based therapeutic strategy are emerging, with an expectation of 
heart tissue regeneration. In addition to skeletal myocytes, blood or bone marrow-derived cells 
and embryonic stem (ES) cells, cardiac stem/progenitor cells from adult hearts have been 
explored as potential candidates for cardiovascular regenerative cell therapy and myocardial 
tissue engineering applications [1]. 
 
 
4.1.1 Cardiac progenitor cells (CPCs) 
A progenitor cell in the heart is defined as an undifferentiated cell that is committed to the 
cardiac lineage and has the capacity to produce differentiated progenies, including 
cardiomyocytes, smooth muscle cells and/or endothelial cells. Resident cardiac progenitor 
cells (CPCs) represent a responsive stem cell reservoir within the adult myocardium. They may 
offer distinct advantages over other adult stem cell types, for cardiovascular therapy, being 
autologous, tissue-specific and pre-committed to the cardiovascular lineages [3]. CPCs are 
reported to exist in the heart of several species, including mouse [4, 5], rat [6, 7], dog [8], pig [9] 
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and human [4, 10, 11] as small clusters of progenitors characterized by the expression of stem 
cell antigens. Different pools of CPCs have been classified according to their properties and 
surface markers: side population, c-kit+, Sca-1+, Islet 1+, SSEA-1+, “cardiospheres” and/or 
“cardiosphere”-derived CPCs [2]. C-Kit+ cells in adult human heart were found in a specific 
microenvironment (“niche”), with a capacity for self-renewal and the ability to regenerate 
myocardium tissue in a rat model of acute MI [12]. Using Sca-1, a different CPC population  
was also isolated from the adult mouse heart. However, their differentiation into 
cardiomyocytes requires the presence of demethylating agents (e.g., 5-azacytidine and 
oxytocine) [13].  
Due to their limited numbers, the study and therapeutic application of resident CPCs depends 
upon their expansion. This result has been achieved by two different approaches. The first 
one is based on their ex vivo isolation and expansion from cardiac biopsies, followed by 
transplantation into the damaged heart [7]; the second one focuses on stimulating and 
boosting CPC proliferation in situ, via administration of specific factors [14]. Although these 
cells hold an intriguing regenerative potential towards cardiovascular repair, several questions 
remain unanswered relating to CPC origin, what markers they express, the degree of overlap 
of the so-called distinct subpopulations and the precise mechanisms by which they benefit the 
injured tissue. 
 
 
4.1.1.1 Cardiospheres and CDCs for myocardial regeneration 
 
CPCs can be isolated from heart tissue biopsies into self-assembled clusters, referred to as 
“cardiospheres”. These cells were shown to express surface stem and endothelial antigen 
markers (c-Kit, Sca-1, CD31, and CD34), suggesting a heterogeneous nature of progenitors at 
different stages, including differentiating progenitors, spontaneously differentiated 
cardiomyocytes and vascular cells [4]. Murine CS showed spontaneous beating soon after their 
generation, while human CS showed to beat only after co-culture with rat cardiomyocytes. CS 
could also be cultured as a monolayer of cardiosphere-derived cells (CDCs), upon mechanical 
dissociation, and expanded over many passages [4]. The in vivo cardiomyogenic potential of 
CS has been verified via transplantation studies into different MI models: when murine CS 
were injected into the ischemic heart of immunodeficient mice, they were shown to 
differentiate into vascular cells as well as myocytes with contractile activity and expression of 
sarcomeric proteins; porcine CDCs, delivered intracoronary in a preclinical model of 
postinfarct left ventricular dysfunction, resulted in the generation of new tissue, reduction of 
infarct size, and improvement of haemodynamics [9]. Although the in vivo cardiomyogenic 
potential in animal MI models was confirmed, further characterization before translation into 
a clinical setting is highly recommended, since the reproducibility and reliability of this 
protocol has been questioned [2]. 
Recently, studies about the application of cardiospheres or CDCs in myocardial tissue 
engineering have been carried out, although the combination of regenerative cells with 
functional scaffolds to create a vitro TE bioconstructs for ischemic heart remains a challenge. 
Chimenti et al. employed porous gelatin foams and collagen based scaffolds (RGD modified) 
as substrates for housing and enhancing the potency of CDCs for myocardial regeneration 
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[15]. They observed that both substrates showed a good cell retention and that the RGD-
collagen scaffold offered an ideal structure for cell spreading, while the gelatin foam 
encouraged a 3D order. The most important result concerned CDCs cardiac commitment, 
that was maintained and promoted inside the constructs, as shown by the analysis of 
expression for the cardiac markers, especially in the collagen based scaffold. Similar results, 
that were achieved with mouse CDCs incorporated in hydrogels, confirmed the feasibility of 
TE approach on resident cardiac progenitor cells [16]. 
 
 
4.1.1.2 Side population (SP) and mesenchymal stem cells (MSCs) for myocardial 
regeneration 
 
The SP cells have been found in several adult tissues, such as skeletal muscle and bone 
marrow [17]. The existence of a cardiac SP was first reported in the postnatal murine 
myocardium, where resident side population cells showing stem cell-like activity and 
cardiomyocyte differentiation potential, were detected [18]. In rodents, cardiac SP cells were 
described as Sca-1+, ckit+, CD34+, CD31−, and CD45− cells, expressing cardiac specific 
transcription factors, such as Gata4, MEF2C and Nkx2.5 upon isolation, and acquiring a 
cardiomyocyte phenotype [18, 19]. In myocardial regeneration studies, SP CPCs showed the 
ability to home to the injured heart and to differentiate in situ into cardiomyocytes, endothelial 
and smooth muscle cells, when intravenously infused into adult rats [20].  
Cardiac SP cells may have heterogeneous nature, containing distinct subpopulations, identified 
by expression of VE-cadherin, CD31, CD34 and Sca1 and consisting of vascular endothelial 
cells, smooth muscle cells and mesenchymal progenitors, including cardiomyogenic precursors 
[21]. Proofs of mesenchymal stem cell existence in mice heart were shown in the work of 
Carlson et al., where a contribution from endogenous MSCs to the infarct fibroblast 
population has been demonstrated. Fibroblasts forming in the scar of an MI should arise from 
an endogenous pool of primitive CD44+ mesenchymal precursors that localize and proliferate 
in the wound within 36 h, as shown by the expression of the cell cycle marker Ki67. This 
population of CD44+ cells lack the haematopoietic marker CD45 as well as the inflammatory 
markers CD18 and CD73, indicating that they are not bone marrow-derived. In addition, a 
portion of these cells are multipotential stem cells that express the stem cell markers CD34, 
TERT, and Nanog and are capable of differentiating into multiple lineages in vitro as well as 
into CD44+ fibroblasts such as those seen in the infarct zone. In conclusion, the study of 
Carlson support the role of endogenous MSCs as important mediators of repair by generating 
and processing the extracellular matrix of the forming scar [22] 
 
 
4.1.2 Cardiac progenitor cells in the present work 
 
In this thesis work, cardiac Mesenchymal Stem Cells and Cardiosphere-Derived Cells were 
isolated from human heart tissue, expanded in vitro and seeded on KBC1250 dense and 
porous scaffolds, in order to test the capability of these substrates to provide a suitable 
microenvironment for the proliferation of these progenitor cells.   
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The PUR substrates were selected on the strength of previous biological results, obtained by 
viability test with cardiomyocytes and discussed in Chapter 2. Cell isolation, expansion and 
culture on polymeric substrates were performed at the Institute of Human Genetics of 
Newcastle University (Dr Annette Meeson’s laboratory). MSCs used in this work were 
detected in the human heart, extracted and characterized for the first time by Dr Rachel 
Oldershaw and Dr Annette Meeson of Newcastle University (United Kingdom) (work under 
publication). In the next section, CDC isolation and culture and MSC culture will be described. 
 
4.2 Materials and methods 
 
4.2.1 CDC isolation and culture 
 
Cardiosphere derived Cells were isolated though the Biopsy Specimen Process [4, 23]. A 
human cardiac biopsy (from female patient, 21 years old) was cut into fragments (1-2 mm3 
pieces) that were washed in phosphate-buffered solution (PBS, Sigma) and partially digested 
enzymatically for 5 minutes at 37°C with 0.05% trypsin (Gibco). The tissue fragments were 
cultured as “explants” on dishes coated with fibronectin (figure 4.1, step 1) for about 4 weeks 
in CEM (Iscove’s Modified Dulbecco’s Medium [IMDM, Gibco] supplemented with 10% fetal 
calf serum, 100 U/mL penicillin G, 100 g/mL streptomycin, 2 mmol/L L-glutamine, and 0.1 
mmol/L 2-mercaptoethanol) at 37°C and 5% CO2. After several days, a layer of cells arose 
from adherent explants. Once confluent, these cells surrounding the explants (cardiosphere-
forming cells) were harvested by gentle enzymatic digestion (figure 4.1, step 2). These cells 
were seeded on poly-D-lysine- coated dishes in cardiosphere growth medium (CGM)(35% 
complete IMDM/65% DMEM–Ham F-12 mix containing 2% B27, 0.1 mmol/L 2-
mercaptoethanol, 10 ng/mL epidermal growth factor [EGF], 20 ng/mL basic fibroblast 
growth factor [bFGF], 40 nmol/L cardiotrophin-1, 40 nmol/L thrombin, and L-Glu, as in 
CEM) (figure 4.1, step 3). Several days later, cells that remained adherent to the poly-D-lysine- 
coated dishes were discarded, whereas detached cardiospheres were plated on fibronectin 
coated flasks and expanded as monolayers (figure 4.1, step 4). CDCs were subsequently 
passaged by trypsinization and splitting at a 1:2 ratio up to obtain an adequate cell number for 
the subsequent culture on PUR substrates. Single cells were counted under phase microscopy 
with a hemocytometer during CDC passaging and before seeding on PUR samples. 
 
 
 
 
 
Fig. 4.1 Specimen processing for human cardiosphere growth and CDC expansion. 
 
 
1 2 3 4
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4.2.2 MSC culture 
 
After cell isolation from a heart tissue biopsy (patient 28 years old), human cardiac MSCs were 
passaged by trypsinization and split 5 times at 1:3 ratio. Also in this case, cells were counted 
under phase microscopy with a hemocytometer before seeding on PUR samples. 
 
 
4.2.3 CDC and MSC culture on PUR samples  
 
KBC1250 films and scaffolds were cut in squared samples (1x1 cm2), sterilized in 
ethanol/water (70/30 v/v) for 1 h and inserted into 96-well plates. Cells were detached using 
trypsin concentrated, resuspended in culture medium, and seeded upon KBC1250 substrates 
and tissue culture plastic (wells), as control (500,000 MSCs/sample and 170,000 
CDCs/sample).  
CDCs were seeded and cultured in Cardiomyocyte Cellutions Differentiation Medium (DV 
Biologics), while MSCs were seeded and cultured for 7 days in MSC medium (Gibco), that 
then was changed to Cardiomyocyte Cellutions Differentiation Medium for other 7 days. The 
seeded constructs were kept in cell incubator (Thermo Scientific Heracell150i for MSCs, 
Sanyo CO2 Incubator for CDCs) and the medium was replaced every two days for both types 
of cells. 
 
 
4.2.3.1 Cell viability and health tests 
 
Cell viability was evaluated through Picogreen assay (Invitrogen), that employ a fluorescent 
nucleic acid stain (Picogreen) for quantitating double-stranded DNA (dsDNA), proportional 
to cell number. The amount of dsDNA was calculated adding a 200-fold diluted Picogreen 
solution in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) to the samples (without 
culture medium and in triplicate) and by referring to a five-point standard curve from 0 to 
1000 ng/ml in TE buffer. The absorbance of sample and standard solutions was recorded in 
the range 485-585 nm by a Fluoroscan Ascent (Thermo Lab System).  
In the case of MSCs, cell health was also investigated through AlamarBlue assay (Invitrogen), 
that is based on detection of cell metabolic activity and incorporates a 
fluorometric/colorimetric indicator. Specifically, the system incorporates an oxidation-
reduction indicator that fluoresces and changes color in response to chemical reduction of 
growth medium resulting from cell activity. AlamarBlue was added to the samples (triplicate), 
that were incubated for 4 h. The absorbance was read in the range 544-585 nm by a the same 
Fluoroscan Ascent that was used for Picogreen assay. Since the results obtained from the 
AlamarBlue assays depend from both the cell metabolic activity and the total number of cells, 
the absorbance values obtained were divided by the corresponding cell amount (DNA), in 
order to obtain values of health/cell, that indicate the averaged health of the single cells. 
Data obtained from Picogreen and AlamarBlue assays were investigated for statistical 
significance using one-way analysis of variance (ANOVA). A p-value less than 0.05 was 
considered significant. 
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4.3 Results 
 
4.3.1 CDC isolation and culture 
 
In figure 4.2. a typical cardiosphere, that was created after cardiosphere-forming cells were 
seeded on poly-D-lysine- coated wells in cardiosphere growth medium, is shown. As already 
described, cardiospheres appear as clusters, characterized by a mixture of cardiac stem cells, 
differentiating progenitors and spontaneously differentiated cardiomyocytes. Vascular cells can 
also be present, depending on the size of the sphere and time in culture. Generally, 
differentiating/differentiated cells die or stop to divide, while stem cell continue to proliferate, 
creating secondary cardiospheres [4]. After transferring proliferated cardiospheres in a 
fibronectin- coated flasks, progenitor cell monolayers were obtained, as shown in figure 4.3. 
They were expanded as a common primary cell culture, achieving about one million of cells 
from a single biopsy after 2 passages (splits). 
 
 
 
Fig. 4.2 A formed cardiosphere  after seeding cardiosphere-forming cells on poly-D-lysine- coated wells. 
 
 
Fig. 4.3 CDC monolayer in fibronectin- coated flask. 
 
100 μm
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4.3.2 CDC quantification on PUR substrates 
Picogreen tests performed after 7 and 14 culture days on KBC1250 films and scaffolds, 
showed interesting results on CDC proliferation on porous scaffolds. In figure 4.4, a 
significant (p<0.05) higher cell number on the porous constructs with respect to films and 
control is observable. This evident difference in cell amount between scaffolds and the other 
two types of substrates could be due to the tridimensional porous structure of the scaffolds, 
that provides for a larger available space, allowing for a higher cell proliferation. This 
proliferation in the porous constructs demonstrated that they are appropriate matrices for 
CDC attachment and growth. 
Between 7 and 14 days of culture, a clear decrease in cell number takes place for all the 
substrates, with a higher cell number (p<0.05) for the scaffolds with respect to films and 
control wells. Since after 7 days we observe a high cell amount on scaffolds, this drop is not 
caused by toxicity effects. This trend could be explained considering that, between days 7 and 
14, there is no more available space where cell can further proliferate and expand.  
 
 
Fig. 4.4 Picogreen results for CDCs: DNA (cell) quantification on KBC1250 films and scaffolds and on tissue 
culture plastic, as control. 
 
4.3.3 MSC quantification and health on PUR substrates 
 
Results obtained by the Picogreen assay, performed after 1, 7 and 14 culture days, are shown 
in figure 4.5. It appears evident that there are significantly less cells at day 1 on the films and 
the scaffolds compared to the control (p<0.05 for both the constructs). This trend may reflect 
the available space for attachment and the initial “hydrophobic” effect of the porous surface. 
Nevertheless, a significant loss of cells on all the substrates is observable after 7 culture days, 
though the drop in number is lower for both the PUR based samples with respect to the 
control. This cell number decrease could be due to the high number of cell initially seeded.  
Between day 7 and day 14, a significant increase in cell number is evident on scaffolds. This 
increase (not present on films and control wells) suggests that the cells have proliferated in the 
porous constructs and they have adapted to the environment, now suitable for their expansion. 
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Cell number decreased on control wells and did not significantly increase on films, probably 
because of the lack of a tridimensional structure and available space where cells can proliferate. 
 
 
 
Fig. 4.5 Picogreen results for MSCs: DNA (cell) quantification on KBC1250 films and scaffolds and on tissue 
culture plastic, as control. 
 
Data about MSC health, obtained from AlamarBlue assay, are reported in figure 4.6. On day 1 
cells were significantly healthier on the scaffold compared to both the film and the control 
(p<0.05). In this case, there is no over seeding (Picogreen results in figure 4.3). and the 
increased surface area of the porous scaffold within the culture environment allowed the cells 
to move in and arrange themselves.  
The health of the cells increased on both the films and the control wells throughout the 
experiment. On scaffolds, cell health increased up to the seventh day of culture, resulting 
twice as the value observed for films and control (p<0.05 for the scaffold with respect to the 
film and the control). This trend suggests that the cells became more adapted to their 
environment, probably because the loss of cells (decrease in cell amount) allowed the cells 
which survived to receive more nutrients and be exposed to more effective gaseous exchange. 
The superior health of the cells on the scaffolds at days 1 and 7 again suggests that the cells 
are in a very suitable environment. 
After 14 culture days a significant decrease in cell health for the scaffold compared to both the 
film and the control (p<0.05) is observable. Since an increase in the number of cells was 
evident between days 7 and 14 (Picogreen results in figure 4.3), it is possible to state that there 
are no toxic effect caused by the scaffold. One technical issue that could affect this result may 
be that PUR scaffolds are initially hydrophobic but can absorb water solution with time. 
Consequently, the scaffolds could retain culture medium (they appeared swelled after 14 days 
compared to smaller time interval) which then diluted the Alamar Blue solution, reducing the 
value in cell health which is recorded. From a biological prospective, the increase in cell 
numbers, as noticed in the DNA graph, causes an increase in competition for resources 
(nutrients and oxygen) which reduces the metabolic activity of the cells. This aspect would be 
particularly relevant for cells inside the scaffold. The observed decrease in cell health may also 
be linked to an initial differentiation process, that generally requires activities such as the 
coordination of genomic programming and the energetic system maturation (from anaerobic 
glycolytic metabolism to the more efficient mitochondrial oxidative metabolism that secure 
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cardiac specification and excitation–contraction coupling) [24, 25]. These hypothesis will be 
assessed by histological studies, that have been planned as future work. 
In conclusion, the scaffold appears to be the best substrate in supporting the cardiac MSCs 
within the first week. However, further optimization (particularly cell seeding density and 
assaying of cell health) will be necessary to demonstrate its positive effect over a longer period 
of time. 
 
 
 
Fig. 4.6 AlamarBlue results for MSCs: cell health on KBC1250 films and scaffolds and on tissue culture plastic, as 
control. 
 
 
4.4 Conclusions 
 
Cardiac progenitor cells were successfully extracted and expanded as cardiosphere derived 
cells, through the formation of heterogeneous cell clusters, called “cardiospheres”. These cells, 
that express progenitor cell markers, were seeded on KBC1250 dense and porous substrates, 
in order to test these constructs as suitable micro-environments for CDC attachment and 
proliferation. Picogreen tests showed that porous scaffold promote CDC growth after 7 
culture days. After 2 weeks a decrease in cell number suggests that probably cells can not 
expand because of the total employment of the available space. 
PUR based constructs were also tested with human mesenchymal stem cells, detected and 
characterized for the first time in human heart from Dr Rachel Oldershaw and Dr Annette 
Meeson from Newcastle University. Picogreen and AlamarBlue assays showed good results 
for the porous substrates both in terms of cell number (after 14 culture days) and cell health 
(after 1 and 7 days). The decrease in cell health after 14 days may be linked to technical 
problems during the tests and/or to the cell competition for nutrients. Another issue, that 
should be examined in depth, is the possibility of an initial differentiation in cardiomyocytes 
that causes a decrease in cell metabolic activity. 
In conclusion, from preliminary tests on human cardiac progenitor cells, KBC1250 porous 
scaffolds resulted promising substrates for both CDCs and MSCs.  
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CHAPTER 5 
Final discussion and conclusions  
 
 
5.1 General discussion  
 
Myocardial infarction is one of the most common cardiovascular diseases, that are the number 
one cause of death in the world [1]. Since adult cardiomyocytes and the progenitor cells 
present in the adult heart have very poor capability to proliferate and differentiate, respectively, 
a myocardial infarction results in the formation of scar tissue with different contractile and 
mechanical properties from that of native tissue [2-4]. To this day, pharmacologic and surgical 
treatments did not reveal sufficiently adequate in completely restoring cardiac functions. As a 
consequence, new approaches of Regenerative Medicine and, in particular, of Tissue 
Engineering, have been considered.  
One of the possible approaches of TE consists in employing a tridimensional construct 
(scaffold or heart patch, in the case of cardiac regeneration), that is generally prepared from 
natural or synthetic polymers. The most important challenge of myocardial TE researchers is 
to prepare adequate constructs combining the required morphological, mechanical, physical 
and biochemical properties, in order to create a suitable microenvironment for cardiac cells, 
both for in vitro and in vivo TE strategies. 
Since one of the most fatal consequences of MI is LV remodeling, which consists in changes 
in size, shape, and function of the infarcted ventricle [5], a critical requirement for a heart 
patch is to mechanically support the infarcted ventricle. Consequently, a heart patch should 
show suitable strength and an elastomeric mechanical behavior, able to temporarily support 
the regeneration of the contractile tissue and restore the right shape and functionality of the 
ventricle. In addition, this scaffold should  temporarily replace the injured tissue, providing a 
transitional support to cell colonization, migration and proliferation and degrading with times 
compatible with native tissue regeneration. In the case of in vitro TE approaches, the scaffold 
should avoid cell loss and control their distribution in the infarcted area. To fulfill these 
functions, myocardial scaffolds should mimic the chemical and biological characteristics of 
cardiac ECM, its structure, morphology and mechanical behavior [6]. 
Aim of this thesis work was to fabricate suitable biomimetic constructs, able to restore 
myocardial functions and promote cardiac tissue regeneration after a myocardial infarction. 
These constructs were prepared as dense (films) and porous (scaffolds) constructs from 
synthetic biodegradable polyurethanes. These polymeric materials were selected thanks to their 
versatility, since they can be prepared starting from a large number of building blocks 
(macrodiols, diisocyanates and chain extenders) and, consequently, their properties can be 
finely tuned. In addition, degradable PURs have been studied for a long time for 
cardiovascular applications, thanks to their biocompatibility and elastomeric behavior that 
allow them to withstand the cyclic stresses of the cardiac contractile tissue [7, 8]. 
In this work, biodegradable poly(ester urethanes) and poly(ether ester urethanes) based on 
PCL and PEG as macrodiols were proposed as starting materials for the fabrication of 
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myocardial patches. PEG was added in low amounts with the aim of tuning wettability, 
mechanical and biological properties of films and scaffolds. L-Lysine Ethyl Ester and Alanine-
Alanine-Lysine (AAK) were selected as chain extenders due to their biocompatibility and 
because AAK peptide allows to modulate biodegradability properties, since the Alanine-
Alanine sequence is a target for the elastase enzyme. 
The chemical, thermal and mechanical analysis of the synthesized PURs showed the successful 
preparation of the polymeric materials with the desired physical-chemical properties for 
myocardial TE applications. Polymers revealed to be easily processable in dense films and 
porous scaffolds. Through the TIPS technique, a tridimensional construct with an anisotropic 
microstructure was obtained, starting from two different PUR formulations (KBC1250 and 
KBC1250-E1500-20). This structure was characterized in both cases by elongated and 
unidirectional pores, which showed  a "structural biomimicry" of the streaked muscle tissue. 
In detail, the scaffold fabricated from KBC1250 showed interconnected porosity with pores 
of about 98 μm. These features seem to promote cell colonization, cell migration and 
nutrients supply [6, 9]. In addition, porous substrates showed melting temperatures well above 
the physiological one, avoiding a decrease in mechanical performance of the construct after 
implant, due to the softening of the material.  
Mechanical tests revealed that the introduction of low amounts of PEG allowed a fine tuning 
of mechanical properties and that, although all the dense films were characterized by an 
elastomeric behavior and high toughness, the film obtained from the PUR containing 20% of 
PEG macrodiol (KBC1250-E1500-20) was characterized by the mechanical parameters closer 
to those required (elastic modulus of myocardial tissue: 20kPa-0.5MPa; strain at break in the 
range 22-90%; stress at break in the ranges 3-15 kPa [7, 8, 10, 11]). Porous devices, which 
were prepared by the formulation KBC1250-E1500-20 and that synthesized from 100% PCL 
macrodiol (KBC1250), showed mechanical properties lower than the corresponding films. 
However, if we consider that an ideal patch should be characterized by Young Moduli 
encompassing from tens of kPa to 1 MPa and by an elastomeric mechanical behaviour, the 
obtained scaffolds are appropriate for myocardial TE applications. They have elastic moduli 
very close to that of native tissue, maximum stress significantly higher than that of the 
myocardial tissue and an elastic mechanical behavior up to about 20% of deformation. 
From what concerns biological properties, the porous structures, regardless of their PEG 
content, showed good results in terms of cardiomyocytes viability and adhesion. The best 
biological response was observed for the porous KBC1250, probably due to its stretched 
microstructure with morphological features (interconnected porosity and pores 98 μm 
diameter that seem to be ideal in promoting cell proliferation and colonization [6, 9, 12].  
Hydrolytic and lipase degradation tests showed a faster weight loss for the scaffolds in the 
presence of the enzyme, probably because the enzymatic degradation mechanism takes place 
on the surface and porous constructs exhibit a larger exposed area. Elastase degradation tests, 
that were performed on KBC1250 and ABC1250 films, demonstrated the possibility to 
increase the degradation rate of PURs through a partial introduction of an enzyme-target 
peptide as chain extender. Nevertheless, a fine tuning of the degradation process was obtained, 
too. If we consider that Guan and co-workers [13] achieved 2-25% weight loss for similar 
polyurethane films introducing 100% AAK peptide in the polymer backbone and performing 
analogous enzymatic degradation tests, it is possible to state that, in this thesis work, the 
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replacement of 50% AAK peptide with L-Lysine resulted in a evident slowing down of the 
degradation process (0-5% weight loss) with respect to what obtained by Guan.  
Based on the optimal biological and mechanical properties of dense and porous KBC1250 
constructs, these substrates were selected to be surface modified with RGD peptides. This 
covalent modification aimed to obtain a “biochemical mimicry” of the natural ECM, and, as a 
consequence, to promote cell adhesion and proliferation. It was performed on films both 
homogeneously and through a silicone mask that allowed for the creation of a linear chemical 
micropattern. Data from literature have shown encouraging results on cardiomyocyte 
proliferation and stem cell differentiation into the cardiac lineage, in in vitro cultures on 
polymeric surfaces with fibronectin and laminin linear micropatterns [14, 15]. In detail, the 
adhesion on the modified strips seem to promote mesenchymal stem cell differentiation 
probably due the stretching of the cells, and cardiomyocyte spatial organization during novel 
tissue formation.   
In this thesis work, surface modification with epitopes of fibronectin and laminin proteins was 
investigated, since the use of the entire proteins involves several disadvantages with respect to 
the use of peptides containing the active sequences. Proteins have to be isolated from other 
organisms and purified, increasing the risk of immune responses and infections. In addition, 
proteins have to be refreshed continuously, since they are object of proteolytic degradation, 
and only a part of the proteins reach the proper orientation for cell adhesion when adsorbed 
on or bound to surfaces[16-18].  
Spectroscopic analysis, increase in surface wettability and colorimetric assays demonstrated the 
successful surface modification of both KBC1250 films and scaffolds, by the covalent 
attachment of RGD peptides. In addition, functionalized films were characterized by an 
optimal hydrophylicity (contact angle value of about 65°), very close to that reported in 
literature [19] and an appropriate peptide density (respectively 3.2 and 1.7 nmol/mm2 for 
surfaces modified homogeneously and with the micropattern), able to promote cell adhesion 
[19, 20]. Amino group quantification and cell viability tests demonstrated indirectly the 
successful use of the siloxane stencil in covalently attaching the RGD peptides on the 
uncovered areas. The presence of peptides on film surfaces affected positively cardiomyocyte 
viability and adhesion, as showed from MTS tests and SEM micrographs, where a stretched 
cell shape and the presence of filaments are evident after 3 culture days. Although an increase 
in surface wettability and a good RGD density were obtained also for the porous constructs, 
the biological response on this type of substrates was not significantly higher after surface 
modification, with a slight increase in cell viability and adhesion measured only after 7 culture 
days. This behaviour may be explained considering that the porous surfaces achieved a contact 
angle value of about 90°, still far from the optimal values for promotion of cell attachment 
and proliferation and/or the possible presence of not covalently bound peptides inside the 
scaffold microstructure, that may induce cell detachment and apoptosis [21-23].  
KBC1250 substrates were also selected to be tested with human cardiac Mesenchymal Stem 
Cells (MSCs) and Cardiosphere Derived Cells (CDCs) for potential in vitro and in vivo MTE 
applications. Cardiac progenitor cells are the best candidates for both cell injection and MTE 
applications, since they are autologous, tissue-specific and pre-committed to the 
cardiovascular lineages [24]. Human cardiac MSCs belong to the stem cell reservoir within the 
adult myocardium and were detected for the first time in a human heart by Dr Rachel 
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Oldershaw and Dr Annette Meeson at Newcastle University (work still unpublished). As a 
consequence, they were tested for the first time on TE substrates for myocardial repair in this 
thesis work. The second type of cells derive from heterogeneous cell clusters, that are 
characterized by a mixture of cardiac stem cells, differentiating progenitors and spontaneously 
differentiated cardiomyocytes (“cardiospheres”) [25, 26]. Although CDCs have been already 
investigated for both cell therapies [27] and TE applications [28], they have been recently 
discovered and several aspects concerning their characteristics and their effects on myocardial 
regeneration have to investigated further [25]. In this thesis work CDCs were successfully 
extracted from human biopsies trough cardiosphere formation in vitro and expanded as a 
common primary cell culture. Subsequent culture of these CDCs and MSCs on KBC1250 
films and scaffolds revealed interesting and encouraging results for the porous constructs for 
MTE applications. Viability cell test showed that scaffold promoted CDC growth after 7 
culture days. Good results for the porous substrates both in terms of cell number (after 14 
culture days) and cell health (after 1 and 7 days) were obtained for MSCs. Nevertheless, a 
decrease in cell health after 14 days was observed. This result may be due to the competition 
for nutrients and gases after an intense cell proliferation or to technical problems during the 
test, such as water uptake with time, that can alter the concentration of the dye (AlamarBlue) 
and affect the final result. Another cause of the observed decrease in cell health may be the 
possible differentiation of these stem cells into cardiomyocytes, since this process determines 
a decrease in cell metabolic activity. This issue should be examined in depth through the study 
of changes in cell morphology and protein expressions. However, from these preliminary tests 
on human cardiac progenitor cells, KBC1250 porous scaffolds resulted promising substrates 
for both CDCs and MSCs.  
 
 
5.2 Conclusions and future developments 
 
In conclusion, the discussed results suggest that the selected synthesised polyurethane 
(KBC1250) is non toxic and the scaffold prepared by TIPS has the requested thermal and 
mechanical properties for MTE applications. In addition, this construct provides a suitable 
environment for cardiac cells (cardiomyocytes and stem cells) and the surface modification 
with RGD peptides can improve and accelerate cell response, in terms of cell adhesion and 
proliferation.  
Results obtained suggest work in order to further examine some aspects concerning 
degradability properties of the scaffolds, the biological effect of the RGD micropattern and 
clarify results related to progenitor cell proliferation and differentiation on the proposed 
substrates.  
First of all, since elastase degradation tests (discussed in Chapter 2) showed the possibility to 
finely tune biodegradation rate of PUR films through a partial introduction of the AAK 
peptide as chain extender in the polymeric backbone, fabrication by TIPS of porous scaffolds 
based on the formulation ABC1250 has been planned as future work, in order to combine a 
controllable biodegradability with a suitable porous microstructure for cell attachment and 
proliferation. Subsequent enzymatic degradation tests on porous structures based on 
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KBC1250 and ABC1250 should be combined to a precise study of the optimal degradation 
times for a heart patch. 
Further suggested activities may concern the surface modification with adhesion-peptides (see 
Chapter 3). The first aspect to be considered is the effectiveness of the linear micropattern in 
promoting cell adhesion and tissue organization, as suggested by data from literature on 
analogous micropatterns of laminin and fibronectin [14, 15]. This novel preliminary work on a 
linear RGD micropattern showed the successful use of the siloxane stencil during the peptide 
functionalization step in allowing the covalent attachment on the exposed areas of the 
polymeric surfaces. Nevertheless, cell tests that can visualize cell alignment along the modified 
strips will be necessary to understand the effect of chemical cues on cell spatial organization. 
The second aspect concerns the biological effect of the functionalization of the proposed 
scaffolds, since the results obtained show an almost unaltered cardiomyocyte response on the 
modified scaffolds with respect to the unmodified ones. As already discussed, this behavior 
could be ascribed to the hydrophobic effect of the surface micro-roughness or the presence of 
adsorbed, not covalently-linked, peptides. As a consequence, these aspects deserve further 
investigation in order to obtain on scaffolds results similar to those obtained on films. 
Increasing bound peptide density could be one possible approach to the decrease substrate 
hydrophobicity. Modified films and scaffolds could be tested also with CDCs and MSCs, in 
order to verify an acceleration and improving of the biological response also for what 
concerns progenitor cells. In particular, the effect of the micropatterned surfaces for 
progenitor cell differentiation into cardiomyocytes, as a consequence of cell stretch and 
alignment, is worth further study.  
Finally, to assess the viable implementation of the proposed constructs (modified and not) as 
implantable devices, able to recruit cardiac cells and restore mechanical and biological 
functions of the infarcted ventricle, in vivo trials are required. These tests will allow to 
investigate also on the degradation times of the devices and to really assess the 
biocompatibility of their biodegradation products. 
 
 
References 
 
1. Global Atlas on cardiovascular disease prevention and control, P.P. S. Mendis, B. Norrving, Editor 
2011, World Health Organization in collaboration with the World Heart Federation and the 
World Stroke Organization: Geneva. 
2. Anversa, P., et al., Myocyte growth and cardiac repair. J Mol Cell Cardiol, 2002. 34(2): p. 91-105. 
3. Dimmeler, S., A.M. Zeiher, and M.D. Schneider, Unchain my heart: the scientific foundations of 
cardiac repair. J Clin Invest, 2005. 115(3): p. 572-83. 
4. Vunjak-Novakovic, G., et al., Challenges in cardiac tissue engineering. Tissue Eng Part B Rev, 2010. 
16(2): p. 169-87. 
5. Sutton, M.G. and N. Sharpe, Left ventricular remodeling after myocardial infarction: pathophysiology and 
therapy. Circulation, 2000. 101(25): p. 2981-8. 
6. Causa, F., P.A. Netti, and L. Ambrosio, A multi-functional scaffold for tissue regeneration: the need to 
engineer a tissue analogue. Biomaterials, 2007. 28(34): p. 5093-9. 
7. Jawad, H., et al., Myocardial tissue engineering: a review. J Tissue Eng Regen Med, 2007. 1(5): p. 
327-42. 
8. Jawad, H., et al., Myocardial tissue engineering. Br Med Bull, 2008. 87: p. 31-47. 
114 
 
9. Cohen, S. and J. Leor, Rebuilding broken hearts. Biologists and engineers working together in the fledgling 
field of tissue engineering are within reach of one of their greatest goals: constructing a living human heart patch. 
Sci Am, 2004. 291(5): p. 44-51. 
10. Bouten, C.V., et al., Substrates for cardiovascular tissue engineering. Adv Drug Deliv Rev, 2011. 63(4-
5): p. 221-41. 
11. Chen Q.Z., H.S.E., Ali N.N., Lyon A.R., Boccaccini A.R. , Biomaterials in cardiac tissue engineering: 
Ten years of research survey. Mater Sci Eng R, 2008. 59: p. 1-37. 
12. Guan, J., K.L. Fujimoto, and W.R. Wagner, Elastase-sensitive elastomeric scaffolds with variable 
anisotropy for soft tissue engineering. Pharmaceutical Research, 2008. 25(10): p. 2400-2412. 
13. Guan, J. and W.R. Wagner, Synthesis, characterization and cytocompatibility of polyurethaneurea 
elastomers with designed elastase sensitivity. Biomacromolecules, 2005. 6(5): p. 2833-42. 
14. McDevitt, T.C., et al., Spatially organized layers of cardiomyocytes on biodegradable polyurethane films for 
myocardial repair. J Biomed Mater Res A, 2003. 66(3): p. 586-95. 
15. Siepe, M., et al., Construction of skeletal myoblast-based polyurethane scaffolds for myocardial repair. Artif 
Organs, 2007. 31(6): p. 425-33. 
16. Hersel, U., C. Dahmen, and H. Kessler, RGD modified polymers: biomaterials for stimulated cell 
adhesion and beyond. Biomaterials, 2003. 24(24): p. 4385-415. 
17. Elbert, D.L. and J.A. Hubbell, Conjugate addition reactions combined with free-radical cross-linking for 
the design of materials for tissue engineering. Biomacromolecules, 2001. 2(2): p. 430-41. 
18. Lhoest, J.B., et al., Fibronectin adsorption, conformation, and orientation on polystyrene substrates studied by 
radiolabeling, XPS, and ToF SIMS. J Biomed Mater Res, 1998. 41(1): p. 95-103. 
19. Lee, J.H., et al., Interaction of Different Types of Cells on Polymer Surfaces with Wettability Gradient. J 
Colloid Interface Sci, 1998. 205(2): p. 323-330. 
20. Maheshwari, G., et al., Cell adhesion and motility depend on nanoscale RGD clustering. J Cell Sci, 2000. 
113 ( Pt 10): p. 1677-86. 
21. Grano, M., et al., Adhesion properties and integrin expression of cultured human osteoclast-like cells. Exp 
Cell Res, 1994. 212(2): p. 209-18. 
22. Noiri, E., et al., Cyclic RGD peptides ameliorate ischemic acute renal failure in rats. Kidney Int, 1994. 
46(4): p. 1050-8. 
23. Stromblad, S., et al., Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin 
alphaVbeta3 during angiogenesis. J Clin Invest, 1996. 98(2): p. 426-33. 
24. Gonzales, C. and T. Pedrazzini, Progenitor cell therapy for heart disease. Exp Cell Res, 2009. 315(18): 
p. 3077-85. 
25. Messina, E., et al., Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ 
Res, 2004. 95(9): p. 911-21. 
26. Smith, R.R., et al., Regenerative potential of cardiosphere-derived cells expanded from percutaneous 
endomyocardial biopsy specimens. Circulation, 2007. 115(7): p. 896-908. 
27. Johnston, P.V., et al., Engraftment, differentiation, and functional benefits of autologous cardiosphere-
derived cells in porcine ischemic cardiomyopathy. Circulation, 2009. 120(12): p. 1075-83, 7 p following 
1083. 
28. Chimenti, I., et al., Human cardiosphere-seeded gelatin and collagen scaffolds as cardiogenic engineered 
bioconstructs. Biomaterials, 2011. 32(35): p. 9271-81. 
 
 
